#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
#Text=Abstract
#Text=Background
#Text=The investigation of large-scale intrinsic connectivity networks in antipsychotic-naïve first-episode schizophrenia increases our understanding of system-level cerebral dysfunction in schizophrenia while enabling control of confounding effects of medication and disease progression.
1-1	0-11	Alterations	_	
1-2	12-14	of	_	
1-3	15-24	Intrinsic	_	
1-4	25-37	Connectivity	_	
1-5	38-46	Networks	_	
1-6	47-49	in	_	
1-7	50-69	Antipsychotic-Naïve	_	
1-8	70-83	First-Episode	_	
1-9	84-97	Schizophrenia	_	
1-10	98-106	Abstract	_	
1-11	107-117	Background	_	
1-12	118-121	The	_	
1-13	122-135	investigation	_	
1-14	136-138	of	_	
1-15	139-150	large-scale	_	
1-16	151-160	intrinsic	_	
1-17	161-173	connectivity	_	
1-18	174-182	networks	_	
1-19	183-185	in	_	
1-20	186-205	antipsychotic-naïve	_	
1-21	206-219	first-episode	_	
1-22	220-233	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-23	234-243	increases	_	
1-24	244-247	our	_	
1-25	248-261	understanding	_	
1-26	262-264	of	_	
1-27	265-277	system-level	_	
1-28	278-286	cerebral	_	
1-29	287-298	dysfunction	_	
1-30	299-301	in	_	
1-31	302-315	schizophrenia	_	
1-32	316-321	while	_	
1-33	322-330	enabling	_	
1-34	331-338	control	_	
1-35	339-341	of	_	
1-36	342-353	confounding	_	
1-37	354-361	effects	_	
1-38	362-364	of	_	
1-39	365-375	medication	_	
1-40	376-379	and	_	
1-41	380-387	disease	_	
1-42	388-399	progression	_	
1-43	399-400	.	_	

#Text=Reports on functional connectivity in antipsychotic-naïve patients have been mixed and the relation between network alterations, psychopathology and cognition is unclear.
2-1	401-408	Reports	_	
2-2	409-411	on	_	
2-3	412-422	functional	_	
2-4	423-435	connectivity	_	
2-5	436-438	in	_	
2-6	439-458	antipsychotic-naïve	_	
2-7	459-467	patients	_	
2-8	468-472	have	_	
2-9	473-477	been	_	
2-10	478-483	mixed	_	
2-11	484-487	and	_	
2-12	488-491	the	_	
2-13	492-500	relation	_	
2-14	501-508	between	_	
2-15	509-516	network	_	
2-16	517-528	alterations	_	
2-17	528-529	,	_	
2-18	530-545	psychopathology	_	
2-19	546-549	and	_	
2-20	550-559	cognition	_	
2-21	560-562	is	_	
2-22	563-570	unclear	_	
2-23	570-571	.	_	

#Text=Methods
#Text=A total number of 47 patients with first-episode schizophrenia who had never received antipsychotic medication and 47 healthy controls were scanned with functional magnetic resonance imaging under resting conditions.
3-1	572-579	Methods	_	
3-2	580-581	A	_	
3-3	582-587	total	_	
3-4	588-594	number	_	
3-5	595-597	of	_	
3-6	598-600	47	_	
3-7	601-609	patients	_	
3-8	610-614	with	_	
3-9	615-628	first-episode	_	
3-10	629-642	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-11	643-646	who	_	
3-12	647-650	had	_	
3-13	651-656	never	_	
3-14	657-665	received	_	
3-15	666-679	antipsychotic	_	
3-16	680-690	medication	_	
3-17	691-694	and	_	
3-18	695-697	47	_	
3-19	698-705	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-20	706-714	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-21	715-719	were	_	
3-22	720-727	scanned	_	
3-23	728-732	with	_	
3-24	733-743	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-25	744-752	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-26	753-762	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-27	763-770	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-28	771-776	under	_	
3-29	777-784	resting	_	
3-30	785-795	conditions	_	
3-31	795-796	.	_	

#Text=Main outcome measures were differences in functional connectivity between groups and the relationship between network alterations, psychopathology and cognition.
4-1	797-801	Main	_	
4-2	802-809	outcome	_	
4-3	810-818	measures	_	
4-4	819-823	were	_	
4-5	824-835	differences	_	
4-6	836-838	in	_	
4-7	839-849	functional	_	
4-8	850-862	connectivity	_	
4-9	863-870	between	_	
4-10	871-877	groups	_	
4-11	878-881	and	_	
4-12	882-885	the	_	
4-13	886-898	relationship	_	
4-14	899-906	between	_	
4-15	907-914	network	_	
4-16	915-926	alterations	_	
4-17	926-927	,	_	
4-18	928-943	psychopathology	_	
4-19	944-947	and	_	
4-20	948-957	cognition	_	
4-21	957-958	.	_	

#Text=Results
#Text=Altered connectivity was found between right central executive network (CEN) and right ventral attention network (VAN) (patients > controls, P = .001), left CEN and left VAN (P = .002), and between posterior default mode network and auditory network (P = .006).
5-1	959-966	Results	_	
5-2	967-974	Altered	_	
5-3	975-987	connectivity	_	
5-4	988-991	was	_	
5-5	992-997	found	_	
5-6	998-1005	between	_	
5-7	1006-1011	right	_	
5-8	1012-1019	central	_	
5-9	1020-1029	executive	_	
5-10	1030-1037	network	_	
5-11	1038-1039	(	_	
5-12	1039-1042	CEN	_	
5-13	1042-1043	)	_	
5-14	1044-1047	and	_	
5-15	1048-1053	right	_	
5-16	1054-1061	ventral	_	
5-17	1062-1071	attention	_	
5-18	1072-1079	network	_	
5-19	1080-1081	(	_	
5-20	1081-1084	VAN	_	
5-21	1084-1085	)	_	
5-22	1086-1087	(	_	
5-23	1087-1095	patients	_	
5-24	1096-1097	>	_	
5-25	1098-1106	controls	_	
5-26	1106-1107	,	_	
5-27	1108-1109	P	_	
5-28	1110-1111	=	_	
5-29	1112-1116	.001	_	
5-30	1116-1117	)	_	
5-31	1117-1118	,	_	
5-32	1119-1123	left	_	
5-33	1124-1127	CEN	_	
5-34	1128-1131	and	_	
5-35	1132-1136	left	_	
5-36	1137-1140	VAN	_	
5-37	1141-1142	(	_	
5-38	1142-1143	P	_	
5-39	1144-1145	=	_	
5-40	1146-1150	.002	_	
5-41	1150-1151	)	_	
5-42	1151-1152	,	_	
5-43	1153-1156	and	_	
5-44	1157-1164	between	_	
5-45	1165-1174	posterior	_	
5-46	1175-1182	default	_	
5-47	1183-1187	mode	_	
5-48	1188-1195	network	_	
5-49	1196-1199	and	_	
5-50	1200-1208	auditory	_	
5-51	1209-1216	network	_	
5-52	1217-1218	(	_	
5-53	1218-1219	P	_	
5-54	1220-1221	=	_	
5-55	1222-1226	.006	_	
5-56	1226-1227	)	_	
5-57	1227-1228	.	_	

#Text=Association between network connectivity and clinical characteristics was found as interactions between the effects of group and sustained attention (P = .005) and between group and processing speed (P = .007) on the connectivity between right CEN and right VAN.
6-1	1229-1240	Association	_	
6-2	1241-1248	between	_	
6-3	1249-1256	network	_	
6-4	1257-1269	connectivity	_	
6-5	1270-1273	and	_	
6-6	1274-1282	clinical	_	
6-7	1283-1298	characteristics	_	
6-8	1299-1302	was	_	
6-9	1303-1308	found	_	
6-10	1309-1311	as	_	
6-11	1312-1324	interactions	_	
6-12	1325-1332	between	_	
6-13	1333-1336	the	_	
6-14	1337-1344	effects	_	
6-15	1345-1347	of	_	
6-16	1348-1353	group	_	
6-17	1354-1357	and	_	
6-18	1358-1367	sustained	_	
6-19	1368-1377	attention	_	
6-20	1378-1379	(	_	
6-21	1379-1380	P	_	
6-22	1381-1382	=	_	
6-23	1383-1387	.005	_	
6-24	1387-1388	)	_	
6-25	1389-1392	and	_	
6-26	1393-1400	between	_	
6-27	1401-1406	group	_	
6-28	1407-1410	and	_	
6-29	1411-1421	processing	_	
6-30	1422-1427	speed	_	
6-31	1428-1429	(	_	
6-32	1429-1430	P	_	
6-33	1431-1432	=	_	
6-34	1433-1437	.007	_	
6-35	1437-1438	)	_	
6-36	1439-1441	on	_	
6-37	1442-1445	the	_	
6-38	1446-1458	connectivity	_	
6-39	1459-1466	between	_	
6-40	1467-1472	right	_	
6-41	1473-1476	CEN	_	
6-42	1477-1480	and	_	
6-43	1481-1486	right	_	
6-44	1487-1490	VAN	_	
6-45	1490-1491	.	_	

#Text=Conclusions
#Text=Our findings suggest that the early phase of schizophrenia is characterized by increased connectivity between fronto-parietal networks suggested to be involved in the control of cognitive and sensory functions.
7-1	1492-1503	Conclusions	_	
7-2	1504-1507	Our	_	
7-3	1508-1516	findings	_	
7-4	1517-1524	suggest	_	
7-5	1525-1529	that	_	
7-6	1530-1533	the	_	
7-7	1534-1539	early	_	
7-8	1540-1545	phase	_	
7-9	1546-1548	of	_	
7-10	1549-1562	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
7-11	1563-1565	is	_	
7-12	1566-1579	characterized	_	
7-13	1580-1582	by	_	
7-14	1583-1592	increased	_	
7-15	1593-1605	connectivity	_	
7-16	1606-1613	between	_	
7-17	1614-1629	fronto-parietal	_	
7-18	1630-1638	networks	_	
7-19	1639-1648	suggested	_	
7-20	1649-1651	to	_	
7-21	1652-1654	be	_	
7-22	1655-1663	involved	_	
7-23	1664-1666	in	_	
7-24	1667-1670	the	_	
7-25	1671-1678	control	_	
7-26	1679-1681	of	_	
7-27	1682-1691	cognitive	_	
7-28	1692-1695	and	_	
7-29	1696-1703	sensory	_	
7-30	1704-1713	functions	_	
7-31	1713-1714	.	_	

#Text=Moreover, the present study suggests that the problem of not disengaging the VAN leads to difficulties with attention and possibly subjective awareness.
8-1	1715-1723	Moreover	_	
8-2	1723-1724	,	_	
8-3	1725-1728	the	_	
8-4	1729-1736	present	_	
8-5	1737-1742	study	_	
8-6	1743-1751	suggests	_	
8-7	1752-1756	that	_	
8-8	1757-1760	the	_	
8-9	1761-1768	problem	_	
8-10	1769-1771	of	_	
8-11	1772-1775	not	_	
8-12	1776-1787	disengaging	_	
8-13	1788-1791	the	_	
8-14	1792-1795	VAN	_	
8-15	1796-1801	leads	_	
8-16	1802-1804	to	_	
8-17	1805-1817	difficulties	_	
8-18	1818-1822	with	_	
8-19	1823-1832	attention	_	
8-20	1833-1836	and	_	
8-21	1837-1845	possibly	_	
8-22	1846-1856	subjective	_	
8-23	1857-1866	awareness	_	
8-24	1866-1867	.	_	

#Text=Introduction
#Text=One of the most direct ways to study the functional organization of the human brain in vivo is by measuring the blood-oxygen-level-dependent (BOLD) -signal under resting conditions.
9-1	1868-1880	Introduction	_	
9-2	1881-1884	One	_	
9-3	1885-1887	of	_	
9-4	1888-1891	the	_	
9-5	1892-1896	most	_	
9-6	1897-1903	direct	_	
9-7	1904-1908	ways	_	
9-8	1909-1911	to	_	
9-9	1912-1917	study	_	
9-10	1918-1921	the	_	
9-11	1922-1932	functional	_	
9-12	1933-1945	organization	_	
9-13	1946-1948	of	_	
9-14	1949-1952	the	_	
9-15	1953-1958	human	_	
9-16	1959-1964	brain	_	
9-17	1965-1967	in	_	
9-18	1968-1972	vivo	_	
9-19	1973-1975	is	_	
9-20	1976-1978	by	_	
9-21	1979-1988	measuring	_	
9-22	1989-1992	the	_	
9-23	1993-2021	blood-oxygen-level-dependent	_	
9-24	2022-2023	(	_	
9-25	2023-2027	BOLD	_	
9-26	2027-2028	)	_	
9-27	2029-2030	-	_	
9-28	2030-2036	signal	_	
9-29	2037-2042	under	_	
9-30	2043-2050	resting	_	
9-31	2051-2061	conditions	_	
9-32	2061-2062	.	_	

#Text=This method has led to the discovery of robust patterns of correlated activity also known as intrinsic connectivity networks (ICN’s).
10-1	2063-2067	This	_	
10-2	2068-2074	method	_	
10-3	2075-2078	has	_	
10-4	2079-2082	led	_	
10-5	2083-2085	to	_	
10-6	2086-2089	the	_	
10-7	2090-2099	discovery	_	
10-8	2100-2102	of	_	
10-9	2103-2109	robust	_	
10-10	2110-2118	patterns	_	
10-11	2119-2121	of	_	
10-12	2122-2132	correlated	_	
10-13	2133-2141	activity	_	
10-14	2142-2146	also	_	
10-15	2147-2152	known	_	
10-16	2153-2155	as	_	
10-17	2156-2165	intrinsic	_	
10-18	2166-2178	connectivity	_	
10-19	2179-2187	networks	_	
10-20	2188-2189	(	_	
10-21	2189-2192	ICN	_	
10-22	2192-2193	’	_	
10-23	2193-2194	s	_	
10-24	2194-2195	)	_	
10-25	2195-2196	.	_	

#Text=Some of these networks have been shown to be associated with core neurocognitive domains and sensory functions like working memory and attention, (central executive network, CEN), self-monitoring (default mode network, DMN), externally directed cognition (dorsal and ventral attention networks, DAN and VAN), experience of salience (salience network, SN), and auditory processing (auditory network).
11-1	2197-2201	Some	_	
11-2	2202-2204	of	_	
11-3	2205-2210	these	_	
11-4	2211-2219	networks	_	
11-5	2220-2224	have	_	
11-6	2225-2229	been	_	
11-7	2230-2235	shown	_	
11-8	2236-2238	to	_	
11-9	2239-2241	be	_	
11-10	2242-2252	associated	_	
11-11	2253-2257	with	_	
11-12	2258-2262	core	_	
11-13	2263-2277	neurocognitive	_	
11-14	2278-2285	domains	_	
11-15	2286-2289	and	_	
11-16	2290-2297	sensory	_	
11-17	2298-2307	functions	_	
11-18	2308-2312	like	_	
11-19	2313-2320	working	_	
11-20	2321-2327	memory	_	
11-21	2328-2331	and	_	
11-22	2332-2341	attention	_	
11-23	2341-2342	,	_	
11-24	2343-2344	(	_	
11-25	2344-2351	central	_	
11-26	2352-2361	executive	_	
11-27	2362-2369	network	_	
11-28	2369-2370	,	_	
11-29	2371-2374	CEN	_	
11-30	2374-2375	)	_	
11-31	2375-2376	,	_	
11-32	2377-2392	self-monitoring	_	
11-33	2393-2394	(	_	
11-34	2394-2401	default	_	
11-35	2402-2406	mode	_	
11-36	2407-2414	network	_	
11-37	2414-2415	,	_	
11-38	2416-2419	DMN	_	
11-39	2419-2420	)	_	
11-40	2420-2421	,	_	
11-41	2422-2432	externally	_	
11-42	2433-2441	directed	_	
11-43	2442-2451	cognition	_	
11-44	2452-2453	(	_	
11-45	2453-2459	dorsal	_	
11-46	2460-2463	and	_	
11-47	2464-2471	ventral	_	
11-48	2472-2481	attention	_	
11-49	2482-2490	networks	_	
11-50	2490-2491	,	_	
11-51	2492-2495	DAN	_	
11-52	2496-2499	and	_	
11-53	2500-2503	VAN	_	
11-54	2503-2504	)	_	
11-55	2504-2505	,	_	
11-56	2506-2516	experience	_	
11-57	2517-2519	of	_	
11-58	2520-2528	salience	_	
11-59	2529-2530	(	_	
11-60	2530-2538	salience	_	
11-61	2539-2546	network	_	
11-62	2546-2547	,	_	
11-63	2548-2550	SN	_	
11-64	2550-2551	)	_	
11-65	2551-2552	,	_	
11-66	2553-2556	and	_	
11-67	2557-2565	auditory	_	
11-68	2566-2576	processing	_	
11-69	2577-2578	(	_	
11-70	2578-2586	auditory	_	
11-71	2587-2594	network	_	
11-72	2594-2595	)	_	
11-73	2595-2596	.	_	

#Text=Since schizophrenia is characterized by abnormalities in these functions the associated ICN’s have been incorporated into a number of models for schizophrenia.
12-1	2597-2602	Since	_	
12-2	2603-2616	schizophrenia	_	
12-3	2617-2619	is	_	
12-4	2620-2633	characterized	_	
12-5	2634-2636	by	_	
12-6	2637-2650	abnormalities	_	
12-7	2651-2653	in	_	
12-8	2654-2659	these	_	
12-9	2660-2669	functions	_	
12-10	2670-2673	the	_	
12-11	2674-2684	associated	_	
12-12	2685-2688	ICN	_	
12-13	2688-2689	’	_	
12-14	2689-2690	s	_	
12-15	2691-2695	have	_	
12-16	2696-2700	been	_	
12-17	2701-2713	incorporated	_	
12-18	2714-2718	into	_	
12-19	2719-2720	a	_	
12-20	2721-2727	number	_	
12-21	2728-2730	of	_	
12-22	2731-2737	models	_	
12-23	2738-2741	for	_	
12-24	2742-2755	schizophrenia	_	
12-25	2755-2756	.	_	

#Text=First, schizophrenia has been proposed to be associated with errors in self-monitoring as a result of decreased communication within the DMN and/or abnormal interaction between the DMN and DAN.
13-1	2757-2762	First	_	
13-2	2762-2763	,	_	
13-3	2764-2777	schizophrenia	_	
13-4	2778-2781	has	_	
13-5	2782-2786	been	_	
13-6	2787-2795	proposed	_	
13-7	2796-2798	to	_	
13-8	2799-2801	be	_	
13-9	2802-2812	associated	_	
13-10	2813-2817	with	_	
13-11	2818-2824	errors	_	
13-12	2825-2827	in	_	
13-13	2828-2843	self-monitoring	_	
13-14	2844-2846	as	_	
13-15	2847-2848	a	_	
13-16	2849-2855	result	_	
13-17	2856-2858	of	_	
13-18	2859-2868	decreased	_	
13-19	2869-2882	communication	_	
13-20	2883-2889	within	_	
13-21	2890-2893	the	_	
13-22	2894-2897	DMN	_	
13-23	2898-2901	and	_	
13-24	2901-2902	/	_	
13-25	2902-2904	or	_	
13-26	2905-2913	abnormal	_	
13-27	2914-2925	interaction	_	
13-28	2926-2933	between	_	
13-29	2934-2937	the	_	
13-30	2938-2941	DMN	_	
13-31	2942-2945	and	_	
13-32	2946-2949	DAN	_	
13-33	2949-2950	.	_	

#Text=Along the same lines, aberrant DMN activity has been proposed to be the result of a failure of the fronto-parietal control system (CEN, SN and VAN) to control the DMN activity.
14-1	2951-2956	Along	_	
14-2	2957-2960	the	_	
14-3	2961-2965	same	_	
14-4	2966-2971	lines	_	
14-5	2971-2972	,	_	
14-6	2973-2981	aberrant	_	
14-7	2982-2985	DMN	_	
14-8	2986-2994	activity	_	
14-9	2995-2998	has	_	
14-10	2999-3003	been	_	
14-11	3004-3012	proposed	_	
14-12	3013-3015	to	_	
14-13	3016-3018	be	_	
14-14	3019-3022	the	_	
14-15	3023-3029	result	_	
14-16	3030-3032	of	_	
14-17	3033-3034	a	_	
14-18	3035-3042	failure	_	
14-19	3043-3045	of	_	
14-20	3046-3049	the	_	
14-21	3050-3065	fronto-parietal	_	
14-22	3066-3073	control	_	
14-23	3074-3080	system	_	
14-24	3081-3082	(	_	
14-25	3082-3085	CEN	_	
14-26	3085-3086	,	_	
14-27	3087-3089	SN	_	
14-28	3090-3093	and	_	
14-29	3094-3097	VAN	_	
14-30	3097-3098	)	_	
14-31	3099-3101	to	_	
14-32	3102-3109	control	_	
14-33	3110-3113	the	_	
14-34	3114-3117	DMN	_	
14-35	3118-3126	activity	_	
14-36	3126-3127	.	_	

#Text=Second, the SN models propose that psychosis occur as a result of inappropriately attached salience.
15-1	3128-3134	Second	_	
15-2	3134-3135	,	_	
15-3	3136-3139	the	_	
15-4	3140-3142	SN	_	
15-5	3143-3149	models	_	
15-6	3150-3157	propose	_	
15-7	3158-3162	that	_	
15-8	3163-3172	psychosis	_	
15-9	3173-3178	occur	_	
15-10	3179-3181	as	_	
15-11	3182-3183	a	_	
15-12	3184-3190	result	_	
15-13	3191-3193	of	_	
15-14	3194-3209	inappropriately	_	
15-15	3210-3218	attached	_	
15-16	3219-3227	salience	_	
15-17	3227-3228	.	_	

#Text=Third, other models focus on network abnormalities between regions involved in directed effort (dorsal anterior cingulate cortex [dACC], posterior cingulate cortex [PCC] and hippocampus) and auditory processing (auditory cortex).
16-1	3229-3234	Third	_	
16-2	3234-3235	,	_	
16-3	3236-3241	other	_	
16-4	3242-3248	models	_	
16-5	3249-3254	focus	_	
16-6	3255-3257	on	_	
16-7	3258-3265	network	_	
16-8	3266-3279	abnormalities	_	
16-9	3280-3287	between	_	
16-10	3288-3295	regions	_	
16-11	3296-3304	involved	_	
16-12	3305-3307	in	_	
16-13	3308-3316	directed	_	
16-14	3317-3323	effort	_	
16-15	3324-3325	(	_	
16-16	3325-3331	dorsal	_	
16-17	3332-3340	anterior	_	
16-18	3341-3350	cingulate	_	
16-19	3351-3357	cortex	_	
16-20	3358-3359	[	_	
16-21	3359-3363	dACC	_	
16-22	3363-3364	]	_	
16-23	3364-3365	,	_	
16-24	3366-3375	posterior	_	
16-25	3376-3385	cingulate	_	
16-26	3386-3392	cortex	_	
16-27	3393-3394	[	_	
16-28	3394-3397	PCC	_	
16-29	3397-3398	]	_	
16-30	3399-3402	and	_	
16-31	3403-3414	hippocampus	_	
16-32	3414-3415	)	_	
16-33	3416-3419	and	_	
16-34	3420-3428	auditory	_	
16-35	3429-3439	processing	_	
16-36	3440-3441	(	_	
16-37	3441-3449	auditory	_	
16-38	3450-3456	cortex	_	
16-39	3456-3457	)	_	
16-40	3457-3458	.	_	

#Text=The overall strength of these models is the focus on system-level neuropathology because the diverse symptoms of schizophrenia are likely to be associated with a break down in large-scale neuronal networks.
17-1	3459-3462	The	_	
17-2	3463-3470	overall	_	
17-3	3471-3479	strength	_	
17-4	3480-3482	of	_	
17-5	3483-3488	these	_	
17-6	3489-3495	models	_	
17-7	3496-3498	is	_	
17-8	3499-3502	the	_	
17-9	3503-3508	focus	_	
17-10	3509-3511	on	_	
17-11	3512-3524	system-level	_	
17-12	3525-3539	neuropathology	_	
17-13	3540-3547	because	_	
17-14	3548-3551	the	_	
17-15	3552-3559	diverse	_	
17-16	3560-3568	symptoms	_	
17-17	3569-3571	of	_	
17-18	3572-3585	schizophrenia	_	
17-19	3586-3589	are	_	
17-20	3590-3596	likely	_	
17-21	3597-3599	to	_	
17-22	3600-3602	be	_	
17-23	3603-3613	associated	_	
17-24	3614-3618	with	_	
17-25	3619-3620	a	_	
17-26	3621-3626	break	_	
17-27	3627-3631	down	_	
17-28	3632-3634	in	_	
17-29	3635-3646	large-scale	_	
17-30	3647-3655	neuronal	_	
17-31	3656-3664	networks	_	
17-32	3664-3665	.	_	

#Text=Several studies have reported alterations in functional connectivity in medicated long-term ill patients with schizophrenia.
18-1	3666-3673	Several	_	
18-2	3674-3681	studies	_	
18-3	3682-3686	have	_	
18-4	3687-3695	reported	_	
18-5	3696-3707	alterations	_	
18-6	3708-3710	in	_	
18-7	3711-3721	functional	_	
18-8	3722-3734	connectivity	_	
18-9	3735-3737	in	_	
18-10	3738-3747	medicated	_	
18-11	3748-3757	long-term	_	
18-12	3758-3761	ill	_	
18-13	3762-3770	patients	_	
18-14	3771-3775	with	_	
18-15	3776-3789	schizophrenia	_	
18-16	3789-3790	.	_	

#Text=Despite a trend towards alterations in cortico-subcortical networks, prefrontal cortex and the DMN, results so far have been inconsistent.
19-1	3791-3798	Despite	_	
19-2	3799-3800	a	_	
19-3	3801-3806	trend	_	
19-4	3807-3814	towards	_	
19-5	3815-3826	alterations	_	
19-6	3827-3829	in	_	
19-7	3830-3849	cortico-subcortical	_	
19-8	3850-3858	networks	_	
19-9	3858-3859	,	_	
19-10	3860-3870	prefrontal	_	
19-11	3871-3877	cortex	_	
19-12	3878-3881	and	_	
19-13	3882-3885	the	_	
19-14	3886-3889	DMN	_	
19-15	3889-3890	,	_	
19-16	3891-3898	results	_	
19-17	3899-3901	so	_	
19-18	3902-3905	far	_	
19-19	3906-3910	have	_	
19-20	3911-3915	been	_	
19-21	3916-3928	inconsistent	_	
19-22	3928-3929	.	_	

#Text=This could be explained by the presence of known confounders such as medication and disease progression.
20-1	3930-3934	This	_	
20-2	3935-3940	could	_	
20-3	3941-3943	be	_	
20-4	3944-3953	explained	_	
20-5	3954-3956	by	_	
20-6	3957-3960	the	_	
20-7	3961-3969	presence	_	
20-8	3970-3972	of	_	
20-9	3973-3978	known	_	
20-10	3979-3990	confounders	_	
20-11	3991-3995	such	_	
20-12	3996-3998	as	_	
20-13	3999-4009	medication	_	
20-14	4010-4013	and	_	
20-15	4014-4021	disease	_	
20-16	4022-4033	progression	_	
20-17	4033-4034	.	_	

#Text=Narrowing the search to studies in Antipsychotic-Naïve First-Episode (ANFE) patients does not provide a clear picture, eg, one study found higher connectivity between PCC, a central part of the DMN, and task positive regions such as dorsolateral prefrontal cortex (DLPFC) compared to another study reporting no alterations of DLPFC connectivity.
21-1	4035-4044	Narrowing	_	
21-2	4045-4048	the	_	
21-3	4049-4055	search	_	
21-4	4056-4058	to	_	
21-5	4059-4066	studies	_	
21-6	4067-4069	in	_	
21-7	4070-4089	Antipsychotic-Naïve	_	
21-8	4090-4103	First-Episode	_	
21-9	4104-4105	(	_	
21-10	4105-4109	ANFE	_	
21-11	4109-4110	)	_	
21-12	4111-4119	patients	_	
21-13	4120-4124	does	_	
21-14	4125-4128	not	_	
21-15	4129-4136	provide	_	
21-16	4137-4138	a	_	
21-17	4139-4144	clear	_	
21-18	4145-4152	picture	_	
21-19	4152-4153	,	_	
21-20	4154-4156	eg	_	
21-21	4156-4157	,	_	
21-22	4158-4161	one	_	
21-23	4162-4167	study	_	
21-24	4168-4173	found	_	
21-25	4174-4180	higher	_	
21-26	4181-4193	connectivity	_	
21-27	4194-4201	between	_	
21-28	4202-4205	PCC	_	
21-29	4205-4206	,	_	
21-30	4207-4208	a	_	
21-31	4209-4216	central	_	
21-32	4217-4221	part	_	
21-33	4222-4224	of	_	
21-34	4225-4228	the	_	
21-35	4229-4232	DMN	_	
21-36	4232-4233	,	_	
21-37	4234-4237	and	_	
21-38	4238-4242	task	_	
21-39	4243-4251	positive	_	
21-40	4252-4259	regions	_	
21-41	4260-4264	such	_	
21-42	4265-4267	as	_	
21-43	4268-4280	dorsolateral	_	
21-44	4281-4291	prefrontal	_	
21-45	4292-4298	cortex	_	
21-46	4299-4300	(	_	
21-47	4300-4305	DLPFC	_	
21-48	4305-4306	)	_	
21-49	4307-4315	compared	_	
21-50	4316-4318	to	_	
21-51	4319-4326	another	_	
21-52	4327-4332	study	_	
21-53	4333-4342	reporting	_	
21-54	4343-4345	no	_	
21-55	4346-4357	alterations	_	
21-56	4358-4360	of	_	
21-57	4361-4366	DLPFC	_	
21-58	4367-4379	connectivity	_	
21-59	4379-4380	.	_	

#Text=Furthermore, one study found increased connectivity within the DMN and increased connectivity between DMN and fronto-parietal networks in ANFE patients, whereas another study reported decreased connectivity between DMN and medial prefrontal cortex (MPFC) that is a part of the DMN, and no alteration in connectivity between DMN and fronto-parietal networks.
22-1	4381-4392	Furthermore	_	
22-2	4392-4393	,	_	
22-3	4394-4397	one	_	
22-4	4398-4403	study	_	
22-5	4404-4409	found	_	
22-6	4410-4419	increased	_	
22-7	4420-4432	connectivity	_	
22-8	4433-4439	within	_	
22-9	4440-4443	the	_	
22-10	4444-4447	DMN	_	
22-11	4448-4451	and	_	
22-12	4452-4461	increased	_	
22-13	4462-4474	connectivity	_	
22-14	4475-4482	between	_	
22-15	4483-4486	DMN	_	
22-16	4487-4490	and	_	
22-17	4491-4506	fronto-parietal	_	
22-18	4507-4515	networks	_	
22-19	4516-4518	in	_	
22-20	4519-4523	ANFE	_	
22-21	4524-4532	patients	_	
22-22	4532-4533	,	_	
22-23	4534-4541	whereas	_	
22-24	4542-4549	another	_	
22-25	4550-4555	study	_	
22-26	4556-4564	reported	_	
22-27	4565-4574	decreased	_	
22-28	4575-4587	connectivity	_	
22-29	4588-4595	between	_	
22-30	4596-4599	DMN	_	
22-31	4600-4603	and	_	
22-32	4604-4610	medial	_	
22-33	4611-4621	prefrontal	_	
22-34	4622-4628	cortex	_	
22-35	4629-4630	(	_	
22-36	4630-4634	MPFC	_	
22-37	4634-4635	)	_	
22-38	4636-4640	that	_	
22-39	4641-4643	is	_	
22-40	4644-4645	a	_	
22-41	4646-4650	part	_	
22-42	4651-4653	of	_	
22-43	4654-4657	the	_	
22-44	4658-4661	DMN	_	
22-45	4661-4662	,	_	
22-46	4663-4666	and	_	
22-47	4667-4669	no	_	
22-48	4670-4680	alteration	_	
22-49	4681-4683	in	_	
22-50	4684-4696	connectivity	_	
22-51	4697-4704	between	_	
22-52	4705-4708	DMN	_	
22-53	4709-4712	and	_	
22-54	4713-4728	fronto-parietal	_	
22-55	4729-4737	networks	_	
22-56	4737-4738	.	_	

#Text=Because of this diversity of findings, the questions of which network alterations are present in the early course of schizophrenia and how they relate to the clinical manifestations in the antipsychotic-naïve state are largely unanswered.
23-1	4739-4746	Because	_	
23-2	4747-4749	of	_	
23-3	4750-4754	this	_	
23-4	4755-4764	diversity	_	
23-5	4765-4767	of	_	
23-6	4768-4776	findings	_	
23-7	4776-4777	,	_	
23-8	4778-4781	the	_	
23-9	4782-4791	questions	_	
23-10	4792-4794	of	_	
23-11	4795-4800	which	_	
23-12	4801-4808	network	_	
23-13	4809-4820	alterations	_	
23-14	4821-4824	are	_	
23-15	4825-4832	present	_	
23-16	4833-4835	in	_	
23-17	4836-4839	the	_	
23-18	4840-4845	early	_	
23-19	4846-4852	course	_	
23-20	4853-4855	of	_	
23-21	4856-4869	schizophrenia	_	
23-22	4870-4873	and	_	
23-23	4874-4877	how	_	
23-24	4878-4882	they	_	
23-25	4883-4889	relate	_	
23-26	4890-4892	to	_	
23-27	4893-4896	the	_	
23-28	4897-4905	clinical	_	
23-29	4906-4920	manifestations	_	
23-30	4921-4923	in	_	
23-31	4924-4927	the	_	
23-32	4928-4947	antipsychotic-naïve	_	
23-33	4948-4953	state	_	
23-34	4954-4957	are	_	
23-35	4958-4965	largely	_	
23-36	4966-4976	unanswered	_	
23-37	4976-4977	.	_	

#Text=In the present study, we used a large cohort of well-characterized ANFE patients to evaluate the abovementioned intrinsic large-scale network models for schizophrenia.
24-1	4978-4980	In	_	
24-2	4981-4984	the	_	
24-3	4985-4992	present	_	
24-4	4993-4998	study	_	
24-5	4998-4999	,	_	
24-6	5000-5002	we	_	
24-7	5003-5007	used	_	
24-8	5008-5009	a	_	
24-9	5010-5015	large	_	
24-10	5016-5022	cohort	_	
24-11	5023-5025	of	_	
24-12	5026-5044	well-characterized	_	
24-13	5045-5049	ANFE	_	
24-14	5050-5058	patients	_	
24-15	5059-5061	to	_	
24-16	5062-5070	evaluate	_	
24-17	5071-5074	the	_	
24-18	5075-5089	abovementioned	_	
24-19	5090-5099	intrinsic	_	
24-20	5100-5111	large-scale	_	
24-21	5112-5119	network	_	
24-22	5120-5126	models	_	
24-23	5127-5130	for	_	
24-24	5131-5144	schizophrenia	_	
24-25	5144-5145	.	_	

#Text=We expected positive symptoms to be associated with DMN connectivity due to the role of the DMN in self-monitoring.
25-1	5146-5148	We	_	
25-2	5149-5157	expected	_	
25-3	5158-5166	positive	_	
25-4	5167-5175	symptoms	_	
25-5	5176-5178	to	_	
25-6	5179-5181	be	_	
25-7	5182-5192	associated	_	
25-8	5193-5197	with	_	
25-9	5198-5201	DMN	_	
25-10	5202-5214	connectivity	_	
25-11	5215-5218	due	_	
25-12	5219-5221	to	_	
25-13	5222-5225	the	_	
25-14	5226-5230	role	_	
25-15	5231-5233	of	_	
25-16	5234-5237	the	_	
25-17	5238-5241	DMN	_	
25-18	5242-5244	in	_	
25-19	5245-5260	self-monitoring	_	
25-20	5260-5261	.	_	

#Text=Moreover, because most studies suggest a global, nonspecific relationship between network alterations and cognitive deficits, we expected a generalized pattern of interactions between group and different cognitive measures on network connectivity.
26-1	5262-5270	Moreover	_	
26-2	5270-5271	,	_	
26-3	5272-5279	because	_	
26-4	5280-5284	most	_	
26-5	5285-5292	studies	_	
26-6	5293-5300	suggest	_	
26-7	5301-5302	a	_	
26-8	5303-5309	global	_	
26-9	5309-5310	,	_	
26-10	5311-5322	nonspecific	_	
26-11	5323-5335	relationship	_	
26-12	5336-5343	between	_	
26-13	5344-5351	network	_	
26-14	5352-5363	alterations	_	
26-15	5364-5367	and	_	
26-16	5368-5377	cognitive	_	
26-17	5378-5386	deficits	_	
26-18	5386-5387	,	_	
26-19	5388-5390	we	_	
26-20	5391-5399	expected	_	
26-21	5400-5401	a	_	
26-22	5402-5413	generalized	_	
26-23	5414-5421	pattern	_	
26-24	5422-5424	of	_	
26-25	5425-5437	interactions	_	
26-26	5438-5445	between	_	
26-27	5446-5451	group	_	
26-28	5452-5455	and	_	
26-29	5456-5465	different	_	
26-30	5466-5475	cognitive	_	
26-31	5476-5484	measures	_	
26-32	5485-5487	on	_	
26-33	5488-5495	network	_	
26-34	5496-5508	connectivity	_	
26-35	5508-5509	.	_	

#Text=Methods
#Text=The study was conducted in accordance with the Declaration of Helsinki II and approved by the Danish national Committee on Biomedical Research Ethics (H-D-2008-088).
27-1	5510-5517	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
27-2	5518-5521	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-3	5522-5527	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-4	5528-5531	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-5	5532-5541	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-6	5542-5544	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-7	5545-5555	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-8	5556-5560	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-9	5561-5564	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-10	5565-5576	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-11	5577-5579	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-12	5580-5588	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-13	5589-5591	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-14	5592-5595	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-15	5596-5604	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-16	5605-5607	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-17	5608-5611	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-18	5612-5618	Danish	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-19	5619-5627	national	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-20	5628-5637	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-21	5638-5640	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-22	5641-5651	Biomedical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-23	5652-5660	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-24	5661-5667	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
27-25	5668-5669	(	_	
27-26	5669-5672	H-D	_	
27-27	5672-5673	-	_	
27-28	5673-5677	2008	_	
27-29	5677-5678	-	_	
27-30	5678-5681	088	_	
27-31	5681-5682	)	_	
27-32	5682-5683	.	_	

#Text=All participants gave signed informed consent to their participation.
28-1	5684-5687	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-2	5688-5700	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-3	5701-5705	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-4	5706-5712	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-5	5713-5721	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-6	5722-5729	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-7	5730-5732	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-8	5733-5738	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-9	5739-5752	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-10	5752-5753	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants
#Text=As part of a multimodal clinical study (PECANS, ClinicalTrials.gov identifier: NCT01154829) a total number of 69 ANFE patients aged 18–45 years were recruited from psychiatric centers in the capital region of Denmark from December 2008 to December 2013.
29-1	5754-5766	Participants	_	
29-2	5767-5769	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-3	5770-5774	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-4	5775-5777	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-5	5778-5779	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-6	5780-5790	multimodal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-7	5791-5799	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-8	5800-5805	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-9	5806-5807	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-10	5807-5813	PECANS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-11	5813-5814	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-12	5815-5833	ClinicalTrials.gov	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-13	5834-5844	identifier	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-14	5844-5845	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-15	5846-5857	NCT01154829	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-16	5857-5858	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-17	5859-5860	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-18	5861-5866	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-19	5867-5873	number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-20	5874-5876	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-21	5877-5879	69	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-22	5880-5884	ANFE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-23	5885-5893	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-24	5894-5898	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-25	5899-5901	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-26	5901-5902	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-27	5902-5904	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-28	5905-5910	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-29	5911-5915	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-30	5916-5925	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-31	5926-5930	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-32	5931-5942	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-33	5943-5950	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-34	5951-5953	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-35	5954-5957	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-36	5958-5965	capital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-37	5966-5972	region	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-38	5973-5975	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-39	5976-5983	Denmark	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-40	5984-5988	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-41	5989-5997	December	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-42	5998-6002	2008	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-43	6003-6005	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-44	6006-6014	December	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-45	6015-6019	2013	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
29-46	6019-6020	.	_	

#Text=Fifty patients were scanned with functional magnetic resonance imaging under resting conditions.
30-1	6021-6026	Fifty	_	
30-2	6027-6035	patients	_	
30-3	6036-6040	were	_	
30-4	6041-6048	scanned	_	
30-5	6049-6053	with	_	
30-6	6054-6064	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
30-7	6065-6073	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
30-8	6074-6083	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
30-9	6084-6091	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
30-10	6092-6097	under	_	
30-11	6098-6105	resting	_	
30-12	6106-6116	conditions	_	
30-13	6116-6117	.	_	

#Text=Three patients were excluded due to excessive head motion leaving 47 patients for further analysis.
31-1	6118-6123	Three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-2	6124-6132	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-3	6133-6137	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-4	6138-6146	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-5	6147-6150	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-6	6151-6153	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-7	6154-6163	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-8	6164-6168	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-9	6169-6175	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-10	6176-6183	leaving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-11	6184-6186	47	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-12	6187-6195	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-13	6196-6199	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-14	6200-6207	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-15	6208-6216	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
31-16	6216-6217	.	_	

#Text=The inclusion criterion was a first-episode of schizophrenia or schizoaffective disorder (ICD-10 criteria).
32-1	6218-6221	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-2	6222-6231	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-3	6232-6241	criterion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-4	6242-6245	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-5	6246-6247	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-6	6248-6261	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-7	6262-6264	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-8	6265-6278	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
32-9	6279-6281	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-10	6282-6297	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[10]	
32-11	6298-6306	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[10]	
32-12	6307-6308	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-13	6308-6311	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-14	6311-6312	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-15	6312-6314	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-16	6315-6323	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-17	6323-6324	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
32-18	6324-6325	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Exclusion criteria were any prior or current treatment with antipsychotic medication.
33-1	6326-6335	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-2	6336-6344	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-3	6345-6349	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-4	6350-6353	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-5	6354-6359	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-6	6360-6362	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-7	6363-6370	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-8	6371-6380	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-9	6381-6385	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-10	6386-6399	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-11	6400-6410	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-12	6410-6411	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=An equal number (n = 47) of healthy controls matched on age, gender, and parental socioeconomic status, with no history of psychiatric illness and no schizophrenia spectrum disorder in first-degree relatives were recruited via a specialized research website.
34-1	6412-6414	An	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-2	6415-6420	equal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-3	6421-6427	number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-4	6428-6429	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-5	6429-6430	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-6	6431-6432	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-7	6433-6435	47	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-8	6435-6436	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-9	6437-6439	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-10	6440-6447	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
34-11	6448-6456	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
34-12	6457-6464	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-13	6465-6467	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-14	6468-6471	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-15	6471-6472	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-16	6473-6479	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-17	6479-6480	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-18	6481-6484	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-19	6485-6493	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-20	6494-6507	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-21	6508-6514	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-22	6514-6515	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-23	6516-6520	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-24	6521-6523	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-25	6524-6531	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-26	6532-6534	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-27	6535-6546	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-28	6547-6554	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-29	6555-6558	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-30	6559-6561	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-31	6562-6575	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
34-32	6576-6584	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-33	6585-6593	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-34	6594-6596	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-35	6597-6609	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-36	6610-6619	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-37	6620-6624	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-38	6625-6634	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-39	6635-6638	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-40	6639-6640	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-41	6641-6652	specialized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-42	6653-6661	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-43	6662-6669	website	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-44	6669-6670	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Additional exclusion criteria for all participants were antidepressants within the last month, severe somatic illness, a history of severe head injury, current diagnosis of drug dependence (ICD-10 criteria) with the acceptance of current occasional drug use (assessed with urine test).
35-1	6671-6681	Additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-2	6682-6691	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-3	6692-6700	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-4	6701-6704	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-5	6705-6708	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-6	6709-6721	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-7	6722-6726	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-8	6727-6742	antidepressants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-9	6743-6749	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-10	6750-6753	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-11	6754-6758	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-12	6759-6764	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-13	6764-6765	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-14	6766-6772	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-15	6773-6780	somatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-16	6781-6788	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-17	6788-6789	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-18	6790-6791	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-19	6792-6799	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-20	6800-6802	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-21	6803-6809	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-22	6810-6814	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-23	6815-6821	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-24	6821-6822	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-25	6823-6830	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-26	6831-6840	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-27	6841-6843	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-28	6844-6848	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-29	6849-6859	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-30	6860-6861	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-31	6861-6864	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-32	6864-6865	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-33	6865-6867	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-34	6868-6876	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-35	6876-6877	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-36	6878-6882	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-37	6883-6886	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-38	6887-6897	acceptance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-39	6898-6900	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-40	6901-6908	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-41	6909-6919	occasional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-42	6920-6924	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-43	6925-6928	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-44	6929-6930	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-45	6930-6938	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-46	6939-6943	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-47	6944-6949	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-48	6950-6954	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-49	6954-6955	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
35-50	6955-6956	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Benzodiazepines were not allowed 12 hours prior to scans (demographic data displayed in Table 1).
36-1	6957-6972	Benzodiazepines	_	
36-2	6973-6977	were	_	
36-3	6978-6981	not	_	
36-4	6982-6989	allowed	_	
36-5	6990-6992	12	_	
36-6	6993-6998	hours	_	
36-7	6999-7004	prior	_	
36-8	7005-7007	to	_	
36-9	7008-7013	scans	_	
36-10	7014-7015	(	_	
36-11	7015-7026	demographic	_	
36-12	7027-7031	data	_	
36-13	7032-7041	displayed	_	
36-14	7042-7044	in	_	
36-15	7045-7050	Table	_	
36-16	7051-7052	1	_	
36-17	7052-7053	)	_	
36-18	7053-7054	.	_	

#Text=Data from this cohort on other modalities has been published in a number of studies.
37-1	7055-7059	Data	_	
37-2	7060-7064	from	_	
37-3	7065-7069	this	_	
37-4	7070-7076	cohort	_	
37-5	7077-7079	on	_	
37-6	7080-7085	other	_	
37-7	7086-7096	modalities	_	
37-8	7097-7100	has	_	
37-9	7101-7105	been	_	
37-10	7106-7115	published	_	
37-11	7116-7118	in	_	
37-12	7119-7120	a	_	
37-13	7121-7127	number	_	
37-14	7128-7130	of	_	
37-15	7131-7138	studies	_	
37-16	7138-7139	.	_	

#Text=Demographics, Psychopathology and Cognitive Measures
#Text=\tSchizophrenia Patients (n = 47)\tHealthy Controls (n = 47)\t \tAge: years\t24.6\t24.7\t \tGender (male/female)\t29/18\t29/18\t \tHandedness: Mean EHI-score\t72 (51)\t84 (40)\t \tEducation: years\t12.1 (2.6)\t14.0 (2.7)\t \tDuration of untreated illness: weeks\t59 (69)\t\t \tSmokersa\t10/14/19/1/3\t11/21/11/2/1\t \tPANSS totalb\t82.6 (17.4)\t\t \t PANSS positive\t20.3 (4.3)\t\t \t PANSS negative\t20.5 (7.3)\t\t \t PANSS general\t41.9 (9.3)\t\t \tGAF\t38 (16)\t\t \tGeneral intelligence (estimated IQ)c\t100.8 (19.6)\t111.5 (12.2)*\t \tProcessing Speed (BACS Symbol coding)d\t55.8 (15.1)\t65.4 (9.5)*\t \tSustained attention (CANTAB RVP A’)e\t0.976 (0.017)\t0.987 (0.014)*\t \tShift and flexibility of attention (CANTAB IED, total errors adjusted)f\t28.1 (21.0)\t18.6 (16.5)**\t \t
#Text=
#Text=Note: PANSS, Positive And Negative Syndrome Scale; GAF, General Assessment of Functioning; IQ, intelligence quotient; RVP, Rapid Visual Information Processing; IED, Intra-Extra Dimensional set shift.
38-1	7140-7152	Demographics	_	
38-2	7152-7153	,	_	
38-3	7154-7169	Psychopathology	_	
38-4	7170-7173	and	_	
38-5	7174-7183	Cognitive	_	
38-6	7184-7192	Measures	_	
38-7	7194-7207	Schizophrenia	_	
38-8	7208-7216	Patients	_	
38-9	7217-7218	(	_	
38-10	7218-7219	n	_	
38-11	7220-7221	=	_	
38-12	7222-7224	47	_	
38-13	7224-7225	)	_	
38-14	7226-7233	Healthy	_	
38-15	7234-7242	Controls	_	
38-16	7243-7244	(	_	
38-17	7244-7245	n	_	
38-18	7246-7247	=	_	
38-19	7248-7250	47	_	
38-20	7250-7251	)	_	
38-21	7254-7257	Age	_	
38-22	7257-7258	:	_	
38-23	7259-7264	years	_	
38-24	7265-7269	24.6	_	
38-25	7270-7274	24.7	_	
38-26	7277-7283	Gender	_	
38-27	7284-7285	(	_	
38-28	7285-7289	male	_	
38-29	7289-7290	/	_	
38-30	7290-7296	female	_	
38-31	7296-7297	)	_	
38-32	7298-7300	29	_	
38-33	7300-7301	/	_	
38-34	7301-7303	18	_	
38-35	7304-7306	29	_	
38-36	7306-7307	/	_	
38-37	7307-7309	18	_	
38-38	7312-7322	Handedness	_	
38-39	7322-7323	:	_	
38-40	7324-7328	Mean	_	
38-41	7329-7338	EHI-score	_	
38-42	7339-7341	72	_	
38-43	7342-7343	(	_	
38-44	7343-7345	51	_	
38-45	7345-7346	)	_	
38-46	7347-7349	84	_	
38-47	7350-7351	(	_	
38-48	7351-7353	40	_	
38-49	7353-7354	)	_	
38-50	7357-7366	Education	_	
38-51	7366-7367	:	_	
38-52	7368-7373	years	_	
38-53	7374-7378	12.1	_	
38-54	7379-7380	(	_	
38-55	7380-7383	2.6	_	
38-56	7383-7384	)	_	
38-57	7385-7389	14.0	_	
38-58	7390-7391	(	_	
38-59	7391-7394	2.7	_	
38-60	7394-7395	)	_	
38-61	7398-7406	Duration	_	
38-62	7407-7409	of	_	
38-63	7410-7419	untreated	_	
38-64	7420-7427	illness	_	
38-65	7427-7428	:	_	
38-66	7429-7434	weeks	_	
38-67	7435-7437	59	_	
38-68	7438-7439	(	_	
38-69	7439-7441	69	_	
38-70	7441-7442	)	_	
38-71	7446-7454	Smokersa	_	
38-72	7455-7457	10	_	
38-73	7457-7458	/	_	
38-74	7458-7460	14	_	
38-75	7460-7461	/	_	
38-76	7461-7463	19	_	
38-77	7463-7464	/	_	
38-78	7464-7465	1	_	
38-79	7465-7466	/	_	
38-80	7466-7467	3	_	
38-81	7468-7470	11	_	
38-82	7470-7471	/	_	
38-83	7471-7473	21	_	
38-84	7473-7474	/	_	
38-85	7474-7476	11	_	
38-86	7476-7477	/	_	
38-87	7477-7478	2	_	
38-88	7478-7479	/	_	
38-89	7479-7480	1	_	
38-90	7483-7488	PANSS	_	
38-91	7489-7495	totalb	_	
38-92	7496-7500	82.6	_	
38-93	7501-7502	(	_	
38-94	7502-7506	17.4	_	
38-95	7506-7507	)	_	
38-96	7512-7517	PANSS	_	
38-97	7518-7526	positive	_	
38-98	7527-7531	20.3	_	
38-99	7532-7533	(	_	
38-100	7533-7536	4.3	_	
38-101	7536-7537	)	_	
38-102	7542-7547	PANSS	_	
38-103	7548-7556	negative	_	
38-104	7557-7561	20.5	_	
38-105	7562-7563	(	_	
38-106	7563-7566	7.3	_	
38-107	7566-7567	)	_	
38-108	7572-7577	PANSS	_	
38-109	7578-7585	general	_	
38-110	7586-7590	41.9	_	
38-111	7591-7592	(	_	
38-112	7592-7595	9.3	_	
38-113	7595-7596	)	_	
38-114	7600-7603	GAF	_	
38-115	7604-7606	38	_	
38-116	7607-7608	(	_	
38-117	7608-7610	16	_	
38-118	7610-7611	)	_	
38-119	7615-7622	General	_	
38-120	7623-7635	intelligence	_	
38-121	7636-7637	(	_	
38-122	7637-7646	estimated	_	
38-123	7647-7649	IQ	_	
38-124	7649-7650	)	_	
38-125	7650-7651	c	_	
38-126	7652-7657	100.8	_	
38-127	7658-7659	(	_	
38-128	7659-7663	19.6	_	
38-129	7663-7664	)	_	
38-130	7665-7670	111.5	_	
38-131	7671-7672	(	_	
38-132	7672-7676	12.2	_	
38-133	7676-7677	)	_	
38-134	7677-7678	*	_	
38-135	7681-7691	Processing	_	
38-136	7692-7697	Speed	_	
38-137	7698-7699	(	_	
38-138	7699-7703	BACS	_	
38-139	7704-7710	Symbol	_	
38-140	7711-7717	coding	_	
38-141	7717-7718	)	_	
38-142	7718-7719	d	_	
38-143	7720-7724	55.8	_	
38-144	7725-7726	(	_	
38-145	7726-7730	15.1	_	
38-146	7730-7731	)	_	
38-147	7732-7736	65.4	_	
38-148	7737-7738	(	_	
38-149	7738-7741	9.5	_	
38-150	7741-7742	)	_	
38-151	7742-7743	*	_	
38-152	7746-7755	Sustained	_	
38-153	7756-7765	attention	_	
38-154	7766-7767	(	_	
38-155	7767-7773	CANTAB	_	
38-156	7774-7777	RVP	_	
38-157	7778-7779	A	_	
38-158	7779-7780	’	_	
38-159	7780-7781	)	_	
38-160	7781-7782	e	_	
38-161	7783-7788	0.976	_	
38-162	7789-7790	(	_	
38-163	7790-7795	0.017	_	
38-164	7795-7796	)	_	
38-165	7797-7802	0.987	_	
38-166	7803-7804	(	_	
38-167	7804-7809	0.014	_	
38-168	7809-7810	)	_	
38-169	7810-7811	*	_	
38-170	7814-7819	Shift	_	
38-171	7820-7823	and	_	
38-172	7824-7835	flexibility	_	
38-173	7836-7838	of	_	
38-174	7839-7848	attention	_	
38-175	7849-7850	(	_	
38-176	7850-7856	CANTAB	_	
38-177	7857-7860	IED	_	
38-178	7860-7861	,	_	
38-179	7862-7867	total	_	
38-180	7868-7874	errors	_	
38-181	7875-7883	adjusted	_	
38-182	7883-7884	)	_	
38-183	7884-7885	f	_	
38-184	7886-7890	28.1	_	
38-185	7891-7892	(	_	
38-186	7892-7896	21.0	_	
38-187	7896-7897	)	_	
38-188	7898-7902	18.6	_	
38-189	7903-7904	(	_	
38-190	7904-7908	16.5	_	
38-191	7908-7909	)	_	
38-192	7909-7910	*	_	
38-193	7910-7911	*	_	
38-194	7916-7920	Note	_	
38-195	7920-7921	:	_	
38-196	7922-7927	PANSS	_	
38-197	7927-7928	,	_	
38-198	7929-7937	Positive	_	
38-199	7938-7941	And	_	
38-200	7942-7950	Negative	_	
38-201	7951-7959	Syndrome	_	
38-202	7960-7965	Scale	_	
38-203	7965-7966	;	_	
38-204	7967-7970	GAF	_	
38-205	7970-7971	,	_	
38-206	7972-7979	General	_	
38-207	7980-7990	Assessment	_	
38-208	7991-7993	of	_	
38-209	7994-8005	Functioning	_	
38-210	8005-8006	;	_	
38-211	8007-8009	IQ	_	
38-212	8009-8010	,	_	
38-213	8011-8023	intelligence	_	
38-214	8024-8032	quotient	_	
38-215	8032-8033	;	_	
38-216	8034-8037	RVP	_	
38-217	8037-8038	,	_	
38-218	8039-8044	Rapid	_	
38-219	8045-8051	Visual	_	
38-220	8052-8063	Information	_	
38-221	8064-8074	Processing	_	
38-222	8074-8075	;	_	
38-223	8076-8079	IED	_	
38-224	8079-8080	,	_	
38-225	8081-8092	Intra-Extra	_	
38-226	8093-8104	Dimensional	_	
38-227	8105-8108	set	_	
38-228	8109-8114	shift	_	
38-229	8114-8115	.	_	

#Text=aSmoking status missing for one healthy control.
39-1	8117-8125	aSmoking	_	
39-2	8126-8132	status	_	
39-3	8133-8140	missing	_	
39-4	8141-8144	for	_	
39-5	8145-8148	one	_	
39-6	8149-8156	healthy	_	
39-7	8157-8164	control	_	
39-8	8164-8165	.	_	

#Text=Smoking categories: never tried/ tried a few times/ use regularly/ abuse/ dependency.
40-1	8166-8173	Smoking	_	
40-2	8174-8184	categories	_	
40-3	8184-8185	:	_	
40-4	8186-8191	never	_	
40-5	8192-8197	tried	_	
40-6	8197-8198	/	_	
40-7	8199-8204	tried	_	
40-8	8205-8206	a	_	
40-9	8207-8210	few	_	
40-10	8211-8216	times	_	
40-11	8216-8217	/	_	
40-12	8218-8221	use	_	
40-13	8222-8231	regularly	_	
40-14	8231-8232	/	_	
40-15	8233-8238	abuse	_	
40-16	8238-8239	/	_	
40-17	8240-8250	dependency	_	
40-18	8250-8251	.	_	

#Text=bPANSS data missing for 2 subjects.
41-1	8253-8259	bPANSS	_	
41-2	8260-8264	data	_	
41-3	8265-8272	missing	_	
41-4	8273-8276	for	_	
41-5	8277-8278	2	_	
41-6	8279-8287	subjects	_	
41-7	8287-8288	.	_	

#Text=c–fVarying n (b: n = 84, c: n = 92, d: n = 91, e: n = 62).
42-1	8290-8300	c–fVarying	_	
42-2	8301-8302	n	_	
42-3	8303-8304	(	_	
42-4	8304-8305	b	_	
42-5	8305-8306	:	_	
42-6	8307-8308	n	_	
42-7	8309-8310	=	_	
42-8	8311-8313	84	_	
42-9	8313-8314	,	_	
42-10	8315-8316	c	_	
42-11	8316-8317	:	_	
42-12	8318-8319	n	_	
42-13	8320-8321	=	_	
42-14	8322-8324	92	_	
42-15	8324-8325	,	_	
42-16	8326-8327	d	_	
42-17	8327-8328	:	_	
42-18	8329-8330	n	_	
42-19	8331-8332	=	_	
42-20	8333-8335	91	_	
42-21	8335-8336	,	_	
42-22	8337-8338	e	_	
42-23	8338-8339	:	_	
42-24	8340-8341	n	_	
42-25	8342-8343	=	_	
42-26	8344-8346	62	_	
42-27	8346-8347	)	_	
42-28	8347-8348	.	_	

#Text=*Significant difference (P < .05); **Borderline significant difference (P = .051).
43-1	8349-8350	*	_	
43-2	8350-8361	Significant	_	
43-3	8362-8372	difference	_	
43-4	8373-8374	(	_	
43-5	8374-8375	P	_	
43-6	8376-8377	<	_	
43-7	8378-8381	.05	_	
43-8	8381-8382	)	_	
43-9	8382-8383	;	_	
43-10	8384-8385	*	_	
43-11	8385-8386	*	_	
43-12	8386-8396	Borderline	_	
43-13	8397-8408	significant	_	
43-14	8409-8419	difference	_	
43-15	8420-8421	(	_	
43-16	8421-8422	P	_	
43-17	8423-8424	=	_	
43-18	8425-8429	.051	_	
43-19	8429-8430	)	_	
43-20	8430-8431	.	_	

#Text=Numbers in () = SD.
44-1	8432-8439	Numbers	_	
44-2	8440-8442	in	_	
44-3	8443-8444	(	_	
44-4	8444-8445	)	_	
44-5	8446-8447	=	_	
44-6	8448-8450	SD	_	
44-7	8450-8451	.	_	

#Text=Clinical Assessments
#Text=To ensure a diagnosis of schizophrenia or schizoaffective disorder in patients and exclusion of psychiatric illness in healthy controls all participants underwent a Schedule of Clinical Assessment in Neuropsychiatry interview (SCAN).
45-1	8452-8460	Clinical	_	
45-2	8461-8472	Assessments	_	
45-3	8473-8475	To	_	
45-4	8476-8482	ensure	_	
45-5	8483-8484	a	_	
45-6	8485-8494	diagnosis	_	
45-7	8495-8497	of	_	
45-8	8498-8511	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
45-9	8512-8514	or	_	
45-10	8515-8530	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[15]	
45-11	8531-8539	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[15]	
45-12	8540-8542	in	_	
45-13	8543-8551	patients	_	
45-14	8552-8555	and	_	
45-15	8556-8565	exclusion	_	
45-16	8566-8568	of	_	
45-17	8569-8580	psychiatric	_	
45-18	8581-8588	illness	_	
45-19	8589-8591	in	_	
45-20	8592-8599	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
45-21	8600-8608	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
45-22	8609-8612	all	_	
45-23	8613-8625	participants	_	
45-24	8626-8635	underwent	_	
45-25	8636-8637	a	_	
45-26	8638-8646	Schedule	_	
45-27	8647-8649	of	_	
45-28	8650-8658	Clinical	_	
45-29	8659-8669	Assessment	_	
45-30	8670-8672	in	_	
45-31	8673-8688	Neuropsychiatry	_	
45-32	8689-8698	interview	_	
45-33	8699-8700	(	_	
45-34	8700-8704	SCAN	_	
45-35	8704-8705	)	_	
45-36	8705-8706	.	_	

#Text=Current psychopathology was estimated with Positive and Negative Syndrome Scale (PANSS).
46-1	8707-8714	Current	_	
46-2	8715-8730	psychopathology	_	
46-3	8731-8734	was	_	
46-4	8735-8744	estimated	_	
46-5	8745-8749	with	_	
46-6	8750-8758	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-7	8759-8762	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-8	8763-8771	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-9	8772-8780	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-10	8781-8786	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-11	8787-8788	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-12	8788-8793	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-13	8793-8794	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[17]	
46-14	8794-8795	.	_	

#Text=Handedness was assessed with Edinburg Handedness Inventory (EHI).
47-1	8796-8806	Handedness	_	
47-2	8807-8810	was	_	
47-3	8811-8819	assessed	_	
47-4	8820-8824	with	_	
47-5	8825-8833	Edinburg	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-6	8834-8844	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-7	8845-8854	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-8	8855-8856	(	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-9	8856-8859	EHI	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-10	8859-8860	)	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[18]	
47-11	8860-8861	.	_	

#Text=Cognitive measures were general intelligence estimated from 4 subtests from the Wechsler Adult Intelligence Scale, 3rd ed.
48-1	8862-8871	Cognitive	_	
48-2	8872-8880	measures	_	
48-3	8881-8885	were	_	
48-4	8886-8893	general	_	
48-5	8894-8906	intelligence	_	
48-6	8907-8916	estimated	_	
48-7	8917-8921	from	_	
48-8	8922-8923	4	_	
48-9	8924-8932	subtests	_	
48-10	8933-8937	from	_	
48-11	8938-8941	the	_	
48-12	8942-8950	Wechsler	_	
48-13	8951-8956	Adult	_	
48-14	8957-8969	Intelligence	_	
48-15	8970-8975	Scale	_	
48-16	8975-8976	,	_	
48-17	8977-8980	3rd	_	
48-18	8981-8983	ed	_	
48-19	8983-8984	.	_	

#Text=(WAIS-III), processing speed assessed using the symbol coding test from Brief Assessment of Cognition in Schizophrenia (BACS), sustained attention assessed using the Rapid Visual Information Processing test (RVP) from Cambridge Neuropsychological Test Automated Battery (CANTAB), and executive function (attentional set shifting) was assessed using Intra-Extra Dimensional Set Shift (IED) from CANTAB (data from the clinical assessments displayed in Table 1).
49-1	8985-8986	(	_	
49-2	8986-8994	WAIS-III	_	
49-3	8994-8995	)	_	
49-4	8995-8996	,	_	
49-5	8997-9007	processing	_	
49-6	9008-9013	speed	_	
49-7	9014-9022	assessed	_	
49-8	9023-9028	using	_	
49-9	9029-9032	the	_	
49-10	9033-9039	symbol	_	
49-11	9040-9046	coding	_	
49-12	9047-9051	test	_	
49-13	9052-9056	from	_	
49-14	9057-9062	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-15	9063-9073	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-16	9074-9076	of	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-17	9077-9086	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-18	9087-9089	in	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-19	9090-9103	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-20	9104-9105	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-21	9105-9109	BACS	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-22	9109-9110	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia[19]	
49-23	9110-9111	,	_	
49-24	9112-9121	sustained	_	
49-25	9122-9131	attention	_	
49-26	9132-9140	assessed	_	
49-27	9141-9146	using	_	
49-28	9147-9150	the	_	
49-29	9151-9156	Rapid	_	
49-30	9157-9163	Visual	_	
49-31	9164-9175	Information	_	
49-32	9176-9186	Processing	_	
49-33	9187-9191	test	_	
49-34	9192-9193	(	_	
49-35	9193-9196	RVP	_	
49-36	9196-9197	)	_	
49-37	9198-9202	from	_	
49-38	9203-9212	Cambridge	_	
49-39	9213-9231	Neuropsychological	_	
49-40	9232-9236	Test	_	
49-41	9237-9246	Automated	_	
49-42	9247-9254	Battery	_	
49-43	9255-9256	(	_	
49-44	9256-9262	CANTAB	_	
49-45	9262-9263	)	_	
49-46	9263-9264	,	_	
49-47	9265-9268	and	_	
49-48	9269-9278	executive	_	
49-49	9279-9287	function	_	
49-50	9288-9289	(	_	
49-51	9289-9300	attentional	_	
49-52	9301-9304	set	_	
49-53	9305-9313	shifting	_	
49-54	9313-9314	)	_	
49-55	9315-9318	was	_	
49-56	9319-9327	assessed	_	
49-57	9328-9333	using	_	
49-58	9334-9345	Intra-Extra	_	
49-59	9346-9357	Dimensional	_	
49-60	9358-9361	Set	_	
49-61	9362-9367	Shift	_	
49-62	9368-9369	(	_	
49-63	9369-9372	IED	_	
49-64	9372-9373	)	_	
49-65	9374-9378	from	_	
49-66	9379-9385	CANTAB	_	
49-67	9386-9387	(	_	
49-68	9387-9391	data	_	
49-69	9392-9396	from	_	
49-70	9397-9400	the	_	
49-71	9401-9409	clinical	_	
49-72	9410-9421	assessments	_	
49-73	9422-9431	displayed	_	
49-74	9432-9434	in	_	
49-75	9435-9440	Table	_	
49-76	9441-9442	1	_	
49-77	9442-9443	)	_	
49-78	9443-9444	.	_	

#Text=MRI Data Acquisition
#Text=Imaging was performed on a Philips Achieva 3.0T whole body MRI scanner (Philips Medical Systems, Best, The Netherlands) using an 8-channel head coil.
50-1	9445-9448	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
50-2	9449-9453	Data	_	
50-3	9454-9465	Acquisition	_	
50-4	9466-9473	Imaging	_	
50-5	9474-9477	was	_	
50-6	9478-9487	performed	_	
50-7	9488-9490	on	_	
50-8	9491-9492	a	_	
50-9	9493-9500	Philips	_	
50-10	9501-9508	Achieva	_	
50-11	9509-9513	3.0T	_	
50-12	9514-9519	whole	_	
50-13	9520-9524	body	_	
50-14	9525-9528	MRI	_	
50-15	9529-9536	scanner	_	
50-16	9537-9538	(	_	
50-17	9538-9545	Philips	_	
50-18	9546-9553	Medical	_	
50-19	9554-9561	Systems	_	
50-20	9561-9562	,	_	
50-21	9563-9567	Best	_	
50-22	9567-9568	,	_	
50-23	9569-9572	The	_	
50-24	9573-9584	Netherlands	_	
50-25	9584-9585	)	_	
50-26	9586-9591	using	_	
50-27	9592-9594	an	_	
50-28	9595-9596	8	_	
50-29	9596-9597	-	_	
50-30	9597-9604	channel	_	
50-31	9605-9609	head	_	
50-32	9610-9614	coil	_	
50-33	9614-9615	.	_	

#Text=Functional images were obtained with a T2*-weighted echo planar imaging sequence (repetition time = 2 s, echo time = 25 ms, flip angle 75°) with a matrix size of 128 × 128 × 38 and field of view = 230 × 230 × 128 mm yielding a voxel-size of 1.8 × 1.8 × 3.4 mm.
51-1	9616-9626	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[20]	
51-2	9627-9633	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[20]	
51-3	9634-9638	were	_	
51-4	9639-9647	obtained	_	
51-5	9648-9652	with	_	
51-6	9653-9654	a	_	
51-7	9655-9657	T2	_	
51-8	9657-9658	*	_	
51-9	9658-9659	-	_	
51-10	9659-9667	weighted	_	
51-11	9668-9672	echo	_	
51-12	9673-9679	planar	_	
51-13	9680-9687	imaging	_	
51-14	9688-9696	sequence	_	
51-15	9697-9698	(	_	
51-16	9698-9708	repetition	_	
51-17	9709-9713	time	_	
51-18	9714-9715	=	_	
51-19	9716-9717	2	_	
51-20	9718-9719	s	_	
51-21	9719-9720	,	_	
51-22	9721-9725	echo	_	
51-23	9726-9730	time	_	
51-24	9731-9732	=	_	
51-25	9733-9735	25	_	
51-26	9736-9738	ms	_	
51-27	9738-9739	,	_	
51-28	9740-9744	flip	_	
51-29	9745-9750	angle	_	
51-30	9751-9753	75	_	
51-31	9753-9754	°	_	
51-32	9754-9755	)	_	
51-33	9756-9760	with	_	
51-34	9761-9762	a	_	
51-35	9763-9769	matrix	_	
51-36	9770-9774	size	_	
51-37	9775-9777	of	_	
51-38	9778-9781	128	_	
51-39	9782-9783	×	_	
51-40	9784-9787	128	_	
51-41	9788-9789	×	_	
51-42	9790-9792	38	_	
51-43	9793-9796	and	_	
51-44	9797-9802	field	_	
51-45	9803-9805	of	_	
51-46	9806-9810	view	_	
51-47	9811-9812	=	_	
51-48	9813-9816	230	_	
51-49	9817-9818	×	_	
51-50	9819-9822	230	_	
51-51	9823-9824	×	_	
51-52	9825-9828	128	_	
51-53	9829-9831	mm	_	
51-54	9832-9840	yielding	_	
51-55	9841-9842	a	_	
51-56	9843-9853	voxel-size	_	
51-57	9854-9856	of	_	
51-58	9857-9860	1.8	_	
51-59	9861-9862	×	_	
51-60	9863-9866	1.8	_	
51-61	9867-9868	×	_	
51-62	9869-9872	3.4	_	
51-63	9873-9875	mm	_	
51-64	9875-9876	.	_	

#Text=Each functional run contained 300 volumes resulting in a total scan time of 10 minutes. fMRI was performed under resting conditions with instructions to stay awake with eyes closed and to not think of anything in particular.
52-1	9877-9881	Each	_	
52-2	9882-9892	functional	_	
52-3	9893-9896	run	_	
52-4	9897-9906	contained	_	
52-5	9907-9910	300	_	
52-6	9911-9918	volumes	_	
52-7	9919-9928	resulting	_	
52-8	9929-9931	in	_	
52-9	9932-9933	a	_	
52-10	9934-9939	total	_	
52-11	9940-9944	scan	_	
52-12	9945-9949	time	_	
52-13	9950-9952	of	_	
52-14	9953-9955	10	_	
52-15	9956-9963	minutes	_	
52-16	9963-9964	.	_	
52-17	9965-9969	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
52-18	9970-9973	was	_	
52-19	9974-9983	performed	_	
52-20	9984-9989	under	_	
52-21	9990-9997	resting	_	
52-22	9998-10008	conditions	_	
52-23	10009-10013	with	_	
52-24	10014-10026	instructions	_	
52-25	10027-10029	to	_	
52-26	10030-10034	stay	_	
52-27	10035-10040	awake	_	
52-28	10041-10045	with	_	
52-29	10046-10050	eyes	_	
52-30	10051-10057	closed	_	
52-31	10058-10061	and	_	
52-32	10062-10064	to	_	
52-33	10065-10068	not	_	
52-34	10069-10074	think	_	
52-35	10075-10077	of	_	
52-36	10078-10086	anything	_	
52-37	10087-10089	in	_	
52-38	10090-10100	particular	_	
52-39	10100-10101	.	_	

#Text=For anatomical reference T1-weighted structural images were acquired (repetition time = 10 ms, echo time = 4.6 ms, flip angle = 8° and voxel-size = 0.79 × 0.79 × 0.8).
53-1	10102-10105	For	_	
53-2	10106-10116	anatomical	_	
53-3	10117-10126	reference	_	
53-4	10127-10129	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]	
53-5	10129-10130	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]	
53-6	10130-10138	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[21]	
53-7	10139-10149	structural	_	
53-8	10150-10156	images	_	
53-9	10157-10161	were	_	
53-10	10162-10170	acquired	_	
53-11	10171-10172	(	_	
53-12	10172-10182	repetition	_	
53-13	10183-10187	time	_	
53-14	10188-10189	=	_	
53-15	10190-10192	10	_	
53-16	10193-10195	ms	_	
53-17	10195-10196	,	_	
53-18	10197-10201	echo	_	
53-19	10202-10206	time	_	
53-20	10207-10208	=	_	
53-21	10209-10212	4.6	_	
53-22	10213-10215	ms	_	
53-23	10215-10216	,	_	
53-24	10217-10221	flip	_	
53-25	10222-10227	angle	_	
53-26	10228-10229	=	_	
53-27	10230-10231	8	_	
53-28	10231-10232	°	_	
53-29	10233-10236	and	_	
53-30	10237-10247	voxel-size	_	
53-31	10248-10249	=	_	
53-32	10250-10254	0.79	_	
53-33	10255-10256	×	_	
53-34	10257-10261	0.79	_	
53-35	10262-10263	×	_	
53-36	10264-10267	0.8	_	
53-37	10267-10268	)	_	
53-38	10268-10269	.	_	

#Text=Preprocessing of fMRI Data
#Text=In order to reduce the effect of head motion, single-subject ICA was done (Probabilistic ICA in FSL’s MELODIC vers. 4.1.9.) using MCFLIRT motion correction tool, and spatial smoothing with a 5 mm Gaussian kernel.
54-1	10270-10283	Preprocessing	_	
54-2	10284-10286	of	_	
54-3	10287-10291	fMRI	_	
54-4	10292-10296	Data	_	
54-5	10297-10299	In	_	
54-6	10300-10305	order	_	
54-7	10306-10308	to	_	
54-8	10309-10315	reduce	_	
54-9	10316-10319	the	_	
54-10	10320-10326	effect	_	
54-11	10327-10329	of	_	
54-12	10330-10334	head	_	
54-13	10335-10341	motion	_	
54-14	10341-10342	,	_	
54-15	10343-10357	single-subject	_	
54-16	10358-10361	ICA	_	
54-17	10362-10365	was	_	
54-18	10366-10370	done	_	
54-19	10371-10372	(	_	
54-20	10372-10385	Probabilistic	_	
54-21	10386-10389	ICA	_	
54-22	10390-10392	in	_	
54-23	10393-10396	FSL	_	
54-24	10396-10397	’	_	
54-25	10397-10398	s	_	
54-26	10399-10406	MELODIC	_	
54-27	10407-10411	vers	_	
54-28	10411-10412	.	_	
54-29	10413-10418	4.1.9	_	
54-30	10418-10419	.	_	
54-31	10419-10420	)	_	
54-32	10421-10426	using	_	
54-33	10427-10434	MCFLIRT	_	
54-34	10435-10441	motion	_	
54-35	10442-10452	correction	_	
54-36	10453-10457	tool	_	
54-37	10457-10458	,	_	
54-38	10459-10462	and	_	
54-39	10463-10470	spatial	_	
54-40	10471-10480	smoothing	_	
54-41	10481-10485	with	_	
54-42	10486-10487	a	_	
54-43	10488-10489	5	_	
54-44	10490-10492	mm	_	
54-45	10493-10501	Gaussian	_	
54-46	10502-10508	kernel	_	
54-47	10508-10509	.	_	

#Text=For each subject, IC’s judged to be motion artifacts were discarded in a semi-automated fashion (supplementary material).
55-1	10510-10513	For	_	
55-2	10514-10518	each	_	
55-3	10519-10526	subject	_	
55-4	10526-10527	,	_	
55-5	10528-10530	IC	_	
55-6	10530-10531	’	_	
55-7	10531-10532	s	_	
55-8	10533-10539	judged	_	
55-9	10540-10542	to	_	
55-10	10543-10545	be	_	
55-11	10546-10552	motion	_	
55-12	10553-10562	artifacts	_	
55-13	10563-10567	were	_	
55-14	10568-10577	discarded	_	
55-15	10578-10580	in	_	
55-16	10581-10582	a	_	
55-17	10583-10597	semi-automated	_	
55-18	10598-10605	fashion	_	
55-19	10606-10607	(	_	
55-20	10607-10620	supplementary	_	
55-21	10621-10629	material	_	
55-22	10629-10630	)	_	
55-23	10630-10631	.	_	

#Text=After initial ICA de-noising each file was de-spiked using Artrepair.
56-1	10632-10637	After	_	
56-2	10638-10645	initial	_	
56-3	10646-10649	ICA	_	
56-4	10650-10660	de-noising	_	
56-5	10661-10665	each	_	
56-6	10666-10670	file	_	
56-7	10671-10674	was	_	
56-8	10675-10684	de-spiked	_	
56-9	10685-10690	using	_	
56-10	10691-10700	Artrepair	_	
56-11	10700-10701	.	_	

#Text=Before group ICA additional preprocessing steps included brain extraction, slice time correction (interleaved), high pass filtering (150 s), registration to the T1 weighted anatomical image and subsequently to the MNI-152 standard space image using FNIRT and finally resampling the 4D dataset to 4 mm isotropic voxels.
57-1	10702-10708	Before	_	
57-2	10709-10714	group	_	
57-3	10715-10718	ICA	_	
57-4	10719-10729	additional	_	
57-5	10730-10743	preprocessing	_	
57-6	10744-10749	steps	_	
57-7	10750-10758	included	_	
57-8	10759-10764	brain	_	
57-9	10765-10775	extraction	_	
57-10	10775-10776	,	_	
57-11	10777-10782	slice	_	
57-12	10783-10787	time	_	
57-13	10788-10798	correction	_	
57-14	10799-10800	(	_	
57-15	10800-10811	interleaved	_	
57-16	10811-10812	)	_	
57-17	10812-10813	,	_	
57-18	10814-10818	high	_	
57-19	10819-10823	pass	_	
57-20	10824-10833	filtering	_	
57-21	10834-10835	(	_	
57-22	10835-10838	150	_	
57-23	10839-10840	s	_	
57-24	10840-10841	)	_	
57-25	10841-10842	,	_	
57-26	10843-10855	registration	_	
57-27	10856-10858	to	_	
57-28	10859-10862	the	_	
57-29	10863-10865	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
57-30	10866-10874	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
57-31	10875-10885	anatomical	_	
57-32	10886-10891	image	_	
57-33	10892-10895	and	_	
57-34	10896-10908	subsequently	_	
57-35	10909-10911	to	_	
57-36	10912-10915	the	_	
57-37	10916-10919	MNI	_	
57-38	10919-10920	-	_	
57-39	10920-10923	152	_	
57-40	10924-10932	standard	_	
57-41	10933-10938	space	_	
57-42	10939-10944	image	_	
57-43	10945-10950	using	_	
57-44	10951-10956	FNIRT	_	
57-45	10957-10960	and	_	
57-46	10961-10968	finally	_	
57-47	10969-10979	resampling	_	
57-48	10980-10983	the	_	
57-49	10984-10986	4D	_	
57-50	10987-10994	dataset	_	
57-51	10995-10997	to	_	
57-52	10998-10999	4	_	
57-53	11000-11002	mm	_	
57-54	11003-11012	isotropic	_	
57-55	11013-11019	voxels	_	
57-56	11019-11020	.	_	

#Text=Group ICA was then performed with FSL’s MELODIC vers. 4.1.9 including variance-normalization of time-courses and automatic dimensionality estimation, ie, MELODIC estimated the number of components automatically from the data.
58-1	11021-11026	Group	_	
58-2	11027-11030	ICA	_	
58-3	11031-11034	was	_	
58-4	11035-11039	then	_	
58-5	11040-11049	performed	_	
58-6	11050-11054	with	_	
58-7	11055-11058	FSL	_	
58-8	11058-11059	’	_	
58-9	11059-11060	s	_	
58-10	11061-11068	MELODIC	_	
58-11	11069-11073	vers	_	
58-12	11073-11074	.	_	
58-13	11075-11080	4.1.9	_	
58-14	11081-11090	including	_	
58-15	11091-11113	variance-normalization	_	
58-16	11114-11116	of	_	
58-17	11117-11129	time-courses	_	
58-18	11130-11133	and	_	
58-19	11134-11143	automatic	_	
58-20	11144-11158	dimensionality	_	
58-21	11159-11169	estimation	_	
58-22	11169-11170	,	_	
58-23	11171-11173	ie	_	
58-24	11173-11174	,	_	
58-25	11175-11182	MELODIC	_	
58-26	11183-11192	estimated	_	
58-27	11193-11196	the	_	
58-28	11197-11203	number	_	
58-29	11204-11206	of	_	
58-30	11207-11217	components	_	
58-31	11218-11231	automatically	_	
58-32	11232-11236	from	_	
58-33	11237-11240	the	_	
58-34	11241-11245	data	_	
58-35	11245-11246	.	_	

#Text=Statistical Analysis of Within Network Connectivity
#Text=According to the large-scale network models described above networks of interest included DMN, SN, CEN, VAN, DAN, and auditory network.
59-1	11247-11258	Statistical	_	
59-2	11259-11267	Analysis	_	
59-3	11268-11270	of	_	
59-4	11271-11277	Within	_	
59-5	11278-11285	Network	_	
59-6	11286-11298	Connectivity	_	
59-7	11299-11308	According	_	
59-8	11309-11311	to	_	
59-9	11312-11315	the	_	
59-10	11316-11327	large-scale	_	
59-11	11328-11335	network	_	
59-12	11336-11342	models	_	
59-13	11343-11352	described	_	
59-14	11353-11358	above	_	
59-15	11359-11367	networks	_	
59-16	11368-11370	of	_	
59-17	11371-11379	interest	_	
59-18	11380-11388	included	_	
59-19	11389-11392	DMN	_	
59-20	11392-11393	,	_	
59-21	11394-11396	SN	_	
59-22	11396-11397	,	_	
59-23	11398-11401	CEN	_	
59-24	11401-11402	,	_	
59-25	11403-11406	VAN	_	
59-26	11406-11407	,	_	
59-27	11408-11411	DAN	_	
59-28	11411-11412	,	_	
59-29	11413-11416	and	_	
59-30	11417-11425	auditory	_	
59-31	11426-11433	network	_	
59-32	11433-11434	.	_	

#Text=Networks of interest were chosen by the criterion of maximum visual resemblance with the well-described resting state networks throughout the literature.
60-1	11435-11443	Networks	_	
60-2	11444-11446	of	_	
60-3	11447-11455	interest	_	
60-4	11456-11460	were	_	
60-5	11461-11467	chosen	_	
60-6	11468-11470	by	_	
60-7	11471-11474	the	_	
60-8	11475-11484	criterion	_	
60-9	11485-11487	of	_	
60-10	11488-11495	maximum	_	
60-11	11496-11502	visual	_	
60-12	11503-11514	resemblance	_	
60-13	11515-11519	with	_	
60-14	11520-11523	the	_	
60-15	11524-11538	well-described	_	
60-16	11539-11546	resting	_	
60-17	11547-11552	state	_	
60-18	11553-11561	networks	_	
60-19	11562-11572	throughout	_	
60-20	11573-11576	the	_	
60-21	11577-11587	literature	_	
60-22	11587-11588	.	_	

#Text=To enable group comparisons the set of spatial maps from the group-average analysis was used to generate subject-specific versions of the spatial maps, and associated time series, using a dual regression approach.
61-1	11589-11591	To	_	
61-2	11592-11598	enable	_	
61-3	11599-11604	group	_	
61-4	11605-11616	comparisons	_	
61-5	11617-11620	the	_	
61-6	11621-11624	set	_	
61-7	11625-11627	of	_	
61-8	11628-11635	spatial	_	
61-9	11636-11640	maps	_	
61-10	11641-11645	from	_	
61-11	11646-11649	the	_	
61-12	11650-11663	group-average	_	
61-13	11664-11672	analysis	_	
61-14	11673-11676	was	_	
61-15	11677-11681	used	_	
61-16	11682-11684	to	_	
61-17	11685-11693	generate	_	
61-18	11694-11710	subject-specific	_	
61-19	11711-11719	versions	_	
61-20	11720-11722	of	_	
61-21	11723-11726	the	_	
61-22	11727-11734	spatial	_	
61-23	11735-11739	maps	_	
61-24	11739-11740	,	_	
61-25	11741-11744	and	_	
61-26	11745-11755	associated	_	
61-27	11756-11760	time	_	
61-28	11761-11767	series	_	
61-29	11767-11768	,	_	
61-30	11769-11774	using	_	
61-31	11775-11776	a	_	
61-32	11777-11781	dual	_	
61-33	11782-11792	regression	_	
61-34	11793-11801	approach	_	
61-35	11801-11802	.	_	

#Text=In order to reduce the effect of motion further, 24 motion parameters (6 rigid body estimates + their 6 derivatives + squares of the 12 parameters) were added as temporal regressors in the second regression.
62-1	11803-11805	In	_	
62-2	11806-11811	order	_	
62-3	11812-11814	to	_	
62-4	11815-11821	reduce	_	
62-5	11822-11825	the	_	
62-6	11826-11832	effect	_	
62-7	11833-11835	of	_	
62-8	11836-11842	motion	_	
62-9	11843-11850	further	_	
62-10	11850-11851	,	_	
62-11	11852-11854	24	_	
62-12	11855-11861	motion	_	
62-13	11862-11872	parameters	_	
62-14	11873-11874	(	_	
62-15	11874-11875	6	_	
62-16	11876-11881	rigid	_	
62-17	11882-11886	body	_	
62-18	11887-11896	estimates	_	
62-19	11897-11898	+	_	
62-20	11899-11904	their	_	
62-21	11905-11906	6	_	
62-22	11907-11918	derivatives	_	
62-23	11919-11920	+	_	
62-24	11921-11928	squares	_	
62-25	11929-11931	of	_	
62-26	11932-11935	the	_	
62-27	11936-11938	12	_	
62-28	11939-11949	parameters	_	
62-29	11949-11950	)	_	
62-30	11951-11955	were	_	
62-31	11956-11961	added	_	
62-32	11962-11964	as	_	
62-33	11965-11973	temporal	_	
62-34	11974-11984	regressors	_	
62-35	11985-11987	in	_	
62-36	11988-11991	the	_	
62-37	11992-11998	second	_	
62-38	11999-12009	regression	_	
62-39	12009-12010	.	_	

#Text=Finally, networks of interest were tested for voxel-wise group differences using FSL’s permutation-testing tool (Randomise) including age, gender and motion summary measures (absolute and frame-wise displacement) as nuisance regressors.
63-1	12011-12018	Finally	_	
63-2	12018-12019	,	_	
63-3	12020-12028	networks	_	
63-4	12029-12031	of	_	
63-5	12032-12040	interest	_	
63-6	12041-12045	were	_	
63-7	12046-12052	tested	_	
63-8	12053-12056	for	_	
63-9	12057-12067	voxel-wise	_	
63-10	12068-12073	group	_	
63-11	12074-12085	differences	_	
63-12	12086-12091	using	_	
63-13	12092-12095	FSL	_	
63-14	12095-12096	’	_	
63-15	12096-12097	s	_	
63-16	12098-12117	permutation-testing	_	
63-17	12118-12122	tool	_	
63-18	12123-12124	(	_	
63-19	12124-12133	Randomise	_	
63-20	12133-12134	)	_	
63-21	12135-12144	including	_	
63-22	12145-12148	age	_	
63-23	12148-12149	,	_	
63-24	12150-12156	gender	_	
63-25	12157-12160	and	_	
63-26	12161-12167	motion	_	
63-27	12168-12175	summary	_	
63-28	12176-12184	measures	_	
63-29	12185-12186	(	_	
63-30	12186-12194	absolute	_	
63-31	12195-12198	and	_	
63-32	12199-12209	frame-wise	_	
63-33	12210-12222	displacement	_	
63-34	12222-12223	)	_	
63-35	12224-12226	as	_	
63-36	12227-12235	nuisance	_	
63-37	12236-12246	regressors	_	
63-38	12246-12247	.	_	

#Text=For the remainder of this work we use the term “network” synonymously with the term “independent component.”
64-1	12248-12251	For	_	
64-2	12252-12255	the	_	
64-3	12256-12265	remainder	_	
64-4	12266-12268	of	_	
64-5	12269-12273	this	_	
64-6	12274-12278	work	_	
64-7	12279-12281	we	_	
64-8	12282-12285	use	_	
64-9	12286-12289	the	_	
64-10	12290-12294	term	_	
64-11	12295-12296	“	_	
64-12	12296-12303	network	_	
64-13	12303-12304	”	_	
64-14	12305-12317	synonymously	_	
64-15	12318-12322	with	_	
64-16	12323-12326	the	_	
64-17	12327-12331	term	_	
64-18	12332-12333	“	_	
64-19	12333-12344	independent	_	
64-20	12345-12354	component	_	
64-21	12354-12355	.	_	
64-22	12355-12356	”	_	

#Text=Statistical analysis was made with threshold-free cluster enhancement, a significance threshold of P < .05 and FWE-correction as implemented in the Randomise tool.
65-1	12357-12368	Statistical	_	
65-2	12369-12377	analysis	_	
65-3	12378-12381	was	_	
65-4	12382-12386	made	_	
65-5	12387-12391	with	_	
65-6	12392-12406	threshold-free	_	
65-7	12407-12414	cluster	_	
65-8	12415-12426	enhancement	_	
65-9	12426-12427	,	_	
65-10	12428-12429	a	_	
65-11	12430-12442	significance	_	
65-12	12443-12452	threshold	_	
65-13	12453-12455	of	_	
65-14	12456-12457	P	_	
65-15	12458-12459	<	_	
65-16	12460-12463	.05	_	
65-17	12464-12467	and	_	
65-18	12468-12482	FWE-correction	_	
65-19	12483-12485	as	_	
65-20	12486-12497	implemented	_	
65-21	12498-12500	in	_	
65-22	12501-12504	the	_	
65-23	12505-12514	Randomise	_	
65-24	12515-12519	tool	_	
65-25	12519-12520	.	_	

#Text=Statistical Analysis of Between Network Connectivity
#Text=In order to obtain pair-wise correlations between the networks of interest we calculated a correlation matrix based on the IC time-series for each subject.
66-1	12521-12532	Statistical	_	
66-2	12533-12541	Analysis	_	
66-3	12542-12544	of	_	
66-4	12545-12552	Between	_	
66-5	12553-12560	Network	_	
66-6	12561-12573	Connectivity	_	
66-7	12574-12576	In	_	
66-8	12577-12582	order	_	
66-9	12583-12585	to	_	
66-10	12586-12592	obtain	_	
66-11	12593-12602	pair-wise	_	
66-12	12603-12615	correlations	_	
66-13	12616-12623	between	_	
66-14	12624-12627	the	_	
66-15	12628-12636	networks	_	
66-16	12637-12639	of	_	
66-17	12640-12648	interest	_	
66-18	12649-12651	we	_	
66-19	12652-12662	calculated	_	
66-20	12663-12664	a	_	
66-21	12665-12676	correlation	_	
66-22	12677-12683	matrix	_	
66-23	12684-12689	based	_	
66-24	12690-12692	on	_	
66-25	12693-12696	the	_	
66-26	12697-12699	IC	_	
66-27	12700-12711	time-series	_	
66-28	12712-12715	for	_	
66-29	12716-12720	each	_	
66-30	12721-12728	subject	_	
66-31	12728-12729	.	_	

#Text=After Fisher transformation, we then tested for (1) group differences, (2) correlation to PANSS scores within the patient group, and (3) interaction between the effects of group and cognitive measures on between-network connectivity with multiple linear regression including age, gender and motion summary measures.
67-1	12730-12735	After	_	
67-2	12736-12742	Fisher	_	
67-3	12743-12757	transformation	_	
67-4	12757-12758	,	_	
67-5	12759-12761	we	_	
67-6	12762-12766	then	_	
67-7	12767-12773	tested	_	
67-8	12774-12777	for	_	
67-9	12778-12779	(	_	
67-10	12779-12780	1	_	
67-11	12780-12781	)	_	
67-12	12782-12787	group	_	
67-13	12788-12799	differences	_	
67-14	12799-12800	,	_	
67-15	12801-12802	(	_	
67-16	12802-12803	2	_	
67-17	12803-12804	)	_	
67-18	12805-12816	correlation	_	
67-19	12817-12819	to	_	
67-20	12820-12825	PANSS	_	
67-21	12826-12832	scores	_	
67-22	12833-12839	within	_	
67-23	12840-12843	the	_	
67-24	12844-12851	patient	_	
67-25	12852-12857	group	_	
67-26	12857-12858	,	_	
67-27	12859-12862	and	_	
67-28	12863-12864	(	_	
67-29	12864-12865	3	_	
67-30	12865-12866	)	_	
67-31	12867-12878	interaction	_	
67-32	12879-12886	between	_	
67-33	12887-12890	the	_	
67-34	12891-12898	effects	_	
67-35	12899-12901	of	_	
67-36	12902-12907	group	_	
67-37	12908-12911	and	_	
67-38	12912-12921	cognitive	_	
67-39	12922-12930	measures	_	
67-40	12931-12933	on	_	
67-41	12934-12949	between-network	_	
67-42	12950-12962	connectivity	_	
67-43	12963-12967	with	_	
67-44	12968-12976	multiple	_	
67-45	12977-12983	linear	_	
67-46	12984-12994	regression	_	
67-47	12995-13004	including	_	
67-48	13005-13008	age	_	
67-49	13008-13009	,	_	
67-50	13010-13016	gender	_	
67-51	13017-13020	and	_	
67-52	13021-13027	motion	_	
67-53	13028-13035	summary	_	
67-54	13036-13044	measures	_	
67-55	13044-13045	.	_	

#Text=Statistical inferences were made using false discovery rate (FDR) at level δ = 0.05 with significance threshold defined as P (j) ≤ δ j/m (j is an index running from 1 to m, m is the total number of tests).
68-1	13046-13057	Statistical	_	
68-2	13058-13068	inferences	_	
68-3	13069-13073	were	_	
68-4	13074-13078	made	_	
68-5	13079-13084	using	_	
68-6	13085-13090	false	_	
68-7	13091-13100	discovery	_	
68-8	13101-13105	rate	_	
68-9	13106-13107	(	_	
68-10	13107-13110	FDR	_	
68-11	13110-13111	)	_	
68-12	13112-13114	at	_	
68-13	13115-13120	level	_	
68-14	13121-13122	δ	_	
68-15	13123-13124	=	_	
68-16	13125-13129	0.05	_	
68-17	13130-13134	with	_	
68-18	13135-13147	significance	_	
68-19	13148-13157	threshold	_	
68-20	13158-13165	defined	_	
68-21	13166-13168	as	_	
68-22	13169-13170	P	_	
68-23	13171-13172	(	_	
68-24	13172-13173	j	_	
68-25	13173-13174	)	_	
68-26	13175-13176	≤	_	
68-27	13177-13178	δ	_	
68-28	13179-13180	j	_	
68-29	13180-13181	/	_	
68-30	13181-13182	m	_	
68-31	13183-13184	(	_	
68-32	13184-13185	j	_	
68-33	13186-13188	is	_	
68-34	13189-13191	an	_	
68-35	13192-13197	index	_	
68-36	13198-13205	running	_	
68-37	13206-13210	from	_	
68-38	13211-13212	1	_	
68-39	13213-13215	to	_	
68-40	13216-13217	m	_	
68-41	13217-13218	,	_	
68-42	13219-13220	m	_	
68-43	13221-13223	is	_	
68-44	13224-13227	the	_	
68-45	13228-13233	total	_	
68-46	13234-13240	number	_	
68-47	13241-13243	of	_	
68-48	13244-13249	tests	_	
68-49	13249-13250	)	_	
68-50	13250-13251	.	_	

#Text=Results
#Text=Networks of Interest
#Text=In total, group ICA resulted in 79 IC’s of which 10 components were chosen as networks of interest according to the network models (figure 1).
69-1	13252-13259	Results	_	
69-2	13260-13268	Networks	_	
69-3	13269-13271	of	_	
69-4	13272-13280	Interest	_	
69-5	13281-13283	In	_	
69-6	13284-13289	total	_	
69-7	13289-13290	,	_	
69-8	13291-13296	group	_	
69-9	13297-13300	ICA	_	
69-10	13301-13309	resulted	_	
69-11	13310-13312	in	_	
69-12	13313-13315	79	_	
69-13	13316-13318	IC	_	
69-14	13318-13319	’	_	
69-15	13319-13320	s	_	
69-16	13321-13323	of	_	
69-17	13324-13329	which	_	
69-18	13330-13332	10	_	
69-19	13333-13343	components	_	
69-20	13344-13348	were	_	
69-21	13349-13355	chosen	_	
69-22	13356-13358	as	_	
69-23	13359-13367	networks	_	
69-24	13368-13370	of	_	
69-25	13371-13379	interest	_	
69-26	13380-13389	according	_	
69-27	13390-13392	to	_	
69-28	13393-13396	the	_	
69-29	13397-13404	network	_	
69-30	13405-13411	models	_	
69-31	13412-13413	(	_	
69-32	13413-13419	figure	_	
69-33	13420-13421	1	_	
69-34	13421-13422	)	_	
69-35	13422-13423	.	_	

#Text=The DMN and the DAN both appeared as anterior and posterior subnetworks whereas the CEN and VAN both were divided into a right and a left hemisphere component.
70-1	13424-13427	The	_	
70-2	13428-13431	DMN	_	
70-3	13432-13435	and	_	
70-4	13436-13439	the	_	
70-5	13440-13443	DAN	_	
70-6	13444-13448	both	_	
70-7	13449-13457	appeared	_	
70-8	13458-13460	as	_	
70-9	13461-13469	anterior	_	
70-10	13470-13473	and	_	
70-11	13474-13483	posterior	_	
70-12	13484-13495	subnetworks	_	
70-13	13496-13503	whereas	_	
70-14	13504-13507	the	_	
70-15	13508-13511	CEN	_	
70-16	13512-13515	and	_	
70-17	13516-13519	VAN	_	
70-18	13520-13524	both	_	
70-19	13525-13529	were	_	
70-20	13530-13537	divided	_	
70-21	13538-13542	into	_	
70-22	13543-13544	a	_	
70-23	13545-13550	right	_	
70-24	13551-13554	and	_	
70-25	13555-13556	a	_	
70-26	13557-13561	left	_	
70-27	13562-13572	hemisphere	_	
70-28	13573-13582	component	_	
70-29	13582-13583	.	_	

#Text=Although the VAN centered on the temporo-parietal junction and fronto-lateral cortex was originally proposed as a right-lateralized network, we chose to include a similar network present in the left hemisphere in the model.
71-1	13584-13592	Although	_	
71-2	13593-13596	the	_	
71-3	13597-13600	VAN	_	
71-4	13601-13609	centered	_	
71-5	13610-13612	on	_	
71-6	13613-13616	the	_	
71-7	13617-13633	temporo-parietal	_	
71-8	13634-13642	junction	_	
71-9	13643-13646	and	_	
71-10	13647-13661	fronto-lateral	_	
71-11	13662-13668	cortex	_	
71-12	13669-13672	was	_	
71-13	13673-13683	originally	_	
71-14	13684-13692	proposed	_	
71-15	13693-13695	as	_	
71-16	13696-13697	a	_	
71-17	13698-13715	right-lateralized	_	
71-18	13716-13723	network	_	
71-19	13723-13724	,	_	
71-20	13725-13727	we	_	
71-21	13728-13733	chose	_	
71-22	13734-13736	to	_	
71-23	13737-13744	include	_	
71-24	13745-13746	a	_	
71-25	13747-13754	similar	_	
71-26	13755-13762	network	_	
71-27	13763-13770	present	_	
71-28	13771-13773	in	_	
71-29	13774-13777	the	_	
71-30	13778-13782	left	_	
71-31	13783-13793	hemisphere	_	
71-32	13794-13796	in	_	
71-33	13797-13800	the	_	
71-34	13801-13806	model	_	
71-35	13806-13807	.	_	

#Text=The PCC, dACC and hippocampus, emphasized in the directed effort model, were comprised in the 2 DMN’s (PCC and hippocampus) and the SN (dACC).
72-1	13808-13811	The	_	
72-2	13812-13815	PCC	_	
72-3	13815-13816	,	_	
72-4	13817-13821	dACC	_	
72-5	13822-13825	and	_	
72-6	13826-13837	hippocampus	_	
72-7	13837-13838	,	_	
72-8	13839-13849	emphasized	_	
72-9	13850-13852	in	_	
72-10	13853-13856	the	_	
72-11	13857-13865	directed	_	
72-12	13866-13872	effort	_	
72-13	13873-13878	model	_	
72-14	13878-13879	,	_	
72-15	13880-13884	were	_	
72-16	13885-13894	comprised	_	
72-17	13895-13897	in	_	
72-18	13898-13901	the	_	
72-19	13902-13903	2	_	
72-20	13904-13907	DMN	_	
72-21	13907-13908	’	_	
72-22	13908-13909	s	_	
72-23	13910-13911	(	_	
72-24	13911-13914	PCC	_	
72-25	13915-13918	and	_	
72-26	13919-13930	hippocampus	_	
72-27	13930-13931	)	_	
72-28	13932-13935	and	_	
72-29	13936-13939	the	_	
72-30	13940-13942	SN	_	
72-31	13943-13944	(	_	
72-32	13944-13948	dACC	_	
72-33	13948-13949	)	_	
72-34	13949-13950	.	_	

#Text=Networks of interest.
73-1	13951-13959	Networks	_	
73-2	13960-13962	of	_	
73-3	13963-13971	interest	_	
73-4	13971-13972	.	_	

#Text=Default mode network (DMN), salience network (SN), central executive network (CEN), ventral attention network (VAN), dorsal attention network (DAN), and auditory network.
74-1	13973-13980	Default	_	
74-2	13981-13985	mode	_	
74-3	13986-13993	network	_	
74-4	13994-13995	(	_	
74-5	13995-13998	DMN	_	
74-6	13998-13999	)	_	
74-7	13999-14000	,	_	
74-8	14001-14009	salience	_	
74-9	14010-14017	network	_	
74-10	14018-14019	(	_	
74-11	14019-14021	SN	_	
74-12	14021-14022	)	_	
74-13	14022-14023	,	_	
74-14	14024-14031	central	_	
74-15	14032-14041	executive	_	
74-16	14042-14049	network	_	
74-17	14050-14051	(	_	
74-18	14051-14054	CEN	_	
74-19	14054-14055	)	_	
74-20	14055-14056	,	_	
74-21	14057-14064	ventral	_	
74-22	14065-14074	attention	_	
74-23	14075-14082	network	_	
74-24	14083-14084	(	_	
74-25	14084-14087	VAN	_	
74-26	14087-14088	)	_	
74-27	14088-14089	,	_	
74-28	14090-14096	dorsal	_	
74-29	14097-14106	attention	_	
74-30	14107-14114	network	_	
74-31	14115-14116	(	_	
74-32	14116-14119	DAN	_	
74-33	14119-14120	)	_	
74-34	14120-14121	,	_	
74-35	14122-14125	and	_	
74-36	14126-14134	auditory	_	
74-37	14135-14142	network	_	
74-38	14142-14143	.	_	

#Text=Functional Connectivity Within Networks
#Text=Spatial maps of networks of interest were similar between groups, and no voxel-wise group differences could be detected at corrected level.
75-1	14144-14154	Functional	_	
75-2	14155-14167	Connectivity	_	
75-3	14168-14174	Within	_	
75-4	14175-14183	Networks	_	
75-5	14184-14191	Spatial	_	
75-6	14192-14196	maps	_	
75-7	14197-14199	of	_	
75-8	14200-14208	networks	_	
75-9	14209-14211	of	_	
75-10	14212-14220	interest	_	
75-11	14221-14225	were	_	
75-12	14226-14233	similar	_	
75-13	14234-14241	between	_	
75-14	14242-14248	groups	_	
75-15	14248-14249	,	_	
75-16	14250-14253	and	_	
75-17	14254-14256	no	_	
75-18	14257-14267	voxel-wise	_	
75-19	14268-14273	group	_	
75-20	14274-14285	differences	_	
75-21	14286-14291	could	_	
75-22	14292-14294	be	_	
75-23	14295-14303	detected	_	
75-24	14304-14306	at	_	
75-25	14307-14316	corrected	_	
75-26	14317-14322	level	_	
75-27	14322-14323	.	_	

#Text=Functional Connectivity Between Networks
#Text=With a total number of 10 networks of interest the number of pairwise tests between networks was ((10–1) × 10)/2 = 45.
76-1	14324-14334	Functional	_	
76-2	14335-14347	Connectivity	_	
76-3	14348-14355	Between	_	
76-4	14356-14364	Networks	_	
76-5	14365-14369	With	_	
76-6	14370-14371	a	_	
76-7	14372-14377	total	_	
76-8	14378-14384	number	_	
76-9	14385-14387	of	_	
76-10	14388-14390	10	_	
76-11	14391-14399	networks	_	
76-12	14400-14402	of	_	
76-13	14403-14411	interest	_	
76-14	14412-14415	the	_	
76-15	14416-14422	number	_	
76-16	14423-14425	of	_	
76-17	14426-14434	pairwise	_	
76-18	14435-14440	tests	_	
76-19	14441-14448	between	_	
76-20	14449-14457	networks	_	
76-21	14458-14461	was	_	
76-22	14462-14463	(	_	
76-23	14463-14464	(	_	
76-24	14464-14466	10	_	
76-25	14466-14467	–	_	
76-26	14467-14468	1	_	
76-27	14468-14469	)	_	
76-28	14470-14471	×	_	
76-29	14472-14474	10	_	
76-30	14474-14475	)	_	
76-31	14475-14476	/	_	
76-32	14476-14477	2	_	
76-33	14478-14479	=	_	
76-34	14480-14482	45	_	
76-35	14482-14483	.	_	

#Text=This analysis revealed significant group difference in connectivity between left CEN and left VAN (P = .001, corrected), between right CEN and right VAN (P = .002, corrected), and between posterior DMN and auditory cortex (P = .006, borderline significant with correction) (figure 2).
77-1	14484-14488	This	_	
77-2	14489-14497	analysis	_	
77-3	14498-14506	revealed	_	
77-4	14507-14518	significant	_	
77-5	14519-14524	group	_	
77-6	14525-14535	difference	_	
77-7	14536-14538	in	_	
77-8	14539-14551	connectivity	_	
77-9	14552-14559	between	_	
77-10	14560-14564	left	_	
77-11	14565-14568	CEN	_	
77-12	14569-14572	and	_	
77-13	14573-14577	left	_	
77-14	14578-14581	VAN	_	
77-15	14582-14583	(	_	
77-16	14583-14584	P	_	
77-17	14585-14586	=	_	
77-18	14587-14591	.001	_	
77-19	14591-14592	,	_	
77-20	14593-14602	corrected	_	
77-21	14602-14603	)	_	
77-22	14603-14604	,	_	
77-23	14605-14612	between	_	
77-24	14613-14618	right	_	
77-25	14619-14622	CEN	_	
77-26	14623-14626	and	_	
77-27	14627-14632	right	_	
77-28	14633-14636	VAN	_	
77-29	14637-14638	(	_	
77-30	14638-14639	P	_	
77-31	14640-14641	=	_	
77-32	14642-14646	.002	_	
77-33	14646-14647	,	_	
77-34	14648-14657	corrected	_	
77-35	14657-14658	)	_	
77-36	14658-14659	,	_	
77-37	14660-14663	and	_	
77-38	14664-14671	between	_	
77-39	14672-14681	posterior	_	
77-40	14682-14685	DMN	_	
77-41	14686-14689	and	_	
77-42	14690-14698	auditory	_	
77-43	14699-14705	cortex	_	
77-44	14706-14707	(	_	
77-45	14707-14708	P	_	
77-46	14709-14710	=	_	
77-47	14711-14715	.006	_	
77-48	14715-14716	,	_	
77-49	14717-14727	borderline	_	
77-50	14728-14739	significant	_	
77-51	14740-14744	with	_	
77-52	14745-14755	correction	_	
77-53	14755-14756	)	_	
77-54	14757-14758	(	_	
77-55	14758-14764	figure	_	
77-56	14765-14766	2	_	
77-57	14766-14767	)	_	
77-58	14767-14768	.	_	

#Text=At uncorrected level group differences were seen between posterior DMN and right VAN (P = .019), posterior DMN and left VAN (P = .029), right CEN and auditory network (P = .030), and between right CEN and anterior DAN (P = .033).
78-1	14769-14771	At	_	
78-2	14772-14783	uncorrected	_	
78-3	14784-14789	level	_	
78-4	14790-14795	group	_	
78-5	14796-14807	differences	_	
78-6	14808-14812	were	_	
78-7	14813-14817	seen	_	
78-8	14818-14825	between	_	
78-9	14826-14835	posterior	_	
78-10	14836-14839	DMN	_	
78-11	14840-14843	and	_	
78-12	14844-14849	right	_	
78-13	14850-14853	VAN	_	
78-14	14854-14855	(	_	
78-15	14855-14856	P	_	
78-16	14857-14858	=	_	
78-17	14859-14863	.019	_	
78-18	14863-14864	)	_	
78-19	14864-14865	,	_	
78-20	14866-14875	posterior	_	
78-21	14876-14879	DMN	_	
78-22	14880-14883	and	_	
78-23	14884-14888	left	_	
78-24	14889-14892	VAN	_	
78-25	14893-14894	(	_	
78-26	14894-14895	P	_	
78-27	14896-14897	=	_	
78-28	14898-14902	.029	_	
78-29	14902-14903	)	_	
78-30	14903-14904	,	_	
78-31	14905-14910	right	_	
78-32	14911-14914	CEN	_	
78-33	14915-14918	and	_	
78-34	14919-14927	auditory	_	
78-35	14928-14935	network	_	
78-36	14936-14937	(	_	
78-37	14937-14938	P	_	
78-38	14939-14940	=	_	
78-39	14941-14945	.030	_	
78-40	14945-14946	)	_	
78-41	14946-14947	,	_	
78-42	14948-14951	and	_	
78-43	14952-14959	between	_	
78-44	14960-14965	right	_	
78-45	14966-14969	CEN	_	
78-46	14970-14973	and	_	
78-47	14974-14982	anterior	_	
78-48	14983-14986	DAN	_	
78-49	14987-14988	(	_	
78-50	14988-14989	P	_	
78-51	14990-14991	=	_	
78-52	14992-14996	.033	_	
78-53	14996-14997	)	_	
78-54	14997-14998	.	_	

#Text=In all cases patients had higher connectivity compared to controls.
79-1	14999-15001	In	_	
79-2	15002-15005	all	_	
79-3	15006-15011	cases	_	
79-4	15012-15020	patients	_	
79-5	15021-15024	had	_	
79-6	15025-15031	higher	_	
79-7	15032-15044	connectivity	_	
79-8	15045-15053	compared	_	
79-9	15054-15056	to	_	
79-10	15057-15065	controls	_	
79-11	15065-15066	.	_	

#Text=Group differences in pairwise correlations between networks of interest.
80-1	15067-15072	Group	_	
80-2	15073-15084	differences	_	
80-3	15085-15087	in	_	
80-4	15088-15096	pairwise	_	
80-5	15097-15109	correlations	_	
80-6	15110-15117	between	_	
80-7	15118-15126	networks	_	
80-8	15127-15129	of	_	
80-9	15130-15138	interest	_	
80-10	15138-15139	.	_	

#Text=The lines indicate stronger mean pairwise correlations in patients compared to controls, false discovery rate (FDR) corrected.
81-1	15140-15143	The	_	
81-2	15144-15149	lines	_	
81-3	15150-15158	indicate	_	
81-4	15159-15167	stronger	_	
81-5	15168-15172	mean	_	
81-6	15173-15181	pairwise	_	
81-7	15182-15194	correlations	_	
81-8	15195-15197	in	_	
81-9	15198-15206	patients	_	
81-10	15207-15215	compared	_	
81-11	15216-15218	to	_	
81-12	15219-15227	controls	_	
81-13	15227-15228	,	_	
81-14	15229-15234	false	_	
81-15	15235-15244	discovery	_	
81-16	15245-15249	rate	_	
81-17	15250-15251	(	_	
81-18	15251-15254	FDR	_	
81-19	15254-15255	)	_	
81-20	15256-15265	corrected	_	
81-21	15265-15266	.	_	

#Text=Functional Connectivity Between Networks and Clinical Characteristics
#Text=The search for associations between network connectivity and clinical symptoms was limited to the networks that showed a significant or borderline significant group difference at corrected level, ie, right and left CEN, right and left VAN, posterior DMN and auditory network.
82-1	15267-15277	Functional	_	
82-2	15278-15290	Connectivity	_	
82-3	15291-15298	Between	_	
82-4	15299-15307	Networks	_	
82-5	15308-15311	and	_	
82-6	15312-15320	Clinical	_	
82-7	15321-15336	Characteristics	_	
82-8	15337-15340	The	_	
82-9	15341-15347	search	_	
82-10	15348-15351	for	_	
82-11	15352-15364	associations	_	
82-12	15365-15372	between	_	
82-13	15373-15380	network	_	
82-14	15381-15393	connectivity	_	
82-15	15394-15397	and	_	
82-16	15398-15406	clinical	_	
82-17	15407-15415	symptoms	_	
82-18	15416-15419	was	_	
82-19	15420-15427	limited	_	
82-20	15428-15430	to	_	
82-21	15431-15434	the	_	
82-22	15435-15443	networks	_	
82-23	15444-15448	that	_	
82-24	15449-15455	showed	_	
82-25	15456-15457	a	_	
82-26	15458-15469	significant	_	
82-27	15470-15472	or	_	
82-28	15473-15483	borderline	_	
82-29	15484-15495	significant	_	
82-30	15496-15501	group	_	
82-31	15502-15512	difference	_	
82-32	15513-15515	at	_	
82-33	15516-15525	corrected	_	
82-34	15526-15531	level	_	
82-35	15531-15532	,	_	
82-36	15533-15535	ie	_	
82-37	15535-15536	,	_	
82-38	15537-15542	right	_	
82-39	15543-15546	and	_	
82-40	15547-15551	left	_	
82-41	15552-15555	CEN	_	
82-42	15555-15556	,	_	
82-43	15557-15562	right	_	
82-44	15563-15566	and	_	
82-45	15567-15571	left	_	
82-46	15572-15575	VAN	_	
82-47	15575-15576	,	_	
82-48	15577-15586	posterior	_	
82-49	15587-15590	DMN	_	
82-50	15591-15594	and	_	
82-51	15595-15603	auditory	_	
82-52	15604-15611	network	_	
82-53	15611-15612	.	_	

#Text=Calculating the correlation between PANSS scores and between-network connectivity did not reveal any significant effects at corrected level.
83-1	15613-15624	Calculating	_	
83-2	15625-15628	the	_	
83-3	15629-15640	correlation	_	
83-4	15641-15648	between	_	
83-5	15649-15654	PANSS	_	
83-6	15655-15661	scores	_	
83-7	15662-15665	and	_	
83-8	15666-15681	between-network	_	
83-9	15682-15694	connectivity	_	
83-10	15695-15698	did	_	
83-11	15699-15702	not	_	
83-12	15703-15709	reveal	_	
83-13	15710-15713	any	_	
83-14	15714-15725	significant	_	
83-15	15726-15733	effects	_	
83-16	15734-15736	at	_	
83-17	15737-15746	corrected	_	
83-18	15747-15752	level	_	
83-19	15752-15753	.	_	

#Text=Only to indicate a trend, a positive correlation was found between positive symptoms and the connectivity between right CEN and auditory network (P = .036, uncorrected), left CEN and left VAN (P = .010, uncorrected), and between left CEN and auditory network (P = .027, uncorrected).
84-1	15754-15758	Only	_	
84-2	15759-15761	to	_	
84-3	15762-15770	indicate	_	
84-4	15771-15772	a	_	
84-5	15773-15778	trend	_	
84-6	15778-15779	,	_	
84-7	15780-15781	a	_	
84-8	15782-15790	positive	_	
84-9	15791-15802	correlation	_	
84-10	15803-15806	was	_	
84-11	15807-15812	found	_	
84-12	15813-15820	between	_	
84-13	15821-15829	positive	_	
84-14	15830-15838	symptoms	_	
84-15	15839-15842	and	_	
84-16	15843-15846	the	_	
84-17	15847-15859	connectivity	_	
84-18	15860-15867	between	_	
84-19	15868-15873	right	_	
84-20	15874-15877	CEN	_	
84-21	15878-15881	and	_	
84-22	15882-15890	auditory	_	
84-23	15891-15898	network	_	
84-24	15899-15900	(	_	
84-25	15900-15901	P	_	
84-26	15902-15903	=	_	
84-27	15904-15908	.036	_	
84-28	15908-15909	,	_	
84-29	15910-15921	uncorrected	_	
84-30	15921-15922	)	_	
84-31	15922-15923	,	_	
84-32	15924-15928	left	_	
84-33	15929-15932	CEN	_	
84-34	15933-15936	and	_	
84-35	15937-15941	left	_	
84-36	15942-15945	VAN	_	
84-37	15946-15947	(	_	
84-38	15947-15948	P	_	
84-39	15949-15950	=	_	
84-40	15951-15955	.010	_	
84-41	15955-15956	,	_	
84-42	15957-15968	uncorrected	_	
84-43	15968-15969	)	_	
84-44	15969-15970	,	_	
84-45	15971-15974	and	_	
84-46	15975-15982	between	_	
84-47	15983-15987	left	_	
84-48	15988-15991	CEN	_	
84-49	15992-15995	and	_	
84-50	15996-16004	auditory	_	
84-51	16005-16012	network	_	
84-52	16013-16014	(	_	
84-53	16014-16015	P	_	
84-54	16016-16017	=	_	
84-55	16018-16022	.027	_	
84-56	16022-16023	,	_	
84-57	16024-16035	uncorrected	_	
84-58	16035-16036	)	_	
84-59	16036-16037	.	_	

#Text=A negative correlation was found between negative symptoms and the connectivity between left CEN and left VAN (P = .005, uncorrected), left CEN and right VAN (P = .048, uncorrected), and between left CEN and auditory network (P = .031, uncorrected).
85-1	16038-16039	A	_	
85-2	16040-16048	negative	_	
85-3	16049-16060	correlation	_	
85-4	16061-16064	was	_	
85-5	16065-16070	found	_	
85-6	16071-16078	between	_	
85-7	16079-16087	negative	_	
85-8	16088-16096	symptoms	_	
85-9	16097-16100	and	_	
85-10	16101-16104	the	_	
85-11	16105-16117	connectivity	_	
85-12	16118-16125	between	_	
85-13	16126-16130	left	_	
85-14	16131-16134	CEN	_	
85-15	16135-16138	and	_	
85-16	16139-16143	left	_	
85-17	16144-16147	VAN	_	
85-18	16148-16149	(	_	
85-19	16149-16150	P	_	
85-20	16151-16152	=	_	
85-21	16153-16157	.005	_	
85-22	16157-16158	,	_	
85-23	16159-16170	uncorrected	_	
85-24	16170-16171	)	_	
85-25	16171-16172	,	_	
85-26	16173-16177	left	_	
85-27	16178-16181	CEN	_	
85-28	16182-16185	and	_	
85-29	16186-16191	right	_	
85-30	16192-16195	VAN	_	
85-31	16196-16197	(	_	
85-32	16197-16198	P	_	
85-33	16199-16200	=	_	
85-34	16201-16205	.048	_	
85-35	16205-16206	,	_	
85-36	16207-16218	uncorrected	_	
85-37	16218-16219	)	_	
85-38	16219-16220	,	_	
85-39	16221-16224	and	_	
85-40	16225-16232	between	_	
85-41	16233-16237	left	_	
85-42	16238-16241	CEN	_	
85-43	16242-16245	and	_	
85-44	16246-16254	auditory	_	
85-45	16255-16262	network	_	
85-46	16263-16264	(	_	
85-47	16264-16265	P	_	
85-48	16266-16267	=	_	
85-49	16268-16272	.031	_	
85-50	16272-16273	,	_	
85-51	16274-16285	uncorrected	_	
85-52	16285-16286	)	_	
85-53	16286-16287	.	_	

#Text=General symptoms were positively correlated with the connectivity between left CEN and left VAN (P = .017, uncorrected), left CEN and right VAN (P = .041, uncorrected), and between right VAN and posterior DMN (P = .007, uncorrected).
86-1	16288-16295	General	_	
86-2	16296-16304	symptoms	_	
86-3	16305-16309	were	_	
86-4	16310-16320	positively	_	
86-5	16321-16331	correlated	_	
86-6	16332-16336	with	_	
86-7	16337-16340	the	_	
86-8	16341-16353	connectivity	_	
86-9	16354-16361	between	_	
86-10	16362-16366	left	_	
86-11	16367-16370	CEN	_	
86-12	16371-16374	and	_	
86-13	16375-16379	left	_	
86-14	16380-16383	VAN	_	
86-15	16384-16385	(	_	
86-16	16385-16386	P	_	
86-17	16387-16388	=	_	
86-18	16389-16393	.017	_	
86-19	16393-16394	,	_	
86-20	16395-16406	uncorrected	_	
86-21	16406-16407	)	_	
86-22	16407-16408	,	_	
86-23	16409-16413	left	_	
86-24	16414-16417	CEN	_	
86-25	16418-16421	and	_	
86-26	16422-16427	right	_	
86-27	16428-16431	VAN	_	
86-28	16432-16433	(	_	
86-29	16433-16434	P	_	
86-30	16435-16436	=	_	
86-31	16437-16441	.041	_	
86-32	16441-16442	,	_	
86-33	16443-16454	uncorrected	_	
86-34	16454-16455	)	_	
86-35	16455-16456	,	_	
86-36	16457-16460	and	_	
86-37	16461-16468	between	_	
86-38	16469-16474	right	_	
86-39	16475-16478	VAN	_	
86-40	16479-16482	and	_	
86-41	16483-16492	posterior	_	
86-42	16493-16496	DMN	_	
86-43	16497-16498	(	_	
86-44	16498-16499	P	_	
86-45	16500-16501	=	_	
86-46	16502-16506	.007	_	
86-47	16506-16507	,	_	
86-48	16508-16519	uncorrected	_	
86-49	16519-16520	)	_	
86-50	16520-16521	.	_	

#Text=Furthermore, general symptoms were negatively correlated with the connectivity between right CEN and left CEN (P = .032, uncorrected).
87-1	16522-16533	Furthermore	_	
87-2	16533-16534	,	_	
87-3	16535-16542	general	_	
87-4	16543-16551	symptoms	_	
87-5	16552-16556	were	_	
87-6	16557-16567	negatively	_	
87-7	16568-16578	correlated	_	
87-8	16579-16583	with	_	
87-9	16584-16587	the	_	
87-10	16588-16600	connectivity	_	
87-11	16601-16608	between	_	
87-12	16609-16614	right	_	
87-13	16615-16618	CEN	_	
87-14	16619-16622	and	_	
87-15	16623-16627	left	_	
87-16	16628-16631	CEN	_	
87-17	16632-16633	(	_	
87-18	16633-16634	P	_	
87-19	16635-16636	=	_	
87-20	16637-16641	.032	_	
87-21	16641-16642	,	_	
87-22	16643-16654	uncorrected	_	
87-23	16654-16655	)	_	
87-24	16655-16656	.	_	

#Text=In a separate analysis, we tested for an interaction between the effects of group and cognitive measures on the between-network connectivity (figure 3).
88-1	16657-16659	In	_	
88-2	16660-16661	a	_	
88-3	16662-16670	separate	_	
88-4	16671-16679	analysis	_	
88-5	16679-16680	,	_	
88-6	16681-16683	we	_	
88-7	16684-16690	tested	_	
88-8	16691-16694	for	_	
88-9	16695-16697	an	_	
88-10	16698-16709	interaction	_	
88-11	16710-16717	between	_	
88-12	16718-16721	the	_	
88-13	16722-16729	effects	_	
88-14	16730-16732	of	_	
88-15	16733-16738	group	_	
88-16	16739-16742	and	_	
88-17	16743-16752	cognitive	_	
88-18	16753-16761	measures	_	
88-19	16762-16764	on	_	
88-20	16765-16768	the	_	
88-21	16769-16784	between-network	_	
88-22	16785-16797	connectivity	_	
88-23	16798-16799	(	_	
88-24	16799-16805	figure	_	
88-25	16806-16807	3	_	
88-26	16807-16808	)	_	
88-27	16808-16809	.	_	

#Text=Significant interactions were revealed between the effects of group and sustained attention (RVP) on the connectivity between right CEN and right VAN (P = .006, corrected), left CEN and left VAN (P = .005, uncorrected), right VAN and posterior DMN (P = .038, uncorrected), and between posterior DMN and auditory network (P = .021, uncorrected).
89-1	16810-16821	Significant	_	
89-2	16822-16834	interactions	_	
89-3	16835-16839	were	_	
89-4	16840-16848	revealed	_	
89-5	16849-16856	between	_	
89-6	16857-16860	the	_	
89-7	16861-16868	effects	_	
89-8	16869-16871	of	_	
89-9	16872-16877	group	_	
89-10	16878-16881	and	_	
89-11	16882-16891	sustained	_	
89-12	16892-16901	attention	_	
89-13	16902-16903	(	_	
89-14	16903-16906	RVP	_	
89-15	16906-16907	)	_	
89-16	16908-16910	on	_	
89-17	16911-16914	the	_	
89-18	16915-16927	connectivity	_	
89-19	16928-16935	between	_	
89-20	16936-16941	right	_	
89-21	16942-16945	CEN	_	
89-22	16946-16949	and	_	
89-23	16950-16955	right	_	
89-24	16956-16959	VAN	_	
89-25	16960-16961	(	_	
89-26	16961-16962	P	_	
89-27	16963-16964	=	_	
89-28	16965-16969	.006	_	
89-29	16969-16970	,	_	
89-30	16971-16980	corrected	_	
89-31	16980-16981	)	_	
89-32	16981-16982	,	_	
89-33	16983-16987	left	_	
89-34	16988-16991	CEN	_	
89-35	16992-16995	and	_	
89-36	16996-17000	left	_	
89-37	17001-17004	VAN	_	
89-38	17005-17006	(	_	
89-39	17006-17007	P	_	
89-40	17008-17009	=	_	
89-41	17010-17014	.005	_	
89-42	17014-17015	,	_	
89-43	17016-17027	uncorrected	_	
89-44	17027-17028	)	_	
89-45	17028-17029	,	_	
89-46	17030-17035	right	_	
89-47	17036-17039	VAN	_	
89-48	17040-17043	and	_	
89-49	17044-17053	posterior	_	
89-50	17054-17057	DMN	_	
89-51	17058-17059	(	_	
89-52	17059-17060	P	_	
89-53	17061-17062	=	_	
89-54	17063-17067	.038	_	
89-55	17067-17068	,	_	
89-56	17069-17080	uncorrected	_	
89-57	17080-17081	)	_	
89-58	17081-17082	,	_	
89-59	17083-17086	and	_	
89-60	17087-17094	between	_	
89-61	17095-17104	posterior	_	
89-62	17105-17108	DMN	_	
89-63	17109-17112	and	_	
89-64	17113-17121	auditory	_	
89-65	17122-17129	network	_	
89-66	17130-17131	(	_	
89-67	17131-17132	P	_	
89-68	17133-17134	=	_	
89-69	17135-17139	.021	_	
89-70	17139-17140	,	_	
89-71	17141-17152	uncorrected	_	
89-72	17152-17153	)	_	
89-73	17153-17154	.	_	

#Text=This analysis also revealed an interaction between the effects of group and processing speed (symbol coding) on the connectivity between right CEN and right VAN (P = .007, borderline significant at corrected level), left CEN and left VAN (P = .006, uncorrected), right CEN and auditory network (P = .045, uncorrected), and between posterior DMN and auditory network (P = .047, uncorrected).
90-1	17155-17159	This	_	
90-2	17160-17168	analysis	_	
90-3	17169-17173	also	_	
90-4	17174-17182	revealed	_	
90-5	17183-17185	an	_	
90-6	17186-17197	interaction	_	
90-7	17198-17205	between	_	
90-8	17206-17209	the	_	
90-9	17210-17217	effects	_	
90-10	17218-17220	of	_	
90-11	17221-17226	group	_	
90-12	17227-17230	and	_	
90-13	17231-17241	processing	_	
90-14	17242-17247	speed	_	
90-15	17248-17249	(	_	
90-16	17249-17255	symbol	_	
90-17	17256-17262	coding	_	
90-18	17262-17263	)	_	
90-19	17264-17266	on	_	
90-20	17267-17270	the	_	
90-21	17271-17283	connectivity	_	
90-22	17284-17291	between	_	
90-23	17292-17297	right	_	
90-24	17298-17301	CEN	_	
90-25	17302-17305	and	_	
90-26	17306-17311	right	_	
90-27	17312-17315	VAN	_	
90-28	17316-17317	(	_	
90-29	17317-17318	P	_	
90-30	17319-17320	=	_	
90-31	17321-17325	.007	_	
90-32	17325-17326	,	_	
90-33	17327-17337	borderline	_	
90-34	17338-17349	significant	_	
90-35	17350-17352	at	_	
90-36	17353-17362	corrected	_	
90-37	17363-17368	level	_	
90-38	17368-17369	)	_	
90-39	17369-17370	,	_	
90-40	17371-17375	left	_	
90-41	17376-17379	CEN	_	
90-42	17380-17383	and	_	
90-43	17384-17388	left	_	
90-44	17389-17392	VAN	_	
90-45	17393-17394	(	_	
90-46	17394-17395	P	_	
90-47	17396-17397	=	_	
90-48	17398-17402	.006	_	
90-49	17402-17403	,	_	
90-50	17404-17415	uncorrected	_	
90-51	17415-17416	)	_	
90-52	17416-17417	,	_	
90-53	17418-17423	right	_	
90-54	17424-17427	CEN	_	
90-55	17428-17431	and	_	
90-56	17432-17440	auditory	_	
90-57	17441-17448	network	_	
90-58	17449-17450	(	_	
90-59	17450-17451	P	_	
90-60	17452-17453	=	_	
90-61	17454-17458	.045	_	
90-62	17458-17459	,	_	
90-63	17460-17471	uncorrected	_	
90-64	17471-17472	)	_	
90-65	17472-17473	,	_	
90-66	17474-17477	and	_	
90-67	17478-17485	between	_	
90-68	17486-17495	posterior	_	
90-69	17496-17499	DMN	_	
90-70	17500-17503	and	_	
90-71	17504-17512	auditory	_	
90-72	17513-17520	network	_	
90-73	17521-17522	(	_	
90-74	17522-17523	P	_	
90-75	17524-17525	=	_	
90-76	17526-17530	.047	_	
90-77	17530-17531	,	_	
90-78	17532-17543	uncorrected	_	
90-79	17543-17544	)	_	
90-80	17544-17545	.	_	

#Text=Furthermore, we found an interaction between the effects of group and general intelligence on the connectivity between right CEN and right VAN (P = .010, uncorrected), right CEN and auditory network (P = .014, uncorrected), left CEN and left VAN (P = .009, uncorrected), posterior DMN and auditory network (P = .021, uncorrected).
91-1	17546-17557	Furthermore	_	
91-2	17557-17558	,	_	
91-3	17559-17561	we	_	
91-4	17562-17567	found	_	
91-5	17568-17570	an	_	
91-6	17571-17582	interaction	_	
91-7	17583-17590	between	_	
91-8	17591-17594	the	_	
91-9	17595-17602	effects	_	
91-10	17603-17605	of	_	
91-11	17606-17611	group	_	
91-12	17612-17615	and	_	
91-13	17616-17623	general	_	
91-14	17624-17636	intelligence	_	
91-15	17637-17639	on	_	
91-16	17640-17643	the	_	
91-17	17644-17656	connectivity	_	
91-18	17657-17664	between	_	
91-19	17665-17670	right	_	
91-20	17671-17674	CEN	_	
91-21	17675-17678	and	_	
91-22	17679-17684	right	_	
91-23	17685-17688	VAN	_	
91-24	17689-17690	(	_	
91-25	17690-17691	P	_	
91-26	17692-17693	=	_	
91-27	17694-17698	.010	_	
91-28	17698-17699	,	_	
91-29	17700-17711	uncorrected	_	
91-30	17711-17712	)	_	
91-31	17712-17713	,	_	
91-32	17714-17719	right	_	
91-33	17720-17723	CEN	_	
91-34	17724-17727	and	_	
91-35	17728-17736	auditory	_	
91-36	17737-17744	network	_	
91-37	17745-17746	(	_	
91-38	17746-17747	P	_	
91-39	17748-17749	=	_	
91-40	17750-17754	.014	_	
91-41	17754-17755	,	_	
91-42	17756-17767	uncorrected	_	
91-43	17767-17768	)	_	
91-44	17768-17769	,	_	
91-45	17770-17774	left	_	
91-46	17775-17778	CEN	_	
91-47	17779-17782	and	_	
91-48	17783-17787	left	_	
91-49	17788-17791	VAN	_	
91-50	17792-17793	(	_	
91-51	17793-17794	P	_	
91-52	17795-17796	=	_	
91-53	17797-17801	.009	_	
91-54	17801-17802	,	_	
91-55	17803-17814	uncorrected	_	
91-56	17814-17815	)	_	
91-57	17815-17816	,	_	
91-58	17817-17826	posterior	_	
91-59	17827-17830	DMN	_	
91-60	17831-17834	and	_	
91-61	17835-17843	auditory	_	
91-62	17844-17851	network	_	
91-63	17852-17853	(	_	
91-64	17853-17854	P	_	
91-65	17855-17856	=	_	
91-66	17857-17861	.021	_	
91-67	17861-17862	,	_	
91-68	17863-17874	uncorrected	_	
91-69	17874-17875	)	_	
91-70	17875-17876	.	_	

#Text=In all these interactions, the correlation between network connectivity and cognitive measures was higher in patients compared to controls.
92-1	17877-17879	In	_	
92-2	17880-17883	all	_	
92-3	17884-17889	these	_	
92-4	17890-17902	interactions	_	
92-5	17902-17903	,	_	
92-6	17904-17907	the	_	
92-7	17908-17919	correlation	_	
92-8	17920-17927	between	_	
92-9	17928-17935	network	_	
92-10	17936-17948	connectivity	_	
92-11	17949-17952	and	_	
92-12	17953-17962	cognitive	_	
92-13	17963-17971	measures	_	
92-14	17972-17975	was	_	
92-15	17976-17982	higher	_	
92-16	17983-17985	in	_	
92-17	17986-17994	patients	_	
92-18	17995-18003	compared	_	
92-19	18004-18006	to	_	
92-20	18007-18015	controls	_	
92-21	18015-18016	.	_	

#Text=The same analysis for an interaction between the effects of group and executive function (IED) on between network connectivity did not reveal any significant results.
93-1	18017-18020	The	_	
93-2	18021-18025	same	_	
93-3	18026-18034	analysis	_	
93-4	18035-18038	for	_	
93-5	18039-18041	an	_	
93-6	18042-18053	interaction	_	
93-7	18054-18061	between	_	
93-8	18062-18065	the	_	
93-9	18066-18073	effects	_	
93-10	18074-18076	of	_	
93-11	18077-18082	group	_	
93-12	18083-18086	and	_	
93-13	18087-18096	executive	_	
93-14	18097-18105	function	_	
93-15	18106-18107	(	_	
93-16	18107-18110	IED	_	
93-17	18110-18111	)	_	
93-18	18112-18114	on	_	
93-19	18115-18122	between	_	
93-20	18123-18130	network	_	
93-21	18131-18143	connectivity	_	
93-22	18144-18147	did	_	
93-23	18148-18151	not	_	
93-24	18152-18158	reveal	_	
93-25	18159-18162	any	_	
93-26	18163-18174	significant	_	
93-27	18175-18182	results	_	
93-28	18182-18183	.	_	

#Text=Interaction between group and cognitive measures on pairwise correlations between networks of interest.
94-1	18184-18195	Interaction	_	
94-2	18196-18203	between	_	
94-3	18204-18209	group	_	
94-4	18210-18213	and	_	
94-5	18214-18223	cognitive	_	
94-6	18224-18232	measures	_	
94-7	18233-18235	on	_	
94-8	18236-18244	pairwise	_	
94-9	18245-18257	correlations	_	
94-10	18258-18265	between	_	
94-11	18266-18274	networks	_	
94-12	18275-18277	of	_	
94-13	18278-18286	interest	_	
94-14	18286-18287	.	_	

#Text=The lines indicate a significant interaction between group and the specific cognitive measures on the pairwise correlation between networks, false discovery rate (FDR) corrected.
95-1	18288-18291	The	_	
95-2	18292-18297	lines	_	
95-3	18298-18306	indicate	_	
95-4	18307-18308	a	_	
95-5	18309-18320	significant	_	
95-6	18321-18332	interaction	_	
95-7	18333-18340	between	_	
95-8	18341-18346	group	_	
95-9	18347-18350	and	_	
95-10	18351-18354	the	_	
95-11	18355-18363	specific	_	
95-12	18364-18373	cognitive	_	
95-13	18374-18382	measures	_	
95-14	18383-18385	on	_	
95-15	18386-18389	the	_	
95-16	18390-18398	pairwise	_	
95-17	18399-18410	correlation	_	
95-18	18411-18418	between	_	
95-19	18419-18427	networks	_	
95-20	18427-18428	,	_	
95-21	18429-18434	false	_	
95-22	18435-18444	discovery	_	
95-23	18445-18449	rate	_	
95-24	18450-18451	(	_	
95-25	18451-18454	FDR	_	
95-26	18454-18455	)	_	
95-27	18456-18465	corrected	_	
95-28	18465-18466	.	_	

#Text=Full line = sustained attention (RVP).
96-1	18467-18471	Full	_	
96-2	18472-18476	line	_	
96-3	18477-18478	=	_	
96-4	18479-18488	sustained	_	
96-5	18489-18498	attention	_	
96-6	18499-18500	(	_	
96-7	18500-18503	RVP	_	
96-8	18503-18504	)	_	
96-9	18504-18505	.	_	

#Text=Dotted line = processing speed (symbol coding).
97-1	18506-18512	Dotted	_	
97-2	18513-18517	line	_	
97-3	18518-18519	=	_	
97-4	18520-18530	processing	_	
97-5	18531-18536	speed	_	
97-6	18537-18538	(	_	
97-7	18538-18544	symbol	_	
97-8	18545-18551	coding	_	
97-9	18551-18552	)	_	
97-10	18552-18553	.	_	

#Text=Discussion
#Text=The present study of a large, well-characterized group of ANFE patients suggests that the early state of schizophrenia is associated with increased connectivity between fronto-parietal networks involved in the control of cognitive and sensory functions.
98-1	18554-18564	Discussion	_	
98-2	18565-18568	The	_	
98-3	18569-18576	present	_	
98-4	18577-18582	study	_	
98-5	18583-18585	of	_	
98-6	18586-18587	a	_	
98-7	18588-18593	large	_	
98-8	18593-18594	,	_	
98-9	18595-18613	well-characterized	_	
98-10	18614-18619	group	_	
98-11	18620-18622	of	_	
98-12	18623-18627	ANFE	_	
98-13	18628-18636	patients	_	
98-14	18637-18645	suggests	_	
98-15	18646-18650	that	_	
98-16	18651-18654	the	_	
98-17	18655-18660	early	_	
98-18	18661-18666	state	_	
98-19	18667-18669	of	_	
98-20	18670-18683	schizophrenia	_	
98-21	18684-18686	is	_	
98-22	18687-18697	associated	_	
98-23	18698-18702	with	_	
98-24	18703-18712	increased	_	
98-25	18713-18725	connectivity	_	
98-26	18726-18733	between	_	
98-27	18734-18749	fronto-parietal	_	
98-28	18750-18758	networks	_	
98-29	18759-18767	involved	_	
98-30	18768-18770	in	_	
98-31	18771-18774	the	_	
98-32	18775-18782	control	_	
98-33	18783-18785	of	_	
98-34	18786-18795	cognitive	_	
98-35	18796-18799	and	_	
98-36	18800-18807	sensory	_	
98-37	18808-18817	functions	_	
98-38	18817-18818	.	_	

#Text=Further, the results suggest that the problem of not disengaging the CEN and the VAN is associated with cognitive deficits.
99-1	18819-18826	Further	_	
99-2	18826-18827	,	_	
99-3	18828-18831	the	_	
99-4	18832-18839	results	_	
99-5	18840-18847	suggest	_	
99-6	18848-18852	that	_	
99-7	18853-18856	the	_	
99-8	18857-18864	problem	_	
99-9	18865-18867	of	_	
99-10	18868-18871	not	_	
99-11	18872-18883	disengaging	_	
99-12	18884-18887	the	_	
99-13	18888-18891	CEN	_	
99-14	18892-18895	and	_	
99-15	18896-18899	the	_	
99-16	18900-18903	VAN	_	
99-17	18904-18906	is	_	
99-18	18907-18917	associated	_	
99-19	18918-18922	with	_	
99-20	18923-18932	cognitive	_	
99-21	18933-18941	deficits	_	
99-22	18941-18942	.	_	

#Text=Alterations in Functional Connectivity
#Text=Our finding of altered connectivity between the CEN’s and VAN’s and between posterior DMN and auditory network are in line with a few previous studies in ANFE (or partly antipsychotic-naïve) patients that have showed altered connectivity of fronto-parietal networks and DMN whereas one study found no alterations of DLPFC connectivity.
100-1	18943-18954	Alterations	_	
100-2	18955-18957	in	_	
100-3	18958-18968	Functional	_	
100-4	18969-18981	Connectivity	_	
100-5	18982-18985	Our	_	
100-6	18986-18993	finding	_	
100-7	18994-18996	of	_	
100-8	18997-19004	altered	_	
100-9	19005-19017	connectivity	_	
100-10	19018-19025	between	_	
100-11	19026-19029	the	_	
100-12	19030-19033	CEN	_	
100-13	19033-19034	’	_	
100-14	19034-19035	s	_	
100-15	19036-19039	and	_	
100-16	19040-19043	VAN	_	
100-17	19043-19044	’	_	
100-18	19044-19045	s	_	
100-19	19046-19049	and	_	
100-20	19050-19057	between	_	
100-21	19058-19067	posterior	_	
100-22	19068-19071	DMN	_	
100-23	19072-19075	and	_	
100-24	19076-19084	auditory	_	
100-25	19085-19092	network	_	
100-26	19093-19096	are	_	
100-27	19097-19099	in	_	
100-28	19100-19104	line	_	
100-29	19105-19109	with	_	
100-30	19110-19111	a	_	
100-31	19112-19115	few	_	
100-32	19116-19124	previous	_	
100-33	19125-19132	studies	_	
100-34	19133-19135	in	_	
100-35	19136-19140	ANFE	_	
100-36	19141-19142	(	_	
100-37	19142-19144	or	_	
100-38	19145-19151	partly	_	
100-39	19152-19171	antipsychotic-naïve	_	
100-40	19171-19172	)	_	
100-41	19173-19181	patients	_	
100-42	19182-19186	that	_	
100-43	19187-19191	have	_	
100-44	19192-19198	showed	_	
100-45	19199-19206	altered	_	
100-46	19207-19219	connectivity	_	
100-47	19220-19222	of	_	
100-48	19223-19238	fronto-parietal	_	
100-49	19239-19247	networks	_	
100-50	19248-19251	and	_	
100-51	19252-19255	DMN	_	
100-52	19256-19263	whereas	_	
100-53	19264-19267	one	_	
100-54	19268-19273	study	_	
100-55	19274-19279	found	_	
100-56	19280-19282	no	_	
100-57	19283-19294	alterations	_	
100-58	19295-19297	of	_	
100-59	19298-19303	DLPFC	_	
100-60	19304-19316	connectivity	_	
100-61	19316-19317	.	_	

#Text=On the other hand, these studies did not report alterations in connectivity between DMN/PCC and auditory network as revealed in the present study, although altered connectivity of PCC and auditory networks was found.
101-1	19318-19320	On	_	
101-2	19321-19324	the	_	
101-3	19325-19330	other	_	
101-4	19331-19335	hand	_	
101-5	19335-19336	,	_	
101-6	19337-19342	these	_	
101-7	19343-19350	studies	_	
101-8	19351-19354	did	_	
101-9	19355-19358	not	_	
101-10	19359-19365	report	_	
101-11	19366-19377	alterations	_	
101-12	19378-19380	in	_	
101-13	19381-19393	connectivity	_	
101-14	19394-19401	between	_	
101-15	19402-19405	DMN	_	
101-16	19405-19406	/	_	
101-17	19406-19409	PCC	_	
101-18	19410-19413	and	_	
101-19	19414-19422	auditory	_	
101-20	19423-19430	network	_	
101-21	19431-19433	as	_	
101-22	19434-19442	revealed	_	
101-23	19443-19445	in	_	
101-24	19446-19449	the	_	
101-25	19450-19457	present	_	
101-26	19458-19463	study	_	
101-27	19463-19464	,	_	
101-28	19465-19473	although	_	
101-29	19474-19481	altered	_	
101-30	19482-19494	connectivity	_	
101-31	19495-19497	of	_	
101-32	19498-19501	PCC	_	
101-33	19502-19505	and	_	
101-34	19506-19514	auditory	_	
101-35	19515-19523	networks	_	
101-36	19524-19527	was	_	
101-37	19528-19533	found	_	
101-38	19533-19534	.	_	

#Text=A recent study in adolescents with auditory hallucinations also suggested altered connectivity between DMN areas and auditory cortex.
102-1	19535-19536	A	_	
102-2	19537-19543	recent	_	
102-3	19544-19549	study	_	
102-4	19550-19552	in	_	
102-5	19553-19564	adolescents	_	
102-6	19565-19569	with	_	
102-7	19570-19578	auditory	_	
102-8	19579-19593	hallucinations	_	
102-9	19594-19598	also	_	
102-10	19599-19608	suggested	_	
102-11	19609-19616	altered	_	
102-12	19617-19629	connectivity	_	
102-13	19630-19637	between	_	
102-14	19638-19641	DMN	_	
102-15	19642-19647	areas	_	
102-16	19648-19651	and	_	
102-17	19652-19660	auditory	_	
102-18	19661-19667	cortex	_	
102-19	19667-19668	.	_	

#Text=In the present study, the SN did not show any network alterations as hypothesized by the network models.
103-1	19669-19671	In	_	
103-2	19672-19675	the	_	
103-3	19676-19683	present	_	
103-4	19684-19689	study	_	
103-5	19689-19690	,	_	
103-6	19691-19694	the	_	
103-7	19695-19697	SN	_	
103-8	19698-19701	did	_	
103-9	19702-19705	not	_	
103-10	19706-19710	show	_	
103-11	19711-19714	any	_	
103-12	19715-19722	network	_	
103-13	19723-19734	alterations	_	
103-14	19735-19737	as	_	
103-15	19738-19750	hypothesized	_	
103-16	19751-19753	by	_	
103-17	19754-19757	the	_	
103-18	19758-19765	network	_	
103-19	19766-19772	models	_	
103-20	19772-19773	.	_	

#Text=This is in line with one of the previous study in ANFE patients showing no alteration of dACC connectivity.
104-1	19774-19778	This	_	
104-2	19779-19781	is	_	
104-3	19782-19784	in	_	
104-4	19785-19789	line	_	
104-5	19790-19794	with	_	
104-6	19795-19798	one	_	
104-7	19799-19801	of	_	
104-8	19802-19805	the	_	
104-9	19806-19814	previous	_	
104-10	19815-19820	study	_	
104-11	19821-19823	in	_	
104-12	19824-19828	ANFE	_	
104-13	19829-19837	patients	_	
104-14	19838-19845	showing	_	
104-15	19846-19848	no	_	
104-16	19849-19859	alteration	_	
104-17	19860-19862	of	_	
104-18	19863-19867	dACC	_	
104-19	19868-19880	connectivity	_	
104-20	19880-19881	.	_	

#Text=Our finding of no voxel-wise alterations in any network of interest are partly in line with a previous study reporting no group differences.
105-1	19882-19885	Our	_	
105-2	19886-19893	finding	_	
105-3	19894-19896	of	_	
105-4	19897-19899	no	_	
105-5	19900-19910	voxel-wise	_	
105-6	19911-19922	alterations	_	
105-7	19923-19925	in	_	
105-8	19926-19929	any	_	
105-9	19930-19937	network	_	
105-10	19938-19940	of	_	
105-11	19941-19949	interest	_	
105-12	19950-19953	are	_	
105-13	19954-19960	partly	_	
105-14	19961-19963	in	_	
105-15	19964-19968	line	_	
105-16	19969-19973	with	_	
105-17	19974-19975	a	_	
105-18	19976-19984	previous	_	
105-19	19985-19990	study	_	
105-20	19991-20000	reporting	_	
105-21	20001-20003	no	_	
105-22	20004-20009	group	_	
105-23	20010-20021	differences	_	
105-24	20021-20022	.	_	

#Text=However, some previous studies have found voxel-wise alterations especially in PCC connectivity.
106-1	20023-20030	However	_	
106-2	20030-20031	,	_	
106-3	20032-20036	some	_	
106-4	20037-20045	previous	_	
106-5	20046-20053	studies	_	
106-6	20054-20058	have	_	
106-7	20059-20064	found	_	
106-8	20065-20075	voxel-wise	_	
106-9	20076-20087	alterations	_	
106-10	20088-20098	especially	_	
106-11	20099-20101	in	_	
106-12	20102-20105	PCC	_	
106-13	20106-20118	connectivity	_	
106-14	20118-20119	.	_	

#Text=Importantly, these inconsistencies between studies may be explained by the wide array of methods applied in functional connectivity studies.
107-1	20120-20131	Importantly	_	
107-2	20131-20132	,	_	
107-3	20133-20138	these	_	
107-4	20139-20154	inconsistencies	_	
107-5	20155-20162	between	_	
107-6	20163-20170	studies	_	
107-7	20171-20174	may	_	
107-8	20175-20177	be	_	
107-9	20178-20187	explained	_	
107-10	20188-20190	by	_	
107-11	20191-20194	the	_	
107-12	20195-20199	wide	_	
107-13	20200-20205	array	_	
107-14	20206-20208	of	_	
107-15	20209-20216	methods	_	
107-16	20217-20224	applied	_	
107-17	20225-20227	in	_	
107-18	20228-20238	functional	_	
107-19	20239-20251	connectivity	_	
107-20	20252-20259	studies	_	
107-21	20259-20260	.	_	

#Text=The CEN and VAN together with the DAN and SN have been suggested to be part of an overall control-system involved broadly in the control of a range of cognitive and sensory functions.
108-1	20261-20264	The	_	
108-2	20265-20268	CEN	_	
108-3	20269-20272	and	_	
108-4	20273-20276	VAN	_	
108-5	20277-20285	together	_	
108-6	20286-20290	with	_	
108-7	20291-20294	the	_	
108-8	20295-20298	DAN	_	
108-9	20299-20302	and	_	
108-10	20303-20305	SN	_	
108-11	20306-20310	have	_	
108-12	20311-20315	been	_	
108-13	20316-20325	suggested	_	
108-14	20326-20328	to	_	
108-15	20329-20331	be	_	
108-16	20332-20336	part	_	
108-17	20337-20339	of	_	
108-18	20340-20342	an	_	
108-19	20343-20350	overall	_	
108-20	20351-20365	control-system	_	
108-21	20366-20374	involved	_	
108-22	20375-20382	broadly	_	
108-23	20383-20385	in	_	
108-24	20386-20389	the	_	
108-25	20390-20397	control	_	
108-26	20398-20400	of	_	
108-27	20401-20402	a	_	
108-28	20403-20408	range	_	
108-29	20409-20411	of	_	
108-30	20412-20421	cognitive	_	
108-31	20422-20425	and	_	
108-32	20426-20433	sensory	_	
108-33	20434-20443	functions	_	
108-34	20443-20444	.	_	

#Text=More specifically, the VAN anchored in the temporo-parietal junction (TPJ) has been suggested to be involved in the detection of behaviorally relevant stimuli and therefore act as a circuit-breaker for the DAN in order to direct attention in an adequate manner.
109-1	20445-20449	More	_	
109-2	20450-20462	specifically	_	
109-3	20462-20463	,	_	
109-4	20464-20467	the	_	
109-5	20468-20471	VAN	_	
109-6	20472-20480	anchored	_	
109-7	20481-20483	in	_	
109-8	20484-20487	the	_	
109-9	20488-20504	temporo-parietal	_	
109-10	20505-20513	junction	_	
109-11	20514-20515	(	_	
109-12	20515-20518	TPJ	_	
109-13	20518-20519	)	_	
109-14	20520-20523	has	_	
109-15	20524-20528	been	_	
109-16	20529-20538	suggested	_	
109-17	20539-20541	to	_	
109-18	20542-20544	be	_	
109-19	20545-20553	involved	_	
109-20	20554-20556	in	_	
109-21	20557-20560	the	_	
109-22	20561-20570	detection	_	
109-23	20571-20573	of	_	
109-24	20574-20586	behaviorally	_	
109-25	20587-20595	relevant	_	
109-26	20596-20603	stimuli	_	
109-27	20604-20607	and	_	
109-28	20608-20617	therefore	_	
109-29	20618-20621	act	_	
109-30	20622-20624	as	_	
109-31	20625-20626	a	_	
109-32	20627-20642	circuit-breaker	_	
109-33	20643-20646	for	_	
109-34	20647-20650	the	_	
109-35	20651-20654	DAN	_	
109-36	20655-20657	in	_	
109-37	20658-20663	order	_	
109-38	20664-20666	to	_	
109-39	20667-20673	direct	_	
109-40	20674-20683	attention	_	
109-41	20684-20686	in	_	
109-42	20687-20689	an	_	
109-43	20690-20698	adequate	_	
109-44	20699-20705	manner	_	
109-45	20705-20706	.	_	

#Text=Furthermore, the VAN has been shown to be involved in attentional control and in determining the intentions or mental states of other people.
110-1	20707-20718	Furthermore	_	
110-2	20718-20719	,	_	
110-3	20720-20723	the	_	
110-4	20724-20727	VAN	_	
110-5	20728-20731	has	_	
110-6	20732-20736	been	_	
110-7	20737-20742	shown	_	
110-8	20743-20745	to	_	
110-9	20746-20748	be	_	
110-10	20749-20757	involved	_	
110-11	20758-20760	in	_	
110-12	20761-20772	attentional	_	
110-13	20773-20780	control	_	
110-14	20781-20784	and	_	
110-15	20785-20787	in	_	
110-16	20788-20799	determining	_	
110-17	20800-20803	the	_	
110-18	20804-20814	intentions	_	
110-19	20815-20817	or	_	
110-20	20818-20824	mental	_	
110-21	20825-20831	states	_	
110-22	20832-20834	of	_	
110-23	20835-20840	other	_	
110-24	20841-20847	people	_	
110-25	20847-20848	.	_	

#Text=The CEN anchored in dorsolateral prefrontal and lateral parietal cortex has been associated with the ability to maintain and manipulate information, problem-solving in accordance with a rule and to make decisions in goal-directed behavior.
111-1	20849-20852	The	_	
111-2	20853-20856	CEN	_	
111-3	20857-20865	anchored	_	
111-4	20866-20868	in	_	
111-5	20869-20881	dorsolateral	_	
111-6	20882-20892	prefrontal	_	
111-7	20893-20896	and	_	
111-8	20897-20904	lateral	_	
111-9	20905-20913	parietal	_	
111-10	20914-20920	cortex	_	
111-11	20921-20924	has	_	
111-12	20925-20929	been	_	
111-13	20930-20940	associated	_	
111-14	20941-20945	with	_	
111-15	20946-20949	the	_	
111-16	20950-20957	ability	_	
111-17	20958-20960	to	_	
111-18	20961-20969	maintain	_	
111-19	20970-20973	and	_	
111-20	20974-20984	manipulate	_	
111-21	20985-20996	information	_	
111-22	20996-20997	,	_	
111-23	20998-21013	problem-solving	_	
111-24	21014-21016	in	_	
111-25	21017-21027	accordance	_	
111-26	21028-21032	with	_	
111-27	21033-21034	a	_	
111-28	21035-21039	rule	_	
111-29	21040-21043	and	_	
111-30	21044-21046	to	_	
111-31	21047-21051	make	_	
111-32	21052-21061	decisions	_	
111-33	21062-21064	in	_	
111-34	21065-21078	goal-directed	_	
111-35	21079-21087	behavior	_	
111-36	21087-21088	.	_	

#Text=PCC is a central part of the DMN involved in internally directed cognition, but it is also suggested to have a regulating function in terms of controlling attention including the shift between internal and external focus.
112-1	21089-21092	PCC	_	
112-2	21093-21095	is	_	
112-3	21096-21097	a	_	
112-4	21098-21105	central	_	
112-5	21106-21110	part	_	
112-6	21111-21113	of	_	
112-7	21114-21117	the	_	
112-8	21118-21121	DMN	_	
112-9	21122-21130	involved	_	
112-10	21131-21133	in	_	
112-11	21134-21144	internally	_	
112-12	21145-21153	directed	_	
112-13	21154-21163	cognition	_	
112-14	21163-21164	,	_	
112-15	21165-21168	but	_	
112-16	21169-21171	it	_	
112-17	21172-21174	is	_	
112-18	21175-21179	also	_	
112-19	21180-21189	suggested	_	
112-20	21190-21192	to	_	
112-21	21193-21197	have	_	
112-22	21198-21199	a	_	
112-23	21200-21210	regulating	_	
112-24	21211-21219	function	_	
112-25	21220-21222	in	_	
112-26	21223-21228	terms	_	
112-27	21229-21231	of	_	
112-28	21232-21243	controlling	_	
112-29	21244-21253	attention	_	
112-30	21254-21263	including	_	
112-31	21264-21267	the	_	
112-32	21268-21273	shift	_	
112-33	21274-21281	between	_	
112-34	21282-21290	internal	_	
112-35	21291-21294	and	_	
112-36	21295-21303	external	_	
112-37	21304-21309	focus	_	
112-38	21309-21310	.	_	

#Text=Interestingly, all network alterations were increased in patients compared to controls.
113-1	21311-21324	Interestingly	_	
113-2	21324-21325	,	_	
113-3	21326-21329	all	_	
113-4	21330-21337	network	_	
113-5	21338-21349	alterations	_	
113-6	21350-21354	were	_	
113-7	21355-21364	increased	_	
113-8	21365-21367	in	_	
113-9	21368-21376	patients	_	
113-10	21377-21385	compared	_	
113-11	21386-21388	to	_	
113-12	21389-21397	controls	_	
113-13	21397-21398	.	_	

#Text=Previous results suggest both increased and decreased connectivity in patients with schizophrenia.
114-1	21399-21407	Previous	_	
114-2	21408-21415	results	_	
114-3	21416-21423	suggest	_	
114-4	21424-21428	both	_	
114-5	21429-21438	increased	_	
114-6	21439-21442	and	_	
114-7	21443-21452	decreased	_	
114-8	21453-21465	connectivity	_	
114-9	21466-21468	in	_	
114-10	21469-21477	patients	_	
114-11	21478-21482	with	_	
114-12	21483-21496	schizophrenia	_	
114-13	21496-21497	.	_	

#Text=In general, it appears that reduced connectivity is the predominant finding throughout the literature regardless of methodology, disease progression and medication status.
115-1	21498-21500	In	_	
115-2	21501-21508	general	_	
115-3	21508-21509	,	_	
115-4	21510-21512	it	_	
115-5	21513-21520	appears	_	
115-6	21521-21525	that	_	
115-7	21526-21533	reduced	_	
115-8	21534-21546	connectivity	_	
115-9	21547-21549	is	_	
115-10	21550-21553	the	_	
115-11	21554-21565	predominant	_	
115-12	21566-21573	finding	_	
115-13	21574-21584	throughout	_	
115-14	21585-21588	the	_	
115-15	21589-21599	literature	_	
115-16	21600-21610	regardless	_	
115-17	21611-21613	of	_	
115-18	21614-21625	methodology	_	
115-19	21625-21626	,	_	
115-20	21627-21634	disease	_	
115-21	21635-21646	progression	_	
115-22	21647-21650	and	_	
115-23	21651-21661	medication	_	
115-24	21662-21668	status	_	
115-25	21668-21669	.	_	

#Text=However, if specific networks are considered increased DMN connectivity is a predominant finding.
116-1	21670-21677	However	_	
116-2	21677-21678	,	_	
116-3	21679-21681	if	_	
116-4	21682-21690	specific	_	
116-5	21691-21699	networks	_	
116-6	21700-21703	are	_	
116-7	21704-21714	considered	_	
116-8	21715-21724	increased	_	
116-9	21725-21728	DMN	_	
116-10	21729-21741	connectivity	_	
116-11	21742-21744	is	_	
116-12	21745-21746	a	_	
116-13	21747-21758	predominant	_	
116-14	21759-21766	finding	_	
116-15	21766-21767	.	_	

#Text=Moreover, increased connectivity is a common finding in ANFE patients.
117-1	21768-21776	Moreover	_	
117-2	21776-21777	,	_	
117-3	21778-21787	increased	_	
117-4	21788-21800	connectivity	_	
117-5	21801-21803	is	_	
117-6	21804-21805	a	_	
117-7	21806-21812	common	_	
117-8	21813-21820	finding	_	
117-9	21821-21823	in	_	
117-10	21824-21828	ANFE	_	
117-11	21829-21837	patients	_	
117-12	21837-21838	.	_	

#Text=In line with this, our results suggest a hyper-coupling between fronto-parietal control networks that make patients unable to disengage networks in a dynamic sense.
118-1	21839-21841	In	_	
118-2	21842-21846	line	_	
118-3	21847-21851	with	_	
118-4	21852-21856	this	_	
118-5	21856-21857	,	_	
118-6	21858-21861	our	_	
118-7	21862-21869	results	_	
118-8	21870-21877	suggest	_	
118-9	21878-21879	a	_	
118-10	21880-21894	hyper-coupling	_	
118-11	21895-21902	between	_	
118-12	21903-21918	fronto-parietal	_	
118-13	21919-21926	control	_	
118-14	21927-21935	networks	_	
118-15	21936-21940	that	_	
118-16	21941-21945	make	_	
118-17	21946-21954	patients	_	
118-18	21955-21961	unable	_	
118-19	21962-21964	to	_	
118-20	21965-21974	disengage	_	
118-21	21975-21983	networks	_	
118-22	21984-21986	in	_	
118-23	21987-21988	a	_	
118-24	21989-21996	dynamic	_	
118-25	21997-22002	sense	_	
118-26	22002-22003	.	_	

#Text=If the VAN is locked in it may also explain why patients are unable to disengage the DMN during tasks.
119-1	22004-22006	If	_	
119-2	22007-22010	the	_	
119-3	22011-22014	VAN	_	
119-4	22015-22017	is	_	
119-5	22018-22024	locked	_	
119-6	22025-22027	in	_	
119-7	22028-22030	it	_	
119-8	22031-22034	may	_	
119-9	22035-22039	also	_	
119-10	22040-22047	explain	_	
119-11	22048-22051	why	_	
119-12	22052-22060	patients	_	
119-13	22061-22064	are	_	
119-14	22065-22071	unable	_	
119-15	22072-22074	to	_	
119-16	22075-22084	disengage	_	
119-17	22085-22088	the	_	
119-18	22089-22092	DMN	_	
119-19	22093-22099	during	_	
119-20	22100-22105	tasks	_	
119-21	22105-22106	.	_	

#Text=Another aspect of the present findings is that the CEN and VAN may be functionally unique to humans.
120-1	22107-22114	Another	_	
120-2	22115-22121	aspect	_	
120-3	22122-22124	of	_	
120-4	22125-22128	the	_	
120-5	22129-22136	present	_	
120-6	22137-22145	findings	_	
120-7	22146-22148	is	_	
120-8	22149-22153	that	_	
120-9	22154-22157	the	_	
120-10	22158-22161	CEN	_	
120-11	22162-22165	and	_	
120-12	22166-22169	VAN	_	
120-13	22170-22173	may	_	
120-14	22174-22176	be	_	
120-15	22177-22189	functionally	_	
120-16	22190-22196	unique	_	
120-17	22197-22199	to	_	
120-18	22200-22206	humans	_	
120-19	22206-22207	.	_	

#Text=One study showed that the functional connectivity of the TPJ is different in humans compared to macaques whereas another study suggested that certain fronto-parietal networks similar to the CEN may be found only in humans.
121-1	22208-22211	One	_	
121-2	22212-22217	study	_	
121-3	22218-22224	showed	_	
121-4	22225-22229	that	_	
121-5	22230-22233	the	_	
121-6	22234-22244	functional	_	
121-7	22245-22257	connectivity	_	
121-8	22258-22260	of	_	
121-9	22261-22264	the	_	
121-10	22265-22268	TPJ	_	
121-11	22269-22271	is	_	
121-12	22272-22281	different	_	
121-13	22282-22284	in	_	
121-14	22285-22291	humans	_	
121-15	22292-22300	compared	_	
121-16	22301-22303	to	_	
121-17	22304-22312	macaques	_	
121-18	22313-22320	whereas	_	
121-19	22321-22328	another	_	
121-20	22329-22334	study	_	
121-21	22335-22344	suggested	_	
121-22	22345-22349	that	_	
121-23	22350-22357	certain	_	
121-24	22358-22373	fronto-parietal	_	
121-25	22374-22382	networks	_	
121-26	22383-22390	similar	_	
121-27	22391-22393	to	_	
121-28	22394-22397	the	_	
121-29	22398-22401	CEN	_	
121-30	22402-22405	may	_	
121-31	22406-22408	be	_	
121-32	22409-22414	found	_	
121-33	22415-22419	only	_	
121-34	22420-22422	in	_	
121-35	22423-22429	humans	_	
121-36	22429-22430	.	_	

#Text=If this is true, our results may point out the evolutionarily novel networks that make us vulnerable to develop the clinical characteristics seen in patients with schizophrenia.
122-1	22431-22433	If	_	
122-2	22434-22438	this	_	
122-3	22439-22441	is	_	
122-4	22442-22446	true	_	
122-5	22446-22447	,	_	
122-6	22448-22451	our	_	
122-7	22452-22459	results	_	
122-8	22460-22463	may	_	
122-9	22464-22469	point	_	
122-10	22470-22473	out	_	
122-11	22474-22477	the	_	
122-12	22478-22492	evolutionarily	_	
122-13	22493-22498	novel	_	
122-14	22499-22507	networks	_	
122-15	22508-22512	that	_	
122-16	22513-22517	make	_	
122-17	22518-22520	us	_	
122-18	22521-22531	vulnerable	_	
122-19	22532-22534	to	_	
122-20	22535-22542	develop	_	
122-21	22543-22546	the	_	
122-22	22547-22555	clinical	_	
122-23	22556-22571	characteristics	_	
122-24	22572-22576	seen	_	
122-25	22577-22579	in	_	
122-26	22580-22588	patients	_	
122-27	22589-22593	with	_	
122-28	22594-22607	schizophrenia	_	
122-29	22607-22608	.	_	

#Text=Functional Connectivity and Clinical Characteristics
#Text=Our hypothesis of an association between positive symptoms and DMN connectivity was not verified.
123-1	22609-22619	Functional	_	
123-2	22620-22632	Connectivity	_	
123-3	22633-22636	and	_	
123-4	22637-22645	Clinical	_	
123-5	22646-22661	Characteristics	_	
123-6	22662-22665	Our	_	
123-7	22666-22676	hypothesis	_	
123-8	22677-22679	of	_	
123-9	22680-22682	an	_	
123-10	22683-22694	association	_	
123-11	22695-22702	between	_	
123-12	22703-22711	positive	_	
123-13	22712-22720	symptoms	_	
123-14	22721-22724	and	_	
123-15	22725-22728	DMN	_	
123-16	22729-22741	connectivity	_	
123-17	22742-22745	was	_	
123-18	22746-22749	not	_	
123-19	22750-22758	verified	_	
123-20	22758-22759	.	_	

#Text=At the trend-level, our results may suggest that positive, negative, and general symptoms are associated with the connectivity of the left CEN and left VAN.
124-1	22760-22762	At	_	
124-2	22763-22766	the	_	
124-3	22767-22778	trend-level	_	
124-4	22778-22779	,	_	
124-5	22780-22783	our	_	
124-6	22784-22791	results	_	
124-7	22792-22795	may	_	
124-8	22796-22803	suggest	_	
124-9	22804-22808	that	_	
124-10	22809-22817	positive	_	
124-11	22817-22818	,	_	
124-12	22819-22827	negative	_	
124-13	22827-22828	,	_	
124-14	22829-22832	and	_	
124-15	22833-22840	general	_	
124-16	22841-22849	symptoms	_	
124-17	22850-22853	are	_	
124-18	22854-22864	associated	_	
124-19	22865-22869	with	_	
124-20	22870-22873	the	_	
124-21	22874-22886	connectivity	_	
124-22	22887-22889	of	_	
124-23	22890-22893	the	_	
124-24	22894-22898	left	_	
124-25	22899-22902	CEN	_	
124-26	22903-22906	and	_	
124-27	22907-22911	left	_	
124-28	22912-22915	VAN	_	
124-29	22915-22916	.	_	

#Text=This may indicate that a specific, left-lateralized hyper-coupling between CEN and VAN is involved broadly in psychopathology.
125-1	22917-22921	This	_	
125-2	22922-22925	may	_	
125-3	22926-22934	indicate	_	
125-4	22935-22939	that	_	
125-5	22940-22941	a	_	
125-6	22942-22950	specific	_	
125-7	22950-22951	,	_	
125-8	22952-22968	left-lateralized	_	
125-9	22969-22983	hyper-coupling	_	
125-10	22984-22991	between	_	
125-11	22992-22995	CEN	_	
125-12	22996-22999	and	_	
125-13	23000-23003	VAN	_	
125-14	23004-23006	is	_	
125-15	23007-23015	involved	_	
125-16	23016-23023	broadly	_	
125-17	23024-23026	in	_	
125-18	23027-23042	psychopathology	_	
125-19	23042-23043	.	_	

#Text=As we expected from previous findings, the cognitive measures also appeared to be associated with network alterations in a generalized manner since the effects of processing speed and sustained attention showed a significant interaction with the effect of group on the connectivity between right CEN and right VAN.
126-1	23044-23046	As	_	
126-2	23047-23049	we	_	
126-3	23050-23058	expected	_	
126-4	23059-23063	from	_	
126-5	23064-23072	previous	_	
126-6	23073-23081	findings	_	
126-7	23081-23082	,	_	
126-8	23083-23086	the	_	
126-9	23087-23096	cognitive	_	
126-10	23097-23105	measures	_	
126-11	23106-23110	also	_	
126-12	23111-23119	appeared	_	
126-13	23120-23122	to	_	
126-14	23123-23125	be	_	
126-15	23126-23136	associated	_	
126-16	23137-23141	with	_	
126-17	23142-23149	network	_	
126-18	23150-23161	alterations	_	
126-19	23162-23164	in	_	
126-20	23165-23166	a	_	
126-21	23167-23178	generalized	_	
126-22	23179-23185	manner	_	
126-23	23186-23191	since	_	
126-24	23192-23195	the	_	
126-25	23196-23203	effects	_	
126-26	23204-23206	of	_	
126-27	23207-23217	processing	_	
126-28	23218-23223	speed	_	
126-29	23224-23227	and	_	
126-30	23228-23237	sustained	_	
126-31	23238-23247	attention	_	
126-32	23248-23254	showed	_	
126-33	23255-23256	a	_	
126-34	23257-23268	significant	_	
126-35	23269-23280	interaction	_	
126-36	23281-23285	with	_	
126-37	23286-23289	the	_	
126-38	23290-23296	effect	_	
126-39	23297-23299	of	_	
126-40	23300-23305	group	_	
126-41	23306-23308	on	_	
126-42	23309-23312	the	_	
126-43	23313-23325	connectivity	_	
126-44	23326-23333	between	_	
126-45	23334-23339	right	_	
126-46	23340-23343	CEN	_	
126-47	23344-23347	and	_	
126-48	23348-23353	right	_	
126-49	23354-23357	VAN	_	
126-50	23357-23358	.	_	

#Text=Because both significant interactions between network connectivity and cognitive measures revealed a higher correlation in patients compared to controls, it may indicate that connectivity between networks is more involved in cognition in patients than in healthy subjects.
127-1	23359-23366	Because	_	
127-2	23367-23371	both	_	
127-3	23372-23383	significant	_	
127-4	23384-23396	interactions	_	
127-5	23397-23404	between	_	
127-6	23405-23412	network	_	
127-7	23413-23425	connectivity	_	
127-8	23426-23429	and	_	
127-9	23430-23439	cognitive	_	
127-10	23440-23448	measures	_	
127-11	23449-23457	revealed	_	
127-12	23458-23459	a	_	
127-13	23460-23466	higher	_	
127-14	23467-23478	correlation	_	
127-15	23479-23481	in	_	
127-16	23482-23490	patients	_	
127-17	23491-23499	compared	_	
127-18	23500-23502	to	_	
127-19	23503-23511	controls	_	
127-20	23511-23512	,	_	
127-21	23513-23515	it	_	
127-22	23516-23519	may	_	
127-23	23520-23528	indicate	_	
127-24	23529-23533	that	_	
127-25	23534-23546	connectivity	_	
127-26	23547-23554	between	_	
127-27	23555-23563	networks	_	
127-28	23564-23566	is	_	
127-29	23567-23571	more	_	
127-30	23572-23580	involved	_	
127-31	23581-23583	in	_	
127-32	23584-23593	cognition	_	
127-33	23594-23596	in	_	
127-34	23597-23605	patients	_	
127-35	23606-23610	than	_	
127-36	23611-23613	in	_	
127-37	23614-23621	healthy	_	
127-38	23622-23630	subjects	_	
127-39	23630-23631	.	_	

#Text=The apparent unspecificity of these associations between clinical characteristics and network alterations could be a result of the presumably central role of the involved networks.
128-1	23632-23635	The	_	
128-2	23636-23644	apparent	_	
128-3	23645-23658	unspecificity	_	
128-4	23659-23661	of	_	
128-5	23662-23667	these	_	
128-6	23668-23680	associations	_	
128-7	23681-23688	between	_	
128-8	23689-23697	clinical	_	
128-9	23698-23713	characteristics	_	
128-10	23714-23717	and	_	
128-11	23718-23725	network	_	
128-12	23726-23737	alterations	_	
128-13	23738-23743	could	_	
128-14	23744-23746	be	_	
128-15	23747-23748	a	_	
128-16	23749-23755	result	_	
128-17	23756-23758	of	_	
128-18	23759-23762	the	_	
128-19	23763-23773	presumably	_	
128-20	23774-23781	central	_	
128-21	23782-23786	role	_	
128-22	23787-23789	of	_	
128-23	23790-23793	the	_	
128-24	23794-23802	involved	_	
128-25	23803-23811	networks	_	
128-26	23811-23812	.	_	

#Text=If, as suggested by the present results, schizophrenia is characterized by a hyper-coupling between fronto-parietal networks involved in the control of other networks important for cognition and sensory functions, it is reasonable to expect diverse psychopathological and general cognitive deficits to arise from these control-network alterations.
129-1	23813-23815	If	_	
129-2	23815-23816	,	_	
129-3	23817-23819	as	_	
129-4	23820-23829	suggested	_	
129-5	23830-23832	by	_	
129-6	23833-23836	the	_	
129-7	23837-23844	present	_	
129-8	23845-23852	results	_	
129-9	23852-23853	,	_	
129-10	23854-23867	schizophrenia	_	
129-11	23868-23870	is	_	
129-12	23871-23884	characterized	_	
129-13	23885-23887	by	_	
129-14	23888-23889	a	_	
129-15	23890-23904	hyper-coupling	_	
129-16	23905-23912	between	_	
129-17	23913-23928	fronto-parietal	_	
129-18	23929-23937	networks	_	
129-19	23938-23946	involved	_	
129-20	23947-23949	in	_	
129-21	23950-23953	the	_	
129-22	23954-23961	control	_	
129-23	23962-23964	of	_	
129-24	23965-23970	other	_	
129-25	23971-23979	networks	_	
129-26	23980-23989	important	_	
129-27	23990-23993	for	_	
129-28	23994-24003	cognition	_	
129-29	24004-24007	and	_	
129-30	24008-24015	sensory	_	
129-31	24016-24025	functions	_	
129-32	24025-24026	,	_	
129-33	24027-24029	it	_	
129-34	24030-24032	is	_	
129-35	24033-24043	reasonable	_	
129-36	24044-24046	to	_	
129-37	24047-24053	expect	_	
129-38	24054-24061	diverse	_	
129-39	24062-24080	psychopathological	_	
129-40	24081-24084	and	_	
129-41	24085-24092	general	_	
129-42	24093-24102	cognitive	_	
129-43	24103-24111	deficits	_	
129-44	24112-24114	to	_	
129-45	24115-24120	arise	_	
129-46	24121-24125	from	_	
129-47	24126-24131	these	_	
129-48	24132-24147	control-network	_	
129-49	24148-24159	alterations	_	
129-50	24159-24160	.	_	

#Text=It is important to note that the CEN, VAN, and DAN overlap substantially with brain regions involved in awareness.
130-1	24161-24163	It	_	
130-2	24164-24166	is	_	
130-3	24167-24176	important	_	
130-4	24177-24179	to	_	
130-5	24180-24184	note	_	
130-6	24185-24189	that	_	
130-7	24190-24193	the	_	
130-8	24194-24197	CEN	_	
130-9	24197-24198	,	_	
130-10	24199-24202	VAN	_	
130-11	24202-24203	,	_	
130-12	24204-24207	and	_	
130-13	24208-24211	DAN	_	
130-14	24212-24219	overlap	_	
130-15	24220-24233	substantially	_	
130-16	24234-24238	with	_	
130-17	24239-24244	brain	_	
130-18	24245-24252	regions	_	
130-19	24253-24261	involved	_	
130-20	24262-24264	in	_	
130-21	24265-24274	awareness	_	
130-22	24274-24275	.	_	

#Text=In healthy subjects the TPJ is activated by stimuli outside the current focus of attention if the stimuli are behaviorally important.
131-1	24276-24278	In	_	
131-2	24279-24286	healthy	_	
131-3	24287-24295	subjects	_	
131-4	24296-24299	the	_	
131-5	24300-24303	TPJ	_	
131-6	24304-24306	is	_	
131-7	24307-24316	activated	_	
131-8	24317-24319	by	_	
131-9	24320-24327	stimuli	_	
131-10	24328-24335	outside	_	
131-11	24336-24339	the	_	
131-12	24340-24347	current	_	
131-13	24348-24353	focus	_	
131-14	24354-24356	of	_	
131-15	24357-24366	attention	_	
131-16	24367-24369	if	_	
131-17	24370-24373	the	_	
131-18	24374-24381	stimuli	_	
131-19	24382-24385	are	_	
131-20	24386-24398	behaviorally	_	
131-21	24399-24408	important	_	
131-22	24408-24409	.	_	

#Text=On the contrary, the TPJ is deactivated when subjects are engaged in attentionally demanding tasks suggesting efficient filtering of distracting information.
132-1	24410-24412	On	_	
132-2	24413-24416	the	_	
132-3	24417-24425	contrary	_	
132-4	24425-24426	,	_	
132-5	24427-24430	the	_	
132-6	24431-24434	TPJ	_	
132-7	24435-24437	is	_	
132-8	24438-24449	deactivated	_	
132-9	24450-24454	when	_	
132-10	24455-24463	subjects	_	
132-11	24464-24467	are	_	
132-12	24468-24475	engaged	_	
132-13	24476-24478	in	_	
132-14	24479-24492	attentionally	_	
132-15	24493-24502	demanding	_	
132-16	24503-24508	tasks	_	
132-17	24509-24519	suggesting	_	
132-18	24520-24529	efficient	_	
132-19	24530-24539	filtering	_	
132-20	24540-24542	of	_	
132-21	24543-24554	distracting	_	
132-22	24555-24566	information	_	
132-23	24566-24567	.	_	

#Text=However, in a recent study investigating the distinction between attention and subjective awareness using a visual task showed that the changes in activity within the TPJ are driven by the degree of subjective awareness that co-varies with attention rather than by attention per se.
133-1	24568-24575	However	_	
133-2	24575-24576	,	_	
133-3	24577-24579	in	_	
133-4	24580-24581	a	_	
133-5	24582-24588	recent	_	
133-6	24589-24594	study	_	
133-7	24595-24608	investigating	_	
133-8	24609-24612	the	_	
133-9	24613-24624	distinction	_	
133-10	24625-24632	between	_	
133-11	24633-24642	attention	_	
133-12	24643-24646	and	_	
133-13	24647-24657	subjective	_	
133-14	24658-24667	awareness	_	
133-15	24668-24673	using	_	
133-16	24674-24675	a	_	
133-17	24676-24682	visual	_	
133-18	24683-24687	task	_	
133-19	24688-24694	showed	_	
133-20	24695-24699	that	_	
133-21	24700-24703	the	_	
133-22	24704-24711	changes	_	
133-23	24712-24714	in	_	
133-24	24715-24723	activity	_	
133-25	24724-24730	within	_	
133-26	24731-24734	the	_	
133-27	24735-24738	TPJ	_	
133-28	24739-24742	are	_	
133-29	24743-24749	driven	_	
133-30	24750-24752	by	_	
133-31	24753-24756	the	_	
133-32	24757-24763	degree	_	
133-33	24764-24766	of	_	
133-34	24767-24777	subjective	_	
133-35	24778-24787	awareness	_	
133-36	24788-24792	that	_	
133-37	24793-24802	co-varies	_	
133-38	24803-24807	with	_	
133-39	24808-24817	attention	_	
133-40	24818-24824	rather	_	
133-41	24825-24829	than	_	
133-42	24830-24832	by	_	
133-43	24833-24842	attention	_	
133-44	24843-24846	per	_	
133-45	24847-24849	se	_	
133-46	24849-24850	.	_	

#Text=The association between sustained attention and the connectivity between the CEN and VAN found in the present study could therefore in part reflect a problem with subjective awareness.
134-1	24851-24854	The	_	
134-2	24855-24866	association	_	
134-3	24867-24874	between	_	
134-4	24875-24884	sustained	_	
134-5	24885-24894	attention	_	
134-6	24895-24898	and	_	
134-7	24899-24902	the	_	
134-8	24903-24915	connectivity	_	
134-9	24916-24923	between	_	
134-10	24924-24927	the	_	
134-11	24928-24931	CEN	_	
134-12	24932-24935	and	_	
134-13	24936-24939	VAN	_	
134-14	24940-24945	found	_	
134-15	24946-24948	in	_	
134-16	24949-24952	the	_	
134-17	24953-24960	present	_	
134-18	24961-24966	study	_	
134-19	24967-24972	could	_	
134-20	24973-24982	therefore	_	
134-21	24983-24985	in	_	
134-22	24986-24990	part	_	
134-23	24991-24998	reflect	_	
134-24	24999-25000	a	_	
134-25	25001-25008	problem	_	
134-26	25009-25013	with	_	
134-27	25014-25024	subjective	_	
134-28	25025-25034	awareness	_	
134-29	25034-25035	.	_	

#Text=Methodological Considerations
#Text=An important aspect to consider is that the functions that can be ascribed to a network depend on the number of dimensions used to parcellate the resting state BOLD-signal, ie, a high number of dimensions will result in more specialized network functions rendering labels such as “the central executive network” heuristic at this stage.
135-1	25036-25050	Methodological	_	
135-2	25051-25065	Considerations	_	
135-3	25066-25068	An	_	
135-4	25069-25078	important	_	
135-5	25079-25085	aspect	_	
135-6	25086-25088	to	_	
135-7	25089-25097	consider	_	
135-8	25098-25100	is	_	
135-9	25101-25105	that	_	
135-10	25106-25109	the	_	
135-11	25110-25119	functions	_	
135-12	25120-25124	that	_	
135-13	25125-25128	can	_	
135-14	25129-25131	be	_	
135-15	25132-25140	ascribed	_	
135-16	25141-25143	to	_	
135-17	25144-25145	a	_	
135-18	25146-25153	network	_	
135-19	25154-25160	depend	_	
135-20	25161-25163	on	_	
135-21	25164-25167	the	_	
135-22	25168-25174	number	_	
135-23	25175-25177	of	_	
135-24	25178-25188	dimensions	_	
135-25	25189-25193	used	_	
135-26	25194-25196	to	_	
135-27	25197-25207	parcellate	_	
135-28	25208-25211	the	_	
135-29	25212-25219	resting	_	
135-30	25220-25225	state	_	
135-31	25226-25237	BOLD-signal	_	
135-32	25237-25238	,	_	
135-33	25239-25241	ie	_	
135-34	25241-25242	,	_	
135-35	25243-25244	a	_	
135-36	25245-25249	high	_	
135-37	25250-25256	number	_	
135-38	25257-25259	of	_	
135-39	25260-25270	dimensions	_	
135-40	25271-25275	will	_	
135-41	25276-25282	result	_	
135-42	25283-25285	in	_	
135-43	25286-25290	more	_	
135-44	25291-25302	specialized	_	
135-45	25303-25310	network	_	
135-46	25311-25320	functions	_	
135-47	25321-25330	rendering	_	
135-48	25331-25337	labels	_	
135-49	25338-25342	such	_	
135-50	25343-25345	as	_	
135-51	25346-25347	“	_	
135-52	25347-25350	the	_	
135-53	25351-25358	central	_	
135-54	25359-25368	executive	_	
135-55	25369-25376	network	_	
135-56	25376-25377	”	_	
135-57	25378-25387	heuristic	_	
135-58	25388-25390	at	_	
135-59	25391-25395	this	_	
135-60	25396-25401	stage	_	
135-61	25401-25402	.	_	

#Text=Moreover, differences in dimensionality estimation are likely to explain some of the inconsistencies in findings across studies, eg, within-network alterations might turn up as between-network alterations with a higher number of dimensions.
136-1	25403-25411	Moreover	_	
136-2	25411-25412	,	_	
136-3	25413-25424	differences	_	
136-4	25425-25427	in	_	
136-5	25428-25442	dimensionality	_	
136-6	25443-25453	estimation	_	
136-7	25454-25457	are	_	
136-8	25458-25464	likely	_	
136-9	25465-25467	to	_	
136-10	25468-25475	explain	_	
136-11	25476-25480	some	_	
136-12	25481-25483	of	_	
136-13	25484-25487	the	_	
136-14	25488-25503	inconsistencies	_	
136-15	25504-25506	in	_	
136-16	25507-25515	findings	_	
136-17	25516-25522	across	_	
136-18	25523-25530	studies	_	
136-19	25530-25531	,	_	
136-20	25532-25534	eg	_	
136-21	25534-25535	,	_	
136-22	25536-25550	within-network	_	
136-23	25551-25562	alterations	_	
136-24	25563-25568	might	_	
136-25	25569-25573	turn	_	
136-26	25574-25576	up	_	
136-27	25577-25579	as	_	
136-28	25580-25595	between-network	_	
136-29	25596-25607	alterations	_	
136-30	25608-25612	with	_	
136-31	25613-25614	a	_	
136-32	25615-25621	higher	_	
136-33	25622-25628	number	_	
136-34	25629-25631	of	_	
136-35	25632-25642	dimensions	_	
136-36	25642-25643	.	_	

#Text=Two major concerns for studies of functional connectivity in schizophrenia are medication effects since antipsychotic medication is known to alter perfusion in grey matter, and motion that affects the estimates of connectivity.
137-1	25644-25647	Two	_	
137-2	25648-25653	major	_	
137-3	25654-25662	concerns	_	
137-4	25663-25666	for	_	
137-5	25667-25674	studies	_	
137-6	25675-25677	of	_	
137-7	25678-25688	functional	_	
137-8	25689-25701	connectivity	_	
137-9	25702-25704	in	_	
137-10	25705-25718	schizophrenia	_	
137-11	25719-25722	are	_	
137-12	25723-25733	medication	_	
137-13	25734-25741	effects	_	
137-14	25742-25747	since	_	
137-15	25748-25761	antipsychotic	_	
137-16	25762-25772	medication	_	
137-17	25773-25775	is	_	
137-18	25776-25781	known	_	
137-19	25782-25784	to	_	
137-20	25785-25790	alter	_	
137-21	25791-25800	perfusion	_	
137-22	25801-25803	in	_	
137-23	25804-25808	grey	_	
137-24	25809-25815	matter	_	
137-25	25815-25816	,	_	
137-26	25817-25820	and	_	
137-27	25821-25827	motion	_	
137-28	25828-25832	that	_	
137-29	25833-25840	affects	_	
137-30	25841-25844	the	_	
137-31	25845-25854	estimates	_	
137-32	25855-25857	of	_	
137-33	25858-25870	connectivity	_	
137-34	25870-25871	.	_	

#Text=We have strived to deal with these effects by including only subjects who had never received antipsychotic medication and by implementing a strategy centered on single subject ICA de-noising that is currently among the most effective ways to deal with motion.
138-1	25872-25874	We	_	
138-2	25875-25879	have	_	
138-3	25880-25887	strived	_	
138-4	25888-25890	to	_	
138-5	25891-25895	deal	_	
138-6	25896-25900	with	_	
138-7	25901-25906	these	_	
138-8	25907-25914	effects	_	
138-9	25915-25917	by	_	
138-10	25918-25927	including	_	
138-11	25928-25932	only	_	
138-12	25933-25941	subjects	_	
138-13	25942-25945	who	_	
138-14	25946-25949	had	_	
138-15	25950-25955	never	_	
138-16	25956-25964	received	_	
138-17	25965-25978	antipsychotic	_	
138-18	25979-25989	medication	_	
138-19	25990-25993	and	_	
138-20	25994-25996	by	_	
138-21	25997-26009	implementing	_	
138-22	26010-26011	a	_	
138-23	26012-26020	strategy	_	
138-24	26021-26029	centered	_	
138-25	26030-26032	on	_	
138-26	26033-26039	single	_	
138-27	26040-26047	subject	_	
138-28	26048-26051	ICA	_	
138-29	26052-26062	de-noising	_	
138-30	26063-26067	that	_	
138-31	26068-26070	is	_	
138-32	26071-26080	currently	_	
138-33	26081-26086	among	_	
138-34	26087-26090	the	_	
138-35	26091-26095	most	_	
138-36	26096-26105	effective	_	
138-37	26106-26110	ways	_	
138-38	26111-26113	to	_	
138-39	26114-26118	deal	_	
138-40	26119-26123	with	_	
138-41	26124-26130	motion	_	
138-42	26130-26131	.	_	

#Text=Despite these efforts the group differences in connectivity presented here could be confounded by group differences in physiological parameters like heart rate and respiration pattern.
139-1	26132-26139	Despite	_	
139-2	26140-26145	these	_	
139-3	26146-26153	efforts	_	
139-4	26154-26157	the	_	
139-5	26158-26163	group	_	
139-6	26164-26175	differences	_	
139-7	26176-26178	in	_	
139-8	26179-26191	connectivity	_	
139-9	26192-26201	presented	_	
139-10	26202-26206	here	_	
139-11	26207-26212	could	_	
139-12	26213-26215	be	_	
139-13	26216-26226	confounded	_	
139-14	26227-26229	by	_	
139-15	26230-26235	group	_	
139-16	26236-26247	differences	_	
139-17	26248-26250	in	_	
139-18	26251-26264	physiological	_	
139-19	26265-26275	parameters	_	
139-20	26276-26280	like	_	
139-21	26281-26286	heart	_	
139-22	26287-26291	rate	_	
139-23	26292-26295	and	_	
139-24	26296-26307	respiration	_	
139-25	26308-26315	pattern	_	
139-26	26315-26316	.	_	

#Text=These effects are likely to be under-sampled with a TR = 2 and represents general caveats of resting-state fMRI.
140-1	26317-26322	These	_	
140-2	26323-26330	effects	_	
140-3	26331-26334	are	_	
140-4	26335-26341	likely	_	
140-5	26342-26344	to	_	
140-6	26345-26347	be	_	
140-7	26348-26361	under-sampled	_	
140-8	26362-26366	with	_	
140-9	26367-26368	a	_	
140-10	26369-26371	TR	_	
140-11	26372-26373	=	_	
140-12	26374-26375	2	_	
140-13	26376-26379	and	_	
140-14	26380-26390	represents	_	
140-15	26391-26398	general	_	
140-16	26399-26406	caveats	_	
140-17	26407-26409	of	_	
140-18	26410-26423	resting-state	_	
140-19	26424-26428	fMRI	_	
140-20	26428-26429	.	_	

#Text=In Conclusion
#Text=As hypothesized in the large-scale network models, the present study revealed altered connectivity between CEN and VAN and between posterior DMN and auditory cortex in the early antipsychotic-naïve state of schizophrenia.
141-1	26430-26432	In	_	
141-2	26433-26443	Conclusion	_	
141-3	26444-26446	As	_	
141-4	26447-26459	hypothesized	_	
141-5	26460-26462	in	_	
141-6	26463-26466	the	_	
141-7	26467-26478	large-scale	_	
141-8	26479-26486	network	_	
141-9	26487-26493	models	_	
141-10	26493-26494	,	_	
141-11	26495-26498	the	_	
141-12	26499-26506	present	_	
141-13	26507-26512	study	_	
141-14	26513-26521	revealed	_	
141-15	26522-26529	altered	_	
141-16	26530-26542	connectivity	_	
141-17	26543-26550	between	_	
141-18	26551-26554	CEN	_	
141-19	26555-26558	and	_	
141-20	26559-26562	VAN	_	
141-21	26563-26566	and	_	
141-22	26567-26574	between	_	
141-23	26575-26584	posterior	_	
141-24	26585-26588	DMN	_	
141-25	26589-26592	and	_	
141-26	26593-26601	auditory	_	
141-27	26602-26608	cortex	_	
141-28	26609-26611	in	_	
141-29	26612-26615	the	_	
141-30	26616-26621	early	_	
141-31	26622-26641	antipsychotic-naïve	_	
141-32	26642-26647	state	_	
141-33	26648-26650	of	_	
141-34	26651-26664	schizophrenia	_	
141-35	26664-26665	.	_	

#Text=As expected, these network alterations were shown to be associated with cognitive deficits in a generalized manner.
142-1	26666-26668	As	_	
142-2	26669-26677	expected	_	
142-3	26677-26678	,	_	
142-4	26679-26684	these	_	
142-5	26685-26692	network	_	
142-6	26693-26704	alterations	_	
142-7	26705-26709	were	_	
142-8	26710-26715	shown	_	
142-9	26716-26718	to	_	
142-10	26719-26721	be	_	
142-11	26722-26732	associated	_	
142-12	26733-26737	with	_	
142-13	26738-26747	cognitive	_	
142-14	26748-26756	deficits	_	
142-15	26757-26759	in	_	
142-16	26760-26761	a	_	
142-17	26762-26773	generalized	_	
142-18	26774-26780	manner	_	
142-19	26780-26781	.	_	

#Text=Our results may indicate that psychopathology is broadly associated especially with left CEN connectivity.
143-1	26782-26785	Our	_	
143-2	26786-26793	results	_	
143-3	26794-26797	may	_	
143-4	26798-26806	indicate	_	
143-5	26807-26811	that	_	
143-6	26812-26827	psychopathology	_	
143-7	26828-26830	is	_	
143-8	26831-26838	broadly	_	
143-9	26839-26849	associated	_	
143-10	26850-26860	especially	_	
143-11	26861-26865	with	_	
143-12	26866-26870	left	_	
143-13	26871-26874	CEN	_	
143-14	26875-26887	connectivity	_	
143-15	26887-26888	.	_	

#Text=Because the CEN, VAN and posterior DMN, dominated by PCC/precuneus activity, have been suggested to be involved with the control of a range of cognitive and sensory functions, it is likely that a problem with disengaging these central control networks leads to the diverse clinical characteristics present in the early course of schizophrenia.
144-1	26889-26896	Because	_	
144-2	26897-26900	the	_	
144-3	26901-26904	CEN	_	
144-4	26904-26905	,	_	
144-5	26906-26909	VAN	_	
144-6	26910-26913	and	_	
144-7	26914-26923	posterior	_	
144-8	26924-26927	DMN	_	
144-9	26927-26928	,	_	
144-10	26929-26938	dominated	_	
144-11	26939-26941	by	_	
144-12	26942-26945	PCC	_	
144-13	26945-26946	/	_	
144-14	26946-26955	precuneus	_	
144-15	26956-26964	activity	_	
144-16	26964-26965	,	_	
144-17	26966-26970	have	_	
144-18	26971-26975	been	_	
144-19	26976-26985	suggested	_	
144-20	26986-26988	to	_	
144-21	26989-26991	be	_	
144-22	26992-27000	involved	_	
144-23	27001-27005	with	_	
144-24	27006-27009	the	_	
144-25	27010-27017	control	_	
144-26	27018-27020	of	_	
144-27	27021-27022	a	_	
144-28	27023-27028	range	_	
144-29	27029-27031	of	_	
144-30	27032-27041	cognitive	_	
144-31	27042-27045	and	_	
144-32	27046-27053	sensory	_	
144-33	27054-27063	functions	_	
144-34	27063-27064	,	_	
144-35	27065-27067	it	_	
144-36	27068-27070	is	_	
144-37	27071-27077	likely	_	
144-38	27078-27082	that	_	
144-39	27083-27084	a	_	
144-40	27085-27092	problem	_	
144-41	27093-27097	with	_	
144-42	27098-27109	disengaging	_	
144-43	27110-27115	these	_	
144-44	27116-27123	central	_	
144-45	27124-27131	control	_	
144-46	27132-27140	networks	_	
144-47	27141-27146	leads	_	
144-48	27147-27149	to	_	
144-49	27150-27153	the	_	
144-50	27154-27161	diverse	_	
144-51	27162-27170	clinical	_	
144-52	27171-27186	characteristics	_	
144-53	27187-27194	present	_	
144-54	27195-27197	in	_	
144-55	27198-27201	the	_	
144-56	27202-27207	early	_	
144-57	27208-27214	course	_	
144-58	27215-27217	of	_	
144-59	27218-27231	schizophrenia	_	
144-60	27231-27232	.	_	

#Text=Supplementary Material
#Text=Supplementary material is available at https://academic.oup.com/schizophreniabulletin/.
145-1	27233-27246	Supplementary	_	
145-2	27247-27255	Material	_	
145-3	27256-27269	Supplementary	_	
145-4	27270-27278	material	_	
145-5	27279-27281	is	_	
145-6	27282-27291	available	_	
145-7	27292-27294	at	_	
145-8	27295-27300	https	_	
145-9	27300-27301	:	_	
145-10	27301-27302	/	_	
145-11	27302-27303	/	_	
145-12	27303-27319	academic.oup.com	_	
145-13	27319-27320	/	_	
145-14	27320-27341	schizophreniabulletin	_	
145-15	27341-27342	/	_	
145-16	27342-27343	.	_	

#Text=Funding
#Text=This study was supported by grants from the Mental Health Services, Capital Region of Denmark and by grant R25-A2701 from the Lundbeck Foundation (Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research).
146-1	27344-27351	Funding	_	
146-2	27352-27356	This	_	
146-3	27357-27362	study	_	
146-4	27363-27366	was	_	
146-5	27367-27376	supported	_	
146-6	27377-27379	by	_	
146-7	27380-27386	grants	_	
146-8	27387-27391	from	_	
146-9	27392-27395	the	_	
146-10	27396-27402	Mental	_	
146-11	27403-27409	Health	_	
146-12	27410-27418	Services	_	
146-13	27418-27419	,	_	
146-14	27420-27427	Capital	_	
146-15	27428-27434	Region	_	
146-16	27435-27437	of	_	
146-17	27438-27445	Denmark	_	
146-18	27446-27449	and	_	
146-19	27450-27452	by	_	
146-20	27453-27458	grant	_	
146-21	27459-27462	R25	_	
146-22	27462-27463	-	_	
146-23	27463-27468	A2701	_	
146-24	27469-27473	from	_	
146-25	27474-27477	the	_	
146-26	27478-27486	Lundbeck	_	
146-27	27487-27497	Foundation	_	
146-28	27498-27499	(	_	
146-29	27499-27505	Center	_	
146-30	27506-27509	for	_	
146-31	27510-27518	Clinical	_	
146-32	27519-27531	Intervention	_	
146-33	27532-27535	and	_	
146-34	27536-27552	Neuropsychiatric	_	
146-35	27553-27566	Schizophrenia	_	
146-36	27567-27575	Research	_	
146-37	27575-27576	)	_	
146-38	27576-27577	.	_	

#Text=The funders had no influence on the design and conduct of the study, no influence on the collection, management, analysis and interpretation of the data, and no influence on the preparation, review or approval of the manuscript.
147-1	27578-27581	The	_	
147-2	27582-27589	funders	_	
147-3	27590-27593	had	_	
147-4	27594-27596	no	_	
147-5	27597-27606	influence	_	
147-6	27607-27609	on	_	
147-7	27610-27613	the	_	
147-8	27614-27620	design	_	
147-9	27621-27624	and	_	
147-10	27625-27632	conduct	_	
147-11	27633-27635	of	_	
147-12	27636-27639	the	_	
147-13	27640-27645	study	_	
147-14	27645-27646	,	_	
147-15	27647-27649	no	_	
147-16	27650-27659	influence	_	
147-17	27660-27662	on	_	
147-18	27663-27666	the	_	
147-19	27667-27677	collection	_	
147-20	27677-27678	,	_	
147-21	27679-27689	management	_	
147-22	27689-27690	,	_	
147-23	27691-27699	analysis	_	
147-24	27700-27703	and	_	
147-25	27704-27718	interpretation	_	
147-26	27719-27721	of	_	
147-27	27722-27725	the	_	
147-28	27726-27730	data	_	
147-29	27730-27731	,	_	
147-30	27732-27735	and	_	
147-31	27736-27738	no	_	
147-32	27739-27748	influence	_	
147-33	27749-27751	on	_	
147-34	27752-27755	the	_	
147-35	27756-27767	preparation	_	
147-36	27767-27768	,	_	
147-37	27769-27775	review	_	
147-38	27776-27778	or	_	
147-39	27779-27787	approval	_	
147-40	27788-27790	of	_	
147-41	27791-27794	the	_	
147-42	27795-27805	manuscript	_	
147-43	27805-27806	.	_	

#Text=References
#Text=Opportunities and limitations of intrinsic functional connectivity MRI
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Are anticorrelated networks in the brain relevant to schizophrenia
#Text=The brain’s default network: anatomy, function, and relevance to disease
#Text=Large-scale brain networks and psychopathology: a unifying triple network model
#Text=Does the salience network play a cardinal role in psychosis?
148-1	27807-27817	References	_	
148-2	27818-27831	Opportunities	_	
148-3	27832-27835	and	_	
148-4	27836-27847	limitations	_	
148-5	27848-27850	of	_	
148-6	27851-27860	intrinsic	_	
148-7	27861-27871	functional	_	
148-8	27872-27884	connectivity	_	
148-9	27885-27888	MRI	_	
148-10	27889-27900	Spontaneous	_	
148-11	27901-27913	fluctuations	_	
148-12	27914-27916	in	_	
148-13	27917-27922	brain	_	
148-14	27923-27931	activity	_	
148-15	27932-27940	observed	_	
148-16	27941-27945	with	_	
148-17	27946-27956	functional	_	
148-18	27957-27965	magnetic	_	
148-19	27966-27975	resonance	_	
148-20	27976-27983	imaging	_	
148-21	27984-27987	Are	_	
148-22	27988-28002	anticorrelated	_	
148-23	28003-28011	networks	_	
148-24	28012-28014	in	_	
148-25	28015-28018	the	_	
148-26	28019-28024	brain	_	
148-27	28025-28033	relevant	_	
148-28	28034-28036	to	_	
148-29	28037-28050	schizophrenia	_	
148-30	28051-28054	The	_	
148-31	28055-28060	brain	_	
148-32	28060-28061	’	_	
148-33	28061-28062	s	_	
148-34	28063-28070	default	_	
148-35	28071-28078	network	_	
148-36	28078-28079	:	_	
148-37	28080-28087	anatomy	_	
148-38	28087-28088	,	_	
148-39	28089-28097	function	_	
148-40	28097-28098	,	_	
148-41	28099-28102	and	_	
148-42	28103-28112	relevance	_	
148-43	28113-28115	to	_	
148-44	28116-28123	disease	_	
148-45	28124-28135	Large-scale	_	
148-46	28136-28141	brain	_	
148-47	28142-28150	networks	_	
148-48	28151-28154	and	_	
148-49	28155-28170	psychopathology	_	
148-50	28170-28171	:	_	
148-51	28172-28173	a	_	
148-52	28174-28182	unifying	_	
148-53	28183-28189	triple	_	
148-54	28190-28197	network	_	
148-55	28198-28203	model	_	
148-56	28204-28208	Does	_	
148-57	28209-28212	the	_	
148-58	28213-28221	salience	_	
148-59	28222-28229	network	_	
148-60	28230-28234	play	_	
148-61	28235-28236	a	_	
148-62	28237-28245	cardinal	_	
148-63	28246-28250	role	_	
148-64	28251-28253	in	_	
148-65	28254-28263	psychosis	_	
148-66	28263-28264	?	_	

#Text=An emerging hypothesis of insular dysfunction
#Text=The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities
#Text=How can the brain’s resting state activity generate hallucinations?
149-1	28265-28267	An	_	
149-2	28268-28276	emerging	_	
149-3	28277-28287	hypothesis	_	
149-4	28288-28290	of	_	
149-5	28291-28298	insular	_	
149-6	28299-28310	dysfunction	_	
149-7	28311-28314	The	_	
149-8	28315-28322	concept	_	
149-9	28323-28325	of	_	
149-10	28326-28334	salience	_	
149-11	28335-28342	network	_	
149-12	28343-28354	dysfunction	_	
149-13	28355-28357	in	_	
149-14	28358-28371	schizophrenia	_	
149-15	28371-28372	:	_	
149-16	28373-28377	from	_	
149-17	28378-28390	neuroimaging	_	
149-18	28391-28403	observations	_	
149-19	28404-28406	to	_	
149-20	28407-28418	therapeutic	_	
149-21	28419-28432	opportunities	_	
149-22	28433-28436	How	_	
149-23	28437-28440	can	_	
149-24	28441-28444	the	_	
149-25	28445-28450	brain	_	
149-26	28450-28451	’	_	
149-27	28451-28452	s	_	
149-28	28453-28460	resting	_	
149-29	28461-28466	state	_	
149-30	28467-28475	activity	_	
149-31	28476-28484	generate	_	
149-32	28485-28499	hallucinations	_	
149-33	28499-28500	?	_	

#Text=A ‘resting state hypothesis’ of auditory verbal hallucinations
#Text=A framework for interpreting functional networks in schizophrenia
#Text=Resting-state networks in schizophrenia
#Text=Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia
#Text=Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study
#Text=A splitting brain: Imbalanced neural networks in schizophrenia
#Text=Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by “resting state” functional magnetic resonance imaging
#Text=Cognition and resting-state functional connectivity in schizophrenia
#Text=Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients
#Text=Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade
#Text=Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia
#Text=Alterations of the brain reward system in antipsychotic naïve schizophrenia patients
#Text=Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment
#Text=Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: A case control study
#Text=Striatal D(2/3) binding potential values in drug-naïve first-episode schizophrenia patients correlate with treatment outcome
#Text=SCAN.
150-1	28501-28502	A	_	
150-2	28503-28504	‘	_	
150-3	28504-28511	resting	_	
150-4	28512-28517	state	_	
150-5	28518-28528	hypothesis	_	
150-6	28528-28529	’	_	
150-7	28530-28532	of	_	
150-8	28533-28541	auditory	_	
150-9	28542-28548	verbal	_	
150-10	28549-28563	hallucinations	_	
150-11	28564-28565	A	_	
150-12	28566-28575	framework	_	
150-13	28576-28579	for	_	
150-14	28580-28592	interpreting	_	
150-15	28593-28603	functional	_	
150-16	28604-28612	networks	_	
150-17	28613-28615	in	_	
150-18	28616-28629	schizophrenia	_	
150-19	28630-28643	Resting-state	_	
150-20	28644-28652	networks	_	
150-21	28653-28655	in	_	
150-22	28656-28669	schizophrenia	_	
150-23	28670-28678	Aberrant	_	
150-24	28679-28688	intrinsic	_	
150-25	28689-28694	brain	_	
150-26	28695-28703	activity	_	
150-27	28704-28707	and	_	
150-28	28708-28717	cognitive	_	
150-29	28718-28725	deficit	_	
150-30	28726-28728	in	_	
150-31	28729-28742	first-episode	_	
150-32	28743-28758	treatment-naive	_	
150-33	28759-28767	patients	_	
150-34	28768-28772	with	_	
150-35	28773-28786	schizophrenia	_	
150-36	28787-28798	Association	_	
150-37	28799-28801	of	_	
150-38	28802-28810	cerebral	_	
150-39	28811-28819	deficits	_	
150-40	28820-28824	with	_	
150-41	28825-28833	clinical	_	
150-42	28834-28842	symptoms	_	
150-43	28843-28845	in	_	
150-44	28846-28865	antipsychotic-naive	_	
150-45	28866-28879	first-episode	_	
150-46	28880-28893	schizophrenia	_	
150-47	28893-28894	:	_	
150-48	28895-28897	an	_	
150-49	28898-28907	optimized	_	
150-50	28908-28919	voxel-based	_	
150-51	28920-28931	morphometry	_	
150-52	28932-28935	and	_	
150-53	28936-28943	resting	_	
150-54	28944-28949	state	_	
150-55	28950-28960	functional	_	
150-56	28961-28973	connectivity	_	
150-57	28974-28979	study	_	
150-58	28980-28981	A	_	
150-59	28982-28991	splitting	_	
150-60	28992-28997	brain	_	
150-61	28997-28998	:	_	
150-62	28999-29009	Imbalanced	_	
150-63	29010-29016	neural	_	
150-64	29017-29025	networks	_	
150-65	29026-29028	in	_	
150-66	29029-29042	schizophrenia	_	
150-67	29043-29053	Short-term	_	
150-68	29054-29061	effects	_	
150-69	29062-29064	of	_	
150-70	29065-29078	antipsychotic	_	
150-71	29079-29088	treatment	_	
150-72	29089-29091	on	_	
150-73	29092-29100	cerebral	_	
150-74	29101-29109	function	_	
150-75	29110-29112	in	_	
150-76	29113-29123	drug-naive	_	
150-77	29124-29137	first-episode	_	
150-78	29138-29151	schizophrenia	_	
150-79	29152-29160	revealed	_	
150-80	29161-29163	by	_	
150-81	29164-29165	“	_	
150-82	29165-29172	resting	_	
150-83	29173-29178	state	_	
150-84	29178-29179	”	_	
150-85	29180-29190	functional	_	
150-86	29191-29199	magnetic	_	
150-87	29200-29209	resonance	_	
150-88	29210-29217	imaging	_	
150-89	29218-29227	Cognition	_	
150-90	29228-29231	and	_	
150-91	29232-29245	resting-state	_	
150-92	29246-29256	functional	_	
150-93	29257-29269	connectivity	_	
150-94	29270-29272	in	_	
150-95	29273-29286	schizophrenia	_	
150-96	29287-29294	Effects	_	
150-97	29295-29297	of	_	
150-98	29298-29306	dopamine	_	
150-99	29307-29309	D2	_	
150-100	29309-29310	/	_	
150-101	29310-29312	D3	_	
150-102	29313-29321	blockade	_	
150-103	29322-29324	on	_	
150-104	29325-29330	human	_	
150-105	29331-29338	sensory	_	
150-106	29339-29342	and	_	
150-107	29343-29355	sensorimotor	_	
150-108	29356-29362	gating	_	
150-109	29363-29365	in	_	
150-110	29366-29375	initially	_	
150-111	29376-29395	antipsychotic-naive	_	
150-112	29395-29396	,	_	
150-113	29397-29410	first-episode	_	
150-114	29411-29424	schizophrenia	_	
150-115	29425-29433	patients	_	
150-116	29434-29441	Frontal	_	
150-117	29442-29451	fasciculi	_	
150-118	29452-29455	and	_	
150-119	29456-29465	psychotic	_	
150-120	29466-29474	symptoms	_	
150-121	29475-29477	in	_	
150-122	29478-29497	antipsychotic-naive	_	
150-123	29498-29506	patients	_	
150-124	29507-29511	with	_	
150-125	29512-29525	schizophrenia	_	
150-126	29526-29532	before	_	
150-127	29533-29536	and	_	
150-128	29537-29542	after	_	
150-129	29543-29544	6	_	
150-130	29545-29550	weeks	_	
150-131	29551-29553	of	_	
150-132	29554-29563	selective	_	
150-133	29564-29572	dopamine	_	
150-134	29573-29575	D2	_	
150-135	29575-29576	/	_	
150-136	29576-29577	3	_	
150-137	29578-29586	receptor	_	
150-138	29587-29595	blockade	_	
150-139	29596-29607	Improvement	_	
150-140	29608-29610	of	_	
150-141	29611-29616	brain	_	
150-142	29617-29623	reward	_	
150-143	29624-29637	abnormalities	_	
150-144	29638-29640	by	_	
150-145	29641-29654	antipsychotic	_	
150-146	29655-29666	monotherapy	_	
150-147	29667-29669	in	_	
150-148	29670-29683	schizophrenia	_	
150-149	29684-29695	Alterations	_	
150-150	29696-29698	of	_	
150-151	29699-29702	the	_	
150-152	29703-29708	brain	_	
150-153	29709-29715	reward	_	
150-154	29716-29722	system	_	
150-155	29723-29725	in	_	
150-156	29726-29739	antipsychotic	_	
150-157	29740-29745	naïve	_	
150-158	29746-29759	schizophrenia	_	
150-159	29760-29768	patients	_	
150-160	29769-29777	Striatal	_	
150-161	29778-29784	reward	_	
150-162	29785-29793	activity	_	
150-163	29794-29797	and	_	
150-164	29798-29822	antipsychotic-associated	_	
150-165	29823-29829	weight	_	
150-166	29830-29836	change	_	
150-167	29837-29839	in	_	
150-168	29840-29848	patients	_	
150-169	29849-29853	with	_	
150-170	29854-29867	schizophrenia	_	
150-171	29868-29878	undergoing	_	
150-172	29879-29886	initial	_	
150-173	29887-29896	treatment	_	
150-174	29897-29905	Systemic	_	
150-175	29906-29915	oxidative	_	
150-176	29916-29919	DNA	_	
150-177	29920-29923	and	_	
150-178	29924-29927	RNA	_	
150-179	29928-29934	damage	_	
150-180	29935-29938	are	_	
150-181	29939-29942	not	_	
150-182	29943-29952	increased	_	
150-183	29953-29959	during	_	
150-184	29960-29965	early	_	
150-185	29966-29972	phases	_	
150-186	29973-29975	of	_	
150-187	29976-29985	psychosis	_	
150-188	29985-29986	:	_	
150-189	29987-29988	A	_	
150-190	29989-29993	case	_	
150-191	29994-30001	control	_	
150-192	30002-30007	study	_	
150-193	30008-30016	Striatal	_	
150-194	30017-30018	D	_	
150-195	30018-30019	(	_	
150-196	30019-30020	2	_	
150-197	30020-30021	/	_	
150-198	30021-30022	3	_	
150-199	30022-30023	)	_	
150-200	30024-30031	binding	_	
150-201	30032-30041	potential	_	
150-202	30042-30048	values	_	
150-203	30049-30051	in	_	
150-204	30052-30062	drug-naïve	_	
150-205	30063-30076	first-episode	_	
150-206	30077-30090	schizophrenia	_	
150-207	30091-30099	patients	_	
150-208	30100-30109	correlate	_	
150-209	30110-30114	with	_	
150-210	30115-30124	treatment	_	
150-211	30125-30132	outcome	_	
150-212	30133-30137	SCAN	_	
150-213	30137-30138	.	_	

#Text=Schedules for Clinical Assessment in Neuropsychiatry
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=The assessment and analysis of handedness: the Edinburgh inventory
#Text=
#Text=The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
#Text=Computerized assessment in neuropsychiatry using CANTAB: discussion paper
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Methods and Software for fMRI analysis for clinical subjects
#Text=
#Text=
#Text=Probabilistic independent component analysis for functional magnetic resonance imaging
#Text=Investigations into resting-state connectivity using independent component analysis
#Text=Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele
#Text=Controlling the false discovery rate: a practical and powerful approach to multiple testing
#Text=Control of goal-directed and stimulus-driven attention in the brain
#Text=Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition
#Text=Functional connectivity anomalies in adolescents with psychotic symptoms
#Text=Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change
#Text=The frontoparietal control system: a central role in mental health
#Text=Saliency, switching, attention and control: a network model of insula function
#Text=Evidence for a frontoparietal control system revealed by intrinsic functional connectivity
#Text=
#Text=The reorienting system of the human brain: from environment to theory of mind
#Text=The role of the right temporoparietal junction in social interaction: how low-level computational processes contribute to meta-cognition
#Text=The role of the right temporoparietal junction in attention and social interaction as revealed by ALE meta-analysis
#Text=A default mode of brain function
#Text=Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function
#Text=Reconciling abnormalities of brain network structure and function in schizophrenia
#Text=Dysconnectivity in schizophrenia: where are we now
#Text=Using short-range and long-range functional connectivity to identify schizophrenia with a family-based case-control design
#Text=Hyperactivity of the default-mode network in first-episode, drug-naive schizophrenia at rest revealed by family-based case-control and traditional case-control designs
#Text=Longitudinal changes in resting-state cerebral activity in patients with first-episode schizophrenia: a 1-year follow-up functional MR Imaging Study
#Text=Brain-wide analysis of functional connectivity in first-episode and chronic stages of schizophrenia
#Text=Abnormal resting-state connectivity in a substantia nigra-related striato-thalamo-cortical network in a large sample of first-episode drug-naive patients with schizophrenia
#Text=Abnormal long- and short-range functional connectivity in adolescent-onset schizophrenia patients: a resting-state fMRI study
#Text=Altered engagement of attention and default networks during target detection in schizophrenia
#Text=Modulation of the default mode network is task-dependant in chronic schizophrenia patients
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Functional evolution of new and expanded attention networks in humans
#Text=Evolutionarily novel functional networks in the human brain
#Text=Right TPJ deactivation during visual search: functional significance and support for a filter hypothesis
#Text=Cortical networks involved in visual awareness independent of visual attention
#Text=Effects of amisulpride on human resting cerebral perfusion
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Impact of in-scanner head motion on multiple measures of functional connectivity: relevance for studies of neurodevelopment in youth
#Text=The influence of head motion on intrinsic functional connectivity MRI
#Text=Evaluation of ICA-AROMA and alternative strategies for motion artifact removal in resting state fMRI
151-1	30139-30148	Schedules	_	
151-2	30149-30152	for	_	
151-3	30153-30161	Clinical	_	
151-4	30162-30172	Assessment	_	
151-5	30173-30175	in	_	
151-6	30176-30191	Neuropsychiatry	_	
151-7	30192-30195	The	_	
151-8	30196-30204	positive	_	
151-9	30205-30208	and	_	
151-10	30209-30217	negative	_	
151-11	30218-30226	syndrome	_	
151-12	30227-30232	scale	_	
151-13	30233-30234	(	_	
151-14	30234-30239	PANSS	_	
151-15	30239-30240	)	_	
151-16	30241-30244	for	_	
151-17	30245-30258	schizophrenia	_	
151-18	30259-30262	The	_	
151-19	30263-30273	assessment	_	
151-20	30274-30277	and	_	
151-21	30278-30286	analysis	_	
151-22	30287-30289	of	_	
151-23	30290-30300	handedness	_	
151-24	30300-30301	:	_	
151-25	30302-30305	the	_	
151-26	30306-30315	Edinburgh	_	
151-27	30316-30325	inventory	_	
151-28	30327-30330	The	_	
151-29	30331-30336	Brief	_	
151-30	30337-30347	Assessment	_	
151-31	30348-30350	of	_	
151-32	30351-30360	Cognition	_	
151-33	30361-30363	in	_	
151-34	30364-30377	Schizophrenia	_	
151-35	30377-30378	:	_	
151-36	30379-30390	reliability	_	
151-37	30390-30391	,	_	
151-38	30392-30403	sensitivity	_	
151-39	30403-30404	,	_	
151-40	30405-30408	and	_	
151-41	30409-30419	comparison	_	
151-42	30420-30424	with	_	
151-43	30425-30426	a	_	
151-44	30427-30435	standard	_	
151-45	30436-30450	neurocognitive	_	
151-46	30451-30458	battery	_	
151-47	30459-30471	Computerized	_	
151-48	30472-30482	assessment	_	
151-49	30483-30485	in	_	
151-50	30486-30501	neuropsychiatry	_	
151-51	30502-30507	using	_	
151-52	30508-30514	CANTAB	_	
151-53	30514-30515	:	_	
151-54	30516-30526	discussion	_	
151-55	30527-30532	paper	_	
151-56	30533-30541	Improved	_	
151-57	30542-30554	optimization	_	
151-58	30555-30558	for	_	
151-59	30559-30562	the	_	
151-60	30563-30569	robust	_	
151-61	30570-30573	and	_	
151-62	30574-30582	accurate	_	
151-63	30583-30589	linear	_	
151-64	30590-30602	registration	_	
151-65	30603-30606	and	_	
151-66	30607-30613	motion	_	
151-67	30614-30624	correction	_	
151-68	30625-30627	of	_	
151-69	30628-30633	brain	_	
151-70	30634-30640	images	_	
151-71	30641-30648	Methods	_	
151-72	30649-30652	and	_	
151-73	30653-30661	Software	_	
151-74	30662-30665	for	_	
151-75	30666-30670	fMRI	_	
151-76	30671-30679	analysis	_	
151-77	30680-30683	for	_	
151-78	30684-30692	clinical	_	
151-79	30693-30701	subjects	_	
151-80	30704-30717	Probabilistic	_	
151-81	30718-30729	independent	_	
151-82	30730-30739	component	_	
151-83	30740-30748	analysis	_	
151-84	30749-30752	for	_	
151-85	30753-30763	functional	_	
151-86	30764-30772	magnetic	_	
151-87	30773-30782	resonance	_	
151-88	30783-30790	imaging	_	
151-89	30791-30805	Investigations	_	
151-90	30806-30810	into	_	
151-91	30811-30824	resting-state	_	
151-92	30825-30837	connectivity	_	
151-93	30838-30843	using	_	
151-94	30844-30855	independent	_	
151-95	30856-30865	component	_	
151-96	30866-30874	analysis	_	
151-97	30875-30883	Distinct	_	
151-98	30884-30892	patterns	_	
151-99	30893-30895	of	_	
151-100	30896-30901	brain	_	
151-101	30902-30910	activity	_	
151-102	30911-30913	in	_	
151-103	30914-30919	young	_	
151-104	30920-30928	carriers	_	
151-105	30929-30931	of	_	
151-106	30932-30935	the	_	
151-107	30936-30949	APOE-epsilon4	_	
151-108	30950-30956	allele	_	
151-109	30957-30968	Controlling	_	
151-110	30969-30972	the	_	
151-111	30973-30978	false	_	
151-112	30979-30988	discovery	_	
151-113	30989-30993	rate	_	
151-114	30993-30994	:	_	
151-115	30995-30996	a	_	
151-116	30997-31006	practical	_	
151-117	31007-31010	and	_	
151-118	31011-31019	powerful	_	
151-119	31020-31028	approach	_	
151-120	31029-31031	to	_	
151-121	31032-31040	multiple	_	
151-122	31041-31048	testing	_	
151-123	31049-31056	Control	_	
151-124	31057-31059	of	_	
151-125	31060-31073	goal-directed	_	
151-126	31074-31077	and	_	
151-127	31078-31093	stimulus-driven	_	
151-128	31094-31103	attention	_	
151-129	31104-31106	in	_	
151-130	31107-31110	the	_	
151-131	31111-31116	brain	_	
151-132	31117-31124	Altered	_	
151-133	31125-31135	functional	_	
151-134	31136-31148	connectivity	_	
151-135	31149-31154	links	_	
151-136	31155-31157	in	_	
151-137	31158-31175	neuroleptic-naïve	_	
151-138	31176-31179	and	_	
151-139	31180-31199	neuroleptic-treated	_	
151-140	31200-31208	patients	_	
151-141	31209-31213	with	_	
151-142	31214-31227	schizophrenia	_	
151-143	31227-31228	,	_	
151-144	31229-31232	and	_	
151-145	31233-31238	their	_	
151-146	31239-31247	relation	_	
151-147	31248-31250	to	_	
151-148	31251-31259	symptoms	_	
151-149	31260-31269	including	_	
151-150	31270-31278	volition	_	
151-151	31279-31289	Functional	_	
151-152	31290-31302	connectivity	_	
151-153	31303-31312	anomalies	_	
151-154	31313-31315	in	_	
151-155	31316-31327	adolescents	_	
151-156	31328-31332	with	_	
151-157	31333-31342	psychotic	_	
151-158	31343-31351	symptoms	_	
151-159	31352-31364	Early-course	_	
151-160	31365-31376	unmedicated	_	
151-161	31377-31390	schizophrenia	_	
151-162	31391-31399	patients	_	
151-163	31400-31407	exhibit	_	
151-164	31408-31416	elevated	_	
151-165	31417-31427	prefrontal	_	
151-166	31428-31440	connectivity	_	
151-167	31441-31451	associated	_	
151-168	31452-31456	with	_	
151-169	31457-31469	longitudinal	_	
151-170	31470-31476	change	_	
151-171	31477-31480	The	_	
151-172	31481-31495	frontoparietal	_	
151-173	31496-31503	control	_	
151-174	31504-31510	system	_	
151-175	31510-31511	:	_	
151-176	31512-31513	a	_	
151-177	31514-31521	central	_	
151-178	31522-31526	role	_	
151-179	31527-31529	in	_	
151-180	31530-31536	mental	_	
151-181	31537-31543	health	_	
151-182	31544-31552	Saliency	_	
151-183	31552-31553	,	_	
151-184	31554-31563	switching	_	
151-185	31563-31564	,	_	
151-186	31565-31574	attention	_	
151-187	31575-31578	and	_	
151-188	31579-31586	control	_	
151-189	31586-31587	:	_	
151-190	31588-31589	a	_	
151-191	31590-31597	network	_	
151-192	31598-31603	model	_	
151-193	31604-31606	of	_	
151-194	31607-31613	insula	_	
151-195	31614-31622	function	_	
151-196	31623-31631	Evidence	_	
151-197	31632-31635	for	_	
151-198	31636-31637	a	_	
151-199	31638-31652	frontoparietal	_	
151-200	31653-31660	control	_	
151-201	31661-31667	system	_	
151-202	31668-31676	revealed	_	
151-203	31677-31679	by	_	
151-204	31680-31689	intrinsic	_	
151-205	31690-31700	functional	_	
151-206	31701-31713	connectivity	_	
151-207	31715-31718	The	_	
151-208	31719-31730	reorienting	_	
151-209	31731-31737	system	_	
151-210	31738-31740	of	_	
151-211	31741-31744	the	_	
151-212	31745-31750	human	_	
151-213	31751-31756	brain	_	
151-214	31756-31757	:	_	
151-215	31758-31762	from	_	
151-216	31763-31774	environment	_	
151-217	31775-31777	to	_	
151-218	31778-31784	theory	_	
151-219	31785-31787	of	_	
151-220	31788-31792	mind	_	
151-221	31793-31796	The	_	
151-222	31797-31801	role	_	
151-223	31802-31804	of	_	
151-224	31805-31808	the	_	
151-225	31809-31814	right	_	
151-226	31815-31830	temporoparietal	_	
151-227	31831-31839	junction	_	
151-228	31840-31842	in	_	
151-229	31843-31849	social	_	
151-230	31850-31861	interaction	_	
151-231	31861-31862	:	_	
151-232	31863-31866	how	_	
151-233	31867-31876	low-level	_	
151-234	31877-31890	computational	_	
151-235	31891-31900	processes	_	
151-236	31901-31911	contribute	_	
151-237	31912-31914	to	_	
151-238	31915-31929	meta-cognition	_	
151-239	31930-31933	The	_	
151-240	31934-31938	role	_	
151-241	31939-31941	of	_	
151-242	31942-31945	the	_	
151-243	31946-31951	right	_	
151-244	31952-31967	temporoparietal	_	
151-245	31968-31976	junction	_	
151-246	31977-31979	in	_	
151-247	31980-31989	attention	_	
151-248	31990-31993	and	_	
151-249	31994-32000	social	_	
151-250	32001-32012	interaction	_	
151-251	32013-32015	as	_	
151-252	32016-32024	revealed	_	
151-253	32025-32027	by	_	
151-254	32028-32031	ALE	_	
151-255	32032-32045	meta-analysis	_	
151-256	32046-32047	A	_	
151-257	32048-32055	default	_	
151-258	32056-32060	mode	_	
151-259	32061-32063	of	_	
151-260	32064-32069	brain	_	
151-261	32070-32078	function	_	
151-262	32079-32085	Medial	_	
151-263	32086-32096	prefrontal	_	
151-264	32097-32103	cortex	_	
151-265	32104-32107	and	_	
151-266	32108-32124	self-referential	_	
151-267	32125-32131	mental	_	
151-268	32132-32140	activity	_	
151-269	32140-32141	:	_	
151-270	32142-32150	relation	_	
151-271	32151-32153	to	_	
151-272	32154-32155	a	_	
151-273	32156-32163	default	_	
151-274	32164-32168	mode	_	
151-275	32169-32171	of	_	
151-276	32172-32177	brain	_	
151-277	32178-32186	function	_	
151-278	32187-32198	Reconciling	_	
151-279	32199-32212	abnormalities	_	
151-280	32213-32215	of	_	
151-281	32216-32221	brain	_	
151-282	32222-32229	network	_	
151-283	32230-32239	structure	_	
151-284	32240-32243	and	_	
151-285	32244-32252	function	_	
151-286	32253-32255	in	_	
151-287	32256-32269	schizophrenia	_	
151-288	32270-32285	Dysconnectivity	_	
151-289	32286-32288	in	_	
151-290	32289-32302	schizophrenia	_	
151-291	32302-32303	:	_	
151-292	32304-32309	where	_	
151-293	32310-32313	are	_	
151-294	32314-32316	we	_	
151-295	32317-32320	now	_	
151-296	32321-32326	Using	_	
151-297	32327-32338	short-range	_	
151-298	32339-32342	and	_	
151-299	32343-32353	long-range	_	
151-300	32354-32364	functional	_	
151-301	32365-32377	connectivity	_	
151-302	32378-32380	to	_	
151-303	32381-32389	identify	_	
151-304	32390-32403	schizophrenia	_	
151-305	32404-32408	with	_	
151-306	32409-32410	a	_	
151-307	32411-32423	family-based	_	
151-308	32424-32436	case-control	_	
151-309	32437-32443	design	_	
151-310	32444-32457	Hyperactivity	_	
151-311	32458-32460	of	_	
151-312	32461-32464	the	_	
151-313	32465-32477	default-mode	_	
151-314	32478-32485	network	_	
151-315	32486-32488	in	_	
151-316	32489-32502	first-episode	_	
151-317	32502-32503	,	_	
151-318	32504-32514	drug-naive	_	
151-319	32515-32528	schizophrenia	_	
151-320	32529-32531	at	_	
151-321	32532-32536	rest	_	
151-322	32537-32545	revealed	_	
151-323	32546-32548	by	_	
151-324	32549-32561	family-based	_	
151-325	32562-32574	case-control	_	
151-326	32575-32578	and	_	
151-327	32579-32590	traditional	_	
151-328	32591-32603	case-control	_	
151-329	32604-32611	designs	_	
151-330	32612-32624	Longitudinal	_	
151-331	32625-32632	changes	_	
151-332	32633-32635	in	_	
151-333	32636-32649	resting-state	_	
151-334	32650-32658	cerebral	_	
151-335	32659-32667	activity	_	
151-336	32668-32670	in	_	
151-337	32671-32679	patients	_	
151-338	32680-32684	with	_	
151-339	32685-32698	first-episode	_	
151-340	32699-32712	schizophrenia	_	
151-341	32712-32713	:	_	
151-342	32714-32715	a	_	
151-343	32716-32717	1	_	
151-344	32717-32718	-	_	
151-345	32718-32722	year	_	
151-346	32723-32732	follow-up	_	
151-347	32733-32743	functional	_	
151-348	32744-32746	MR	_	
151-349	32747-32754	Imaging	_	
151-350	32755-32760	Study	_	
151-351	32761-32771	Brain-wide	_	
151-352	32772-32780	analysis	_	
151-353	32781-32783	of	_	
151-354	32784-32794	functional	_	
151-355	32795-32807	connectivity	_	
151-356	32808-32810	in	_	
151-357	32811-32824	first-episode	_	
151-358	32825-32828	and	_	
151-359	32829-32836	chronic	_	
151-360	32837-32843	stages	_	
151-361	32844-32846	of	_	
151-362	32847-32860	schizophrenia	_	
151-363	32861-32869	Abnormal	_	
151-364	32870-32883	resting-state	_	
151-365	32884-32896	connectivity	_	
151-366	32897-32899	in	_	
151-367	32900-32901	a	_	
151-368	32902-32912	substantia	_	
151-369	32913-32926	nigra-related	_	
151-370	32927-32951	striato-thalamo-cortical	_	
151-371	32952-32959	network	_	
151-372	32960-32962	in	_	
151-373	32963-32964	a	_	
151-374	32965-32970	large	_	
151-375	32971-32977	sample	_	
151-376	32978-32980	of	_	
151-377	32981-32994	first-episode	_	
151-378	32995-33005	drug-naive	_	
151-379	33006-33014	patients	_	
151-380	33015-33019	with	_	
151-381	33020-33033	schizophrenia	_	
151-382	33034-33042	Abnormal	_	
151-383	33043-33047	long	_	
151-384	33047-33048	-	_	
151-385	33049-33052	and	_	
151-386	33053-33064	short-range	_	
151-387	33065-33075	functional	_	
151-388	33076-33088	connectivity	_	
151-389	33089-33091	in	_	
151-390	33092-33108	adolescent-onset	_	
151-391	33109-33122	schizophrenia	_	
151-392	33123-33131	patients	_	
151-393	33131-33132	:	_	
151-394	33133-33134	a	_	
151-395	33135-33148	resting-state	_	
151-396	33149-33153	fMRI	_	
151-397	33154-33159	study	_	
151-398	33160-33167	Altered	_	
151-399	33168-33178	engagement	_	
151-400	33179-33181	of	_	
151-401	33182-33191	attention	_	
151-402	33192-33195	and	_	
151-403	33196-33203	default	_	
151-404	33204-33212	networks	_	
151-405	33213-33219	during	_	
151-406	33220-33226	target	_	
151-407	33227-33236	detection	_	
151-408	33237-33239	in	_	
151-409	33240-33253	schizophrenia	_	
151-410	33254-33264	Modulation	_	
151-411	33265-33267	of	_	
151-412	33268-33271	the	_	
151-413	33272-33279	default	_	
151-414	33280-33284	mode	_	
151-415	33285-33292	network	_	
151-416	33293-33295	is	_	
151-417	33296-33310	task-dependant	_	
151-418	33311-33313	in	_	
151-419	33314-33321	chronic	_	
151-420	33322-33335	schizophrenia	_	
151-421	33336-33344	patients	_	
151-422	33345-33358	Hyperactivity	_	
151-423	33359-33362	and	_	
151-424	33363-33380	hyperconnectivity	_	
151-425	33381-33383	of	_	
151-426	33384-33387	the	_	
151-427	33388-33395	default	_	
151-428	33396-33403	network	_	
151-429	33404-33406	in	_	
151-430	33407-33420	schizophrenia	_	
151-431	33421-33424	and	_	
151-432	33425-33427	in	_	
151-433	33428-33440	first-degree	_	
151-434	33441-33450	relatives	_	
151-435	33451-33453	of	_	
151-436	33454-33461	persons	_	
151-437	33462-33466	with	_	
151-438	33467-33480	schizophrenia	_	
151-439	33481-33491	Functional	_	
151-440	33492-33501	evolution	_	
151-441	33502-33504	of	_	
151-442	33505-33508	new	_	
151-443	33509-33512	and	_	
151-444	33513-33521	expanded	_	
151-445	33522-33531	attention	_	
151-446	33532-33540	networks	_	
151-447	33541-33543	in	_	
151-448	33544-33550	humans	_	
151-449	33551-33565	Evolutionarily	_	
151-450	33566-33571	novel	_	
151-451	33572-33582	functional	_	
151-452	33583-33591	networks	_	
151-453	33592-33594	in	_	
151-454	33595-33598	the	_	
151-455	33599-33604	human	_	
151-456	33605-33610	brain	_	
151-457	33611-33616	Right	_	
151-458	33617-33620	TPJ	_	
151-459	33621-33633	deactivation	_	
151-460	33634-33640	during	_	
151-461	33641-33647	visual	_	
151-462	33648-33654	search	_	
151-463	33654-33655	:	_	
151-464	33656-33666	functional	_	
151-465	33667-33679	significance	_	
151-466	33680-33683	and	_	
151-467	33684-33691	support	_	
151-468	33692-33695	for	_	
151-469	33696-33697	a	_	
151-470	33698-33704	filter	_	
151-471	33705-33715	hypothesis	_	
151-472	33716-33724	Cortical	_	
151-473	33725-33733	networks	_	
151-474	33734-33742	involved	_	
151-475	33743-33745	in	_	
151-476	33746-33752	visual	_	
151-477	33753-33762	awareness	_	
151-478	33763-33774	independent	_	
151-479	33775-33777	of	_	
151-480	33778-33784	visual	_	
151-481	33785-33794	attention	_	
151-482	33795-33802	Effects	_	
151-483	33803-33805	of	_	
151-484	33806-33817	amisulpride	_	
151-485	33818-33820	on	_	
151-486	33821-33826	human	_	
151-487	33827-33834	resting	_	
151-488	33835-33843	cerebral	_	
151-489	33844-33853	perfusion	_	
151-490	33854-33862	Spurious	_	
151-491	33863-33866	but	_	
151-492	33867-33877	systematic	_	
151-493	33878-33890	correlations	_	
151-494	33891-33893	in	_	
151-495	33894-33904	functional	_	
151-496	33905-33917	connectivity	_	
151-497	33918-33921	MRI	_	
151-498	33922-33930	networks	_	
151-499	33931-33936	arise	_	
151-500	33937-33941	from	_	
151-501	33942-33949	subject	_	
151-502	33950-33956	motion	_	
151-503	33957-33963	Impact	_	
151-504	33964-33966	of	_	
151-505	33967-33977	in-scanner	_	
151-506	33978-33982	head	_	
151-507	33983-33989	motion	_	
151-508	33990-33992	on	_	
151-509	33993-34001	multiple	_	
151-510	34002-34010	measures	_	
151-511	34011-34013	of	_	
151-512	34014-34024	functional	_	
151-513	34025-34037	connectivity	_	
151-514	34037-34038	:	_	
151-515	34039-34048	relevance	_	
151-516	34049-34052	for	_	
151-517	34053-34060	studies	_	
151-518	34061-34063	of	_	
151-519	34064-34080	neurodevelopment	_	
151-520	34081-34083	in	_	
151-521	34084-34089	youth	_	
151-522	34090-34093	The	_	
151-523	34094-34103	influence	_	
151-524	34104-34106	of	_	
151-525	34107-34111	head	_	
151-526	34112-34118	motion	_	
151-527	34119-34121	on	_	
151-528	34122-34131	intrinsic	_	
151-529	34132-34142	functional	_	
151-530	34143-34155	connectivity	_	
151-531	34156-34159	MRI	_	
151-532	34160-34170	Evaluation	_	
151-533	34171-34173	of	_	
151-534	34174-34183	ICA-AROMA	_	
151-535	34184-34187	and	_	
151-536	34188-34199	alternative	_	
151-537	34200-34210	strategies	_	
151-538	34211-34214	for	_	
151-539	34215-34221	motion	_	
151-540	34222-34230	artifact	_	
151-541	34231-34238	removal	_	
151-542	34239-34241	in	_	
151-543	34242-34249	resting	_	
151-544	34250-34255	state	_	
151-545	34256-34260	fMRI	_	
